WO2022117045A1 - 一种t细胞衔接器治疗剂的开发和应用 - Google Patents

一种t细胞衔接器治疗剂的开发和应用 Download PDF

Info

Publication number
WO2022117045A1
WO2022117045A1 PCT/CN2021/135121 CN2021135121W WO2022117045A1 WO 2022117045 A1 WO2022117045 A1 WO 2022117045A1 CN 2021135121 W CN2021135121 W CN 2021135121W WO 2022117045 A1 WO2022117045 A1 WO 2022117045A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
variable region
heavy chain
amino acid
light chain
Prior art date
Application number
PCT/CN2021/135121
Other languages
English (en)
French (fr)
Inventor
徐刚
陈博
王莹
Original Assignee
康诺亚生物医药科技（成都）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康诺亚生物医药科技（成都）有限公司 filed Critical 康诺亚生物医药科技（成都）有限公司
Priority to AU2021390122A priority Critical patent/AU2021390122A1/en
Priority to KR1020237022053A priority patent/KR20230117178A/ko
Priority to JP2023533951A priority patent/JP2023552198A/ja
Priority to EP21900071.8A priority patent/EP4257607A1/en
Priority to CA3200652A priority patent/CA3200652A1/en
Priority to CN202180081608.XA priority patent/CN116669761A/zh
Publication of WO2022117045A1 publication Critical patent/WO2022117045A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Definitions

  • the present disclosure relates to the development and application of a T cell engager therapeutic agent, in particular a bispecific antibody that binds BCMA and CD3, and applications thereof.
  • BCMA B-cell maturation antigen
  • APRIL A Proliferation Inducing Ligand
  • multiple myeloma is the second most common disease, mostly in middle-aged and elderly people.
  • the accumulation of malignantly proliferating plasma cells in the bone marrow of patients can lead to bone marrow failure and immune dysfunction, and is often accompanied by multiple osteolytic lesions, hypercalcemia, anemia, and kidney damage.
  • new drugs including proteasome inhibitors, immunomodulators, and targeted antibodies, have significantly prolonged the survival of patients, almost all patients still experience relapse.
  • CAR-T cells chimeric antigen receptor T-cells
  • CAR-T cells chimeric antigen receptor T-cells
  • T cell bispecific antibody (or T cell adapter) is a special antibody molecule constructed artificially, which can recognize the target cell surface antigen (antigen arm) through one end and bind T cell CD3 receptor (CD3 arm) through the other end. ).
  • CD3 on T cells is aggregated to activate T cells and kill tumors.
  • BCMAxCD3 bispecific molecules are T cell bispecific (TCB) antibodies that target BCMA expressed on myeloma cells and CD3 ⁇ chain (CD3e) present on T cells.
  • TAB T cell bispecific
  • the mechanism of action of the BCMA ⁇ CD3 bispecific molecule involves simultaneous binding to BCMA+ myeloma cells and CD3+ T cells, resulting in T cell activation and T cell-mediated cell killing.
  • TCR During normal immune response, TCR binds to exogenous peptide-human leukocyte antigen complex (HLA) on infected or mutated cells with low affinity (about 1-100 ⁇ M), transduces activation signals into the nucleus through CD3, activates transcription factors and The expression of its downstream proteins (cytokines, granzymes, perforin, etc.), where the intensity of the signal generated by the TCR complex will determine the fate of T cells.
  • HLA peptide-human leukocyte antigen complex
  • the epsilon, gamma, delta, and zeta subunits of the signaling complex associate with each other to form CD3 epsilon-gamma heterodimers, CD3 epsilon-delta heterodimers, and CD3 zeta-zeta homodimers.
  • the CD3 bispecific antibodies developed in the early stage were mostly based on a few mouse-derived antibodies such as OKT3, L2K, UCHT1 and TR66, with high affinity.
  • CD3 antibody In clinical studies, it was found that the high affinity of CD3 antibody will lead to excessive activation of T cells and release a large number of cytokines, resulting in cytokine storm syndrome; at the same time, high affinity will also lead to the enrichment of bispecific antibodies in secondary lymphoid organs , reducing exposure in tumor tissue.
  • the binding ability of the Fc part of the antibody to the Fc ⁇ receptor is another important factor affecting drug safety. Since the Fc ⁇ receptor is expressed in a variety of normal tissues, the binding of the bispecific antibody to the Fc ⁇ receptor on the cell membrane through Fc can lead to other factors.
  • the CD3 receptor bound at one end is cross-linked and activated due to the aggregation of Fc ⁇ receptors, resulting in severe off-target toxicity.
  • the early market catumaxomab caused rapid cytokine release due to the binding of the Fc segment to the Fc ⁇ receptor expressed by liver Kupffer cells .
  • human IgG2 subtype or IgG4 subtype with weak Fc ⁇ receptor binding ability, or by further amino acid substitution at the corresponding position of CH2, for example, Armour et al.
  • Armour KL et al Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities, Eur J Immunol.
  • Newman et al introduced mutations Ser228Pro and Leu235Glu in IgG4 to stabilize the IgG4 structure while reducing the binding to Fc ⁇ receptors (Newman R. et al, Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+)T cells in chimpanzees, Clin Immunol. 2001 Feb; 98(2):164-74,), Idusogie et al.
  • the present disclosure provides a new BCMA antibody with high affinity to BCMA protein.
  • the present disclosure also provides a novel BCMA-CD3 ⁇ bispecific antibody formed by BCMA antibody and CD3 antibody.
  • the BCMA-CD3 ⁇ bispecific antibody adopts a full-length IgG configuration.
  • the ⁇ bispecific antibody is preferentially localized to BCMA+ tumor tissue.
  • activated T cells can be recruited to effectively kill target cells.
  • T cells are not activated in the presence of target cells; at the same time, ⁇ bispecific antibodies do not bind to receptors such as Fc ⁇ RI, Fc ⁇ RIIA and Fc ⁇ RIIIA, reducing the risk of cytokine storm.
  • this novel BCMA-CD3 ⁇ bispecific antibody can effectively inhibit tumor growth, and its efficacy is better than that of similar antibodies.
  • the present disclosure provides an antibody or antigen-binding portion thereof that binds BCMA.
  • the present disclosure provides a bispecific antibody or antigen-binding portion thereof.
  • the present disclosure provides nucleic acids encoding bispecific antibodies or antigen-binding portions thereof as previously described.
  • the present disclosure provides vectors comprising the aforementioned nucleic acids.
  • the present disclosure provides a cell comprising the aforementioned nucleic acid or vector.
  • the present disclosure provides a pharmaceutical composition or kit comprising an antibody, or antigen-binding portion thereof, or an encoding nucleic acid thereof, as previously described, and a pharmaceutically acceptable carrier.
  • the present disclosure provides antibody-drug conjugates comprising the aforementioned antibodies, or antigen-binding portions thereof, bispecific or multispecific molecules thereof, covalently attached to a therapeutic moiety.
  • the present disclosure provides a method of treating a disorder associated with BCMA, comprising the steps of: administering to a mammal a therapeutically effective amount of the aforementioned antibody or antigen-binding fragment thereof, nucleic acid, vector, cell, and/or pharmaceutical composition .
  • the present disclosure provides use of the aforementioned antibodies or antigen-binding fragments thereof, nucleic acids, vectors, cells and/or pharmaceutical compositions in the manufacture of a medicament or kit for treating a BCMA-related disorder in a mammal.
  • the antibodies of the present disclosure can be used for a variety of applications, including detection of BCMA protein, diagnosis, treatment or prevention of BCMA-related diseases.
  • Figure 1 shows the SDS-PAGE results of human, cynomolgus monkey BCMA-mFc bivalent recombinant protein and BCMA-hFc kih monovalent recombinant protein.
  • Figure 2 shows flow cytometric detection of human and cynomolgus monkey BCMA stable cells, both human BCMA stable cells (CHO-hBCMA-2C2) and cynomolgus monkey BCMA stable cells (CHO-cynoBCMA-1A2) express high levels of BCMA .
  • Figure 3 shows the SDS-PAGE results of CD3 ⁇ -Fc recombinant protein.
  • Figure 4 shows the binding of humanized CD3 antibody to CD3 ⁇ -Fc recombinant protein.
  • Figure 5 shows the binding of humanized CD3 antibodies to Jurkat cells.
  • Figure 6 shows the binding of BCMA x CD3 ⁇ bispecific antibody to BCMA stably transfected cells.
  • Figure 7 shows that the BCMAxCD3 ⁇ bispecific antibody binds BCMA+ tumor cells with high affinity.
  • Figure 8 shows the binding of the BCMAxCD3 ⁇ bispecific antibody to Jurkat cells.
  • FIG. 9 shows the binding of BCMA ⁇ CD3 ⁇ bispecific antibody to human peripheral blood T cells
  • Figure 10 shows the killing of NCI-H929 cells and the activation of T cells by BCMA ⁇ CD3 ⁇ bispecific antibody, wherein, Figure 10A shows the killing of NCI-H929 cells, and Figure 10B shows the activation of T cells.
  • Figure 11 shows the killing of RPMI-8226 cells and the activation of T cells by BCMAxCD3 ⁇ bispecific antibody, wherein Figure 11A shows the killing of RPMI-8226 cells, and Figure 11B shows the activation of T cells.
  • Figure 12 shows activation of T cell signaling pathways by BCMAxCD3 ⁇ bispecific antibodies.
  • Figure 13 shows the activation of peripheral blood T cells by BCMAxCD3 ⁇ bispecific antibody.
  • Figure 14 shows the binding of the BCMAxCD3 ⁇ bispecific antibody to activated Fc ⁇ R receptors.
  • Figure 15 shows the blocking of BCMA binding to the receptor APRIL by the BCMAxCD3 ⁇ bispecific antibody.
  • FIG. 16 shows the inhibitory effect of BCMA ⁇ CD3 ⁇ bispecific antibody on the subcutaneous NCI-H929 xenograft model of immunodeficient mice.
  • BCMA may refer to a concept collectively referring to BCMA itself and any variants, isoforms and paralogs present in animals and preferably in humans.
  • human BCMA refers to BCMA of human origin, and may preferably have, but is not limited to, the amino acid sequence of Genbank Accession No. AB052772.1.
  • anti-BCMA antibody and "BCMA-binding antibody” refer to an antibody capable of binding BCMA with sufficient affinity such that the antibody is useful in targeting BCMA as a diagnostic and/or therapeutic agent.
  • the degree of binding of an anti-BCMA antibody to an unrelated non-BCMA protein is less than about 10% of the binding of the antibody to BCMA, as measured by, eg, a radioimmunoassay (RIA).
  • RIA radioimmunoassay
  • the antibody that binds BCMA has ⁇ 1 ⁇ M, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (eg, 10 ⁇ 8 M or less, eg, 10 ⁇ 8 M to 10" 13M , eg 10" 9M to 10" 13M ) dissociation constant ( Kd ).
  • anti-BCMA antibodies bind to BCMA epitopes that are conserved among BCMAs from different species.
  • CD3 refers to any native CD3 from any vertebrate source, including mammals, such as primates (eg, humans), non-human primates (eg, cynomolgus monkeys), and rodents (eg, mice and rats), unless otherwise specified.
  • the term encompasses "full-length” unprocessed CD3 as well as any form of CD3 derived from processing in a cell.
  • the term also encompasses naturally occurring variants of CD3, such as splice variants or allelic variants.
  • the CD3 is human CD3, particularly the epsilon subunit of human CD3 (CD3 ⁇ ).
  • the amino acid sequence of human CD3 ⁇ is shown in UniProt (www.uniprot.org) accession number P07766 (version 144), or NCBI (www.ncbi.nlm.nih.gov/) RefSeq NP_000724.1.
  • the amino acid sequence of cynomolgus monkey [Macaca fascicularis] CD3 ⁇ is shown in NCBI GenBank no.BAB71849.1.
  • cell surface is used according to its normal meaning in the art and thus includes the exterior of the cell accessible by binding to proteins and other molecules.
  • the term “about” or “approximately” means within plus or minus 10% of the given value or range. Where a whole number is required, the term refers to within plus or minus 10% of the given value or range, rounded up or down to the nearest whole number.
  • the phrase "substantially identical" can be understood as exhibiting at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, Antibody chains of 97%, 98%, 99% or more sequence identity.
  • nucleic acid sequences the term is to be understood as exhibiting at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98 A nucleotide sequence of %, 99% or greater sequence identity.
  • sequence identity has an art-recognized meaning, and the percent sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along regions of the molecule. While many methods exist for measuring the identity between two polynucleotides or polypeptides, the term “identity” is well known to the skilled artisan (Carrillo, H. & Lipman, D., SIAM J Applied Math 48:1073 (1988) ).
  • substitutional variant is one in which at least one amino acid residue in the native sequence has been removed and a different amino acid inserted in its same position.
  • the substitutions can be single, wherein only one amino acid is substituted in the molecule, or multiple, wherein the same molecule has two or more amino acids substituted. Multiple substitutions can be made at consecutive sites.
  • one amino acid may be substituted by multiple residues, wherein such variants include both substitutions and insertions.
  • An “insertional” variant is one in which one or more amino acids are inserted into an amino acid immediately adjacent to a specific position in a native sequence. Immediately adjacent to an amino acid means attachment to the alpha-carboxyl or alpha-amino functional group of the amino acid.
  • a “deletion” variant is one in which one or more amino acids in the native amino acid sequence have been removed. Typically, deletion variants have one or two amino acids deleted in a specific region of their molecule.
  • variable domains of antibodies refers to certain portions of related molecules that differ widely in sequence between antibodies and are used for the specific recognition and binding of a particular antibody against its specific target. However, the variability is not evenly distributed throughout the variable domains of antibodies. Variability is concentrated in three segments called complementarity determining regions (CDRs; ie CDR1, CDR2 and CDR3) or hypervariable regions, all located within the variable domains of light and heavy chains. The more conserved portions of the variable domains are referred to as framework (FR) regions or framework sequences.
  • CDRs complementarity determining regions
  • FR framework regions
  • Each variable domain of native heavy and light chains includes four FR regions, predominantly in a beta-sheet configuration, linked by three CDRs that form loops that connect the beta-sheet structure and Partial ⁇ -sheet structures are formed in some cases.
  • the CDRs of each chain are usually linked in proximity by FR regions and, with the aid of CDRs from other chains, contribute to the formation of antibody target binding sites (epitopes or determinants).
  • the numbering of immunoglobulin amino acid residues is according to the immunoglobulin amino acid residue numbering system of Kabat et al., unless otherwise indicated.
  • a CDR can have the ability to specifically bind to the cognate epitope.
  • an "antibody fragment” or “antigen-binding fragment” of an antibody refers to any portion of a full-length antibody that is less than full-length, but which comprises at least a portion of the variable region (eg, one or more of the variable regions of said antibody that binds an antigen) CDRs and/or one or more antibody binding sites), and thus retain binding specificity and at least part of the specific binding capacity of the full-length antibody.
  • an antigen-binding fragment refers to an antibody fragment comprising an antigen-binding portion that binds to the same antigen as the antibody from which the antibody fragment is derived.
  • Antibody fragments include antibody derivatives produced by enzymatic treatment of full-length antibodies, as well as synthetically produced derivatives, eg, recombinantly produced derivatives.
  • Antibodies include antibody fragments. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab') 2 , single chain Fv (scFv), Fv, dsFv, diabodies, Fd and Fd' fragments and other fragments, including modified fragments.
  • the fragments may comprise multiple chains linked together, eg, by disulfide bonds and/or by peptide linkers.
  • Antibody fragments generally comprise at least or about 50 amino acids, and typically at least or about 200 amino acids.
  • Antigen-binding fragments include any antibody fragment that, when inserted into the antibody framework (eg, by substituting the corresponding region), results in an antibody that immunospecifically binds (ie, exhibits a Ka of at least or at least about 107-108 M -1 ) to an antigen .
  • a "functional fragment” or “analog of an anti-BCMA antibody” is a fragment or analog that prevents or substantially reduces the ability of the receptor to bind a ligand or initiate signal transduction.
  • a functional fragment generally has the same meaning as an "antibody fragment” and, with respect to an antibody, may refer to a fragment that prevents or substantially reduces the ability of the receptor to bind a ligand or initiate signal transduction, eg, Fv, Fab , F(ab') 2 , and so on.
  • "Fv" fragments consist of a dimer ( VH - VL dimer) formed by non-covalent association of the variable domains of a heavy chain and the variable domains of a light chain. In this configuration, the three CDRs of each variable domain interact to define the target binding site on the surface of the VH - VL dimer, as is the case with intact antibodies. The six CDRs collectively confer the target-binding specificity of the intact antibody. However, even a single variable domain (or half of an Fv that includes only 3 target-specific CDRs) can still have the ability to recognize and bind targets.
  • BsAb Bispecific antibody
  • a bispecific antibody and/or antigen-binding molecule Contains two antigen binding sites, each of which is specific for a different antigenic determinant.
  • the bispecific antibody and/or antigen binding molecule is capable of binding two antigenic determinants simultaneously, particularly two antigenic determinants expressed on two different cells.
  • monoclonal antibody refers to a population of identical antibodies, meaning that each individual antibody molecule in the monoclonal antibody population is identical to other antibody molecules. This property is in contrast to that of polyclonal populations of antibodies, which comprise antibodies with a variety of different sequences.
  • Monoclonal antibodies can be prepared by a number of well-known methods (Smith et al. (2004) J. Clin. Pathol. 57, 912-917; and Nelson et al., J Clin Pathol (2000), 53, 111-117).
  • monoclonal antibodies can be prepared by immortalizing B cells, eg, by fusion with myeloma cells to generate hybridoma cell lines or by infecting B cells with a virus such as EBV.
  • Recombinant techniques can also be used to prepare antibodies from clonal populations of host cells in vitro by transforming the host cells with a plasmid carrying an artificial sequence of nucleotides encoding the antibody.
  • hybridomas refers to a cell or cell line (usually myeloma or lymphoma cells) produced by fusing antibody-producing lymphocytes and non-antibody-producing cancer cells.
  • hybridomas can proliferate and provide continuous supply to produce specific monoclonal antibodies. Methods for generating hybridomas are known in the art.
  • hybridomas When referring to the term “hybridoma” or “hybridoma cell”, it also includes subclones and progeny cells of hybridomas.
  • a full-length antibody is one that has two full-length heavy chains (eg, VH-CH1-CH2-CH3 or VH-CH1-CH2-CH3-CH4) and two full-length light chains (VL-CL) and a hinge region antibodies, such as those naturally produced by antibody-secreting B cells and those produced synthetically with the same domains.
  • chimeric antibody refers to an antibody in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody of antibodies.
  • Humanized antibodies refer to non-human (eg, mouse) forms of antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (eg, Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) containing minimal sequence derived from non-human immunoglobulins.
  • the humanized antibody is a human immunoglobulin (recipient antibody) in which the complementarity determining region (CDR) residues of the recipient antibody are derived from a non-human species with the desired specificity, affinity and capacity ( donor antibody) such as mouse, rat or rabbit CDR residue substitutions.
  • CDR complementarity determining region
  • telomeres can be mutated amino acid residues within the CDR1, CDR2 and/or CDR3 regions of VH and/or VL, thereby improving one or more binding properties (eg, affinity) of the antibody .
  • PCR-mediated mutagenesis can be performed to introduce mutations whose effect on antibody binding or other functional properties can be assessed using the in vitro or in vivo assays described herein. Typically, conservative mutations are introduced. Such mutations can be amino acid substitutions, additions or deletions.
  • CDR refers to a complementarity-determining region
  • each of the heavy and light chains of antibody molecules is known to have 3 CDRs.
  • the CDRs are also referred to as hypervariable regions, and are present in the variable regions of each heavy and light chain of antibodies, with sites of very high variability in the primary structure of the CDRs.
  • the CDRs of the heavy chain are represented by CDR1, CDR2, and CDR3 derived from the amino terminal of the amino terminal sequence of the heavy chain
  • CDRs of the light chain are represented by CDR1, CDR2, and CDR3 derived from the amino terminal of the amino terminal sequence of the light chain.
  • epitopic determinants refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.
  • Epitopic determinants typically comprise chemically active surface profiles of molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural characteristics as well as specific charge characteristics.
  • an antibody that immunospecifically binds (or specifically binds) an antigen has an affinity constant Ka of about or 1 ⁇ 10 7 M -1 or 1 ⁇ 10 8 M -1 or greater (or 1 ⁇ 10-7 M or 1 ⁇ 10 ⁇ 8 M or lower dissociation constant (Kd)) binds to the antigen.
  • Affinity constants can be determined by standard kinetic methods of antibody responses, eg, immunoassays, surface plasmon resonance (SPR) (Rich and Myszka (2000) Curr. Opin. Biotechnol 11:54; Englebienne (1998) Analyst. 123: 1599), isothermal titration calorimetry (ITC), or other kinetic interaction assays known in the art; see also U.S. Pat. No. 7,229,619 describing exemplary SPR and ITC methods for calculating binding affinity of antibodies No).
  • SPR surface plasmon resonance
  • ITC isothermal titration calorimetry
  • nucleic acid molecules refer to an oligomer or polymer comprising at least two linked nucleotides or nucleotide derivatives, including usually linked together by phosphodiester bonds Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • nucleic acid molecule is intended to include DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, and can be cDNA.
  • an isolated nucleic acid molecule is one that is separated from other nucleic acid molecules present in the natural source of the nucleic acid molecule.
  • An "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material or culture medium when prepared by recombinant techniques, or substantially free of chemical precursors or other chemical components when chemically synthesized.
  • Exemplary isolated nucleic acid molecules provided herein include isolated nucleic acid molecules encoding the provided antibodies or antigen-binding fragments.
  • operably linked in reference to nucleic acid sequences, regions, elements or domains means that the nucleic acid regions are functionally related to each other.
  • a promoter can be operably linked to a nucleic acid encoding a polypeptide such that the promoter regulates or mediates transcription of the nucleic acid.
  • conservative sequence modifications of the sequences described in the Sequence Listing described herein, ie, nucleotide and amino acid sequence modifications that do not eliminate binding of the antibody to the antigen encoded by the nucleotide sequence or containing the amino acid sequence.
  • conservative sequence modifications include conservative nucleotide and amino acid substitutions and nucleotide and amino acid additions and deletions.
  • modifications can be introduced into the Sequence Listing described herein by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative sequence modifications include conservative amino acid substitutions in which amino acid residues are replaced with amino acid residues having similar side chains. Families of amino acid residues with similar side chains are defined in the art.
  • amino acids with basic side chains eg, lysine, arginine, histidine
  • amino acids with acidic side chains eg, aspartic acid, glutamic acid
  • amino acids with uncharged polar side chains amino acids e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
  • amino acids with non-polar side chains e.g. alanine, valine
  • leucine, isoleucine, proline, phenylalanine, methionine amino acids with beta branched side chains
  • a predicted non-essential amino acid residue in an anti-BCMA antibody is preferably replaced by another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of nucleotides and amino acids that do not abolish antigen binding are well known in the art (for example, see Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al., Protein Eng. 12 ( 10): 879-884 (1999); Burks et al., Proc. Natl. Acad. Sci. USA 94: 412-417 (1997)).
  • mutations can be introduced randomly along all or a portion of the anti-BCMA antibody coding sequence, eg, by saturation mutagenesis, and the resulting modified anti-BCMA antibodies can be screened for improved binding activity.
  • expression refers to the process by which a polypeptide is produced by transcription and translation of a polynucleotide. Expression levels of a polypeptide can be assessed using any method known in the art, including, for example, methods that determine the amount of polypeptide produced from a host cell. Such methods may include, but are not limited to, quantification of polypeptides in cell lysates by ELISA, Coomassie blue staining followed by gel electrophoresis, Lowry protein assay, and Bradford protein assay.
  • a "host cell” is a cell used to receive, maintain, replicate and amplify a vector. Host cells can also be used to express the polypeptide encoded by the vector. When the host cell divides, the nucleic acid contained in the vector replicates, thereby amplifying the nucleic acid.
  • Host cells can be eukaryotic cells or prokaryotic cells. Suitable host cells include, but are not limited to, CHO cells, various COS cells, HeLa cells, HEK cells such as HEK 293 cells.
  • a "vector" is a replicable nucleic acid from which one or more heterologous proteins can be expressed when transformed into an appropriate host cell.
  • References to vectors include those into which nucleic acids encoding polypeptides or fragments thereof can be introduced, typically by restriction digestion and ligation. References to vectors also include those that contain nucleic acid encoding a polypeptide. Vectors are used to introduce nucleic acid encoding a polypeptide into a host cell, to amplify the nucleic acid, or to express/display the polypeptide encoded by the nucleic acid. Vectors generally remain episomal, but can be designed to integrate the gene or portion thereof into the chromosome of the genome. Also contemplated are artificial chromosome vectors, such as yeast artificial vectors and mammalian artificial chromosomes. The selection and use of such vehicles is well known to those skilled in the art.
  • a vector also includes a "viral vector” or “viral vector.”
  • a viral vector is an engineered virus that is operably linked to a foreign gene to transfer (either as a vehicle or shuttle) the foreign gene into a cell.
  • an "expression vector” includes a vector capable of expressing DNA operably linked to regulatory sequences, such as promoter regions, capable of affecting the expression of such DNA fragments. Such additional fragments may include promoter and terminator sequences, and optionally, one or more origins of replication, one or more selectable markers, enhancers, polyadenylation signals, and the like. Expression vectors are typically derived from plasmid or viral DNA, or may contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, phage, recombinant virus, or other vector, which, when introduced into an appropriate host cell, results in the expression of cloned DNA. Appropriate expression vectors are well known to those skilled in the art and include those that are replicable in eukaryotic and/or prokaryotic cells as well as those that remain episomal or that integrate into the host cell genome.
  • treating an individual with a disease or condition means that the individual's symptoms are partially or completely alleviated, or remain unchanged following treatment.
  • treatment includes prevention, treatment and/or cure.
  • Prevention refers to preventing an underlying disease and/or preventing the worsening of symptoms or the development of a disease.
  • Treatment also includes any provided antibodies or antigen-binding fragments thereof and any pharmaceutical uses of the compositions provided herein.
  • therapeutic effect refers to an effect resulting from treatment of an individual that alters, generally ameliorates or ameliorates the symptoms of a disease or condition, or cures the disease or condition.
  • a “therapeutically effective amount” or “therapeutically effective dose” refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is an amount necessary to prevent, cure, ameliorate, retard or partially retard the symptoms of a disease or disorder.
  • a prophylactically effective amount or “prophylactically effective dose” refers to an amount of a substance, compound, material or composition comprising a compound that, when administered to a subject, will have the desired prophylactic effect, eg, prevent or delay a disease or symptom occurrence or recurrence, and reduce the likelihood of occurrence or recurrence of disease or symptoms.
  • a fully prophylactically effective dose need not occur by administering one dose, and may occur only after administering a series of doses. Thus, a prophylactically effective amount can be administered in one or more administrations.
  • the term "patient” refers to a mammal, such as a human.
  • the present disclosure provides a bispecific antibody, or antigen-binding portion thereof, comprising:
  • a first antigen-binding portion or antigen-binding fragment thereof of a BCMA antigen that binds to the surface of a target cell comprising a first heavy chain and a first light chain
  • the first antigen-binding portion comprising a Combined first binding domain
  • the first binding domain comprises amino acid sequence selected from SEQ ID NO: 12, 13, 14, 26, 27, 28, 36, 37, 43, 44, 50, 55, 56, Heavy chain CDRs of 57, 65, 66, 71, 72, 73, 147 or any variant thereof, and/or selected from the amino acid sequence SEQ ID NO: 17, 18, 19, 22, 23, 31, 32, 33, 40, 47, 60, 61, 62, 76, 77, 78, 83, 84, 87, 88, 89, 92, 144 or the light chain CDRs of any variant; and
  • a second antigen-binding portion or antigen-binding fragment thereof that binds to the CD3 antigen on the surface of the T cell comprising a second heavy chain and a second light chain, the second antigen-binding portion comprising a second antigen-binding portion Binding of the second binding domain.
  • the first binding domain comprises a heavy chain CDR1 selected from the amino acid sequence SEQ ID NO: 12, 26, 55, 65, 71 or any variant thereof, selected from the amino acid sequence SEQ ID NO: 12, 26, 55, 65, 71 or any variant thereof Heavy chain CDR2 of ID NO: 13, 27, 36, 43, 50, 56, 66, 72, 147 or any variant thereof, selected from the amino acid sequence SEQ ID NO: 14, 28, 37, 44, 57, 73 or The heavy chain CDR3 of any variant thereof; and/or the first binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 22, 31, 47, 60, 76, 83, 87, 92, 144 or any variant thereof
  • the light chain CDR1 is selected from the light chain CDR2 of the amino acid sequence SEQ ID NO: 18, 23, 32, 40, 61, 77, 84, 88 or any variant thereof, selected from the amino acid sequence SEQ ID NO: 19, 33, Light chain CDR3
  • the heavy chain CDR1, CDR2 and CDR3 sequences of the first binding domain are selected from the group consisting of: the first heavy chain CDR1, CDR2 and CDR3 sequence, first heavy chain CDR1, CDR2 and CDR3 sequence of amino acid sequence SEQ ID NO: 26, 27, 28, first heavy chain CDR1, CDR2 and CDR3 sequence of amino acid sequence SEQ ID NO: 12, 36, 37, amino acid
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 13, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 17, 18, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 13, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 22, 23, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 26, 27, 28, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 31, 32, 33 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 36, 37, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 17, 40, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 43, 44, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 47, 18, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 50, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 17, 40, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of amino acid sequences SEQ ID NOs: 55, 56, 57, and the first heavy chain CDR1, CDR2 and CDR3 sequences comprising amino acid sequences of SEQ ID NOs: 60, 61, 62 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences SEQ ID NOs: 12, 13, 14, and the first heavy chain CDR1, CDR2 and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 17, 40, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 65, 66, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 17, 40, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2, and CDR3 sequences of amino acid sequences SEQ ID NOs: 71, 72, 73, and the first heavy chain CDR1, CDR2, and CDR3 sequences comprising amino acid sequences of SEQ ID NOs: 76, 77, 78 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 13, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 83, 84, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 13, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 87, 88, 89 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 12, 13, 14, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 92, 23, 19 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises the first heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences of SEQ ID NOs: 71, 147, 73, and the first heavy chain comprising the amino acid sequences of SEQ ID NOs: 144, 77, 78 A light chain CDR1, CDR2 and CDR3 sequence.
  • the first binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 24, 34, 41, 48, 53, 63, 69, 79, 145, 150, 154 , 158, 162, 166, 170 or the first heavy chain variable region of any variant thereof, and/or comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15, 20, 29, 38, 45, 51, 58, 67, 74, 81, 85, 90, 142, 148, 152, 156, 160, 164, 168, or the first light chain variable region of any variant thereof.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 10 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 15 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 10 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 20 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 24 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 29 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 34 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 38 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO:41 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO:45 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 48 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 51 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO:53 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO:58 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 10 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 38 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO:63 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO:67 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO:69 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO:74 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO:79 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO:81 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 10 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 85 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 10 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 90 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 145 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 142 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 150 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 148 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 154 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 152 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 158 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 156 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 162 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 160 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 166 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 164 or any variant thereof chain variable region.
  • the first binding domain comprises the first heavy chain variable region of amino acid sequence SEQ ID NO: 170 or any variant thereof, and the first light chain of amino acid sequence SEQ ID NO: 168 or any variant thereof chain variable region.
  • the second binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 114, 115, 116, 119, 122, 125, 128, 131, 134, 135 or any variation thereof and/or a light chain CDR selected from the amino acid sequence of SEQ ID NO: 95, 96, 97, 102, 103, 108, 111 or any variant thereof.
  • the second binding domain comprises a second heavy chain CDRl selected from the amino acid sequence of SEQ ID NO: 114, 119, 134 or any variant thereof, selected from the amino acid sequence of SEQ ID NO: 115, 135 or its
  • the heavy chain CDR1, CDR2 and CDR3 sequences of the second binding domain are selected from the group consisting of: the second heavy chain CDR1, CDR2 and CDR3 sequences of amino acid sequences SEQ ID NOs: 114, 115, 116, amino acid sequence SEQ ID NOs: 114, 115, 116
  • the second binding domain comprises the second heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences SEQ ID NOs: 114, 115, 116, and the second heavy chain CDR1, CDR2 and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 95, 96, 97 Two light chain CDR1, CDR2 and CDR3 sequences.
  • the second binding domain comprises the second heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences SEQ ID NOs: 114, 115, 116, and the second heavy chain CDR1, CDR2 and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 102, 103, 97 Two light chain CDR1, CDR2 and CDR3 sequences.
  • the second binding domain comprises the second heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences SEQ ID NOs: 114, 115, 116, and the second heavy chain CDR1, CDR2 and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 95, 96, 108 Two light chain CDR1, CDR2 and CDR3 sequences.
  • the second binding domain comprises the second heavy chain CDR1, CDR2 and CDR3 sequences of the amino acid sequences SEQ ID NOs: 114, 115, 116, and the second heavy chain CDR1, CDR2 and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 95, 111, 108 Two light chain CDR1, CDR2 and CDR3 sequences.
  • the second binding domain comprises a second heavy chain selectable from the amino acid sequence of SEQ ID NO: 112, 117, 120, 123, 126, 129, 132, 136, 138, 140, or any variant thereof.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 136 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 93 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 138 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 93 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 138 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 98 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 138 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 100 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 112 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 106 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 136 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 106 or any variant thereof chain variable region.
  • the second binding domain comprises a second heavy chain variable region of amino acid sequence SEQ ID NO: 138 or any variant thereof, and a second light chain variable region of amino acid sequence SEQ ID NO: 106 or any variant thereof chain variable region.
  • first light chain of the first antigen-binding portion is a kappa-type light chain
  • second light chain of the second antigen-binding portion is a ⁇ -type light chain
  • the second light chain variable region of the second antigen-binding portion has a Gln 40 Glu mutation ( V ⁇ CD3 :Gln 40 Glu); the second heavy chain variable region of the second antigen-binding portion has Gln 39 Lys Mutation (VH CD3 :Gln 39 Lys).
  • the first light chain variable region of the first antigen-binding portion has a Gln 42 Lys mutation (V ⁇ BCMA : Gln 42 Lys)
  • the first heavy chain variable region of the first antigen-binding portion has a Gln 42 Lys mutation
  • the region has a Gln 39 Glu mutation (VH BCMA : Gln 39 Glu).
  • the Fc portion of the first antigen-binding portion of the bispecific antibody and the Fc portion of the second antigen-binding portion employ a knob-into-hole structure.
  • the Fc portion adopts a human IgG4 knob-into-hole structure.
  • the first heavy chain comprises a heavy chain selected from the group consisting of SEQ ID NOs: 174, 178, or any variant thereof
  • the first light chain comprises a light chain selected from the group consisting of SEQ ID NOs: 172, 176, or any variant thereof chain.
  • the first heavy chain comprises a heavy chain selected from SEQ ID NO: 174 or any variant thereof
  • the first light chain comprises a light chain selected from SEQ ID NO: 172 or any variant thereof.
  • the first heavy chain comprises a heavy chain selected from SEQ ID NO: 174 or any variant thereof
  • the first light chain comprises a light chain selected from SEQ ID NO: 176 or any variant thereof.
  • the first heavy chain comprises a heavy chain selected from SEQ ID NO: 178 or any variant thereof
  • the first light chain comprises a light chain selected from SEQ ID NO: 172 or any variant thereof.
  • the first heavy chain comprises a heavy chain selected from SEQ ID NO: 178 or any variant thereof
  • the first light chain comprises a light chain selected from SEQ ID NO: 176 or any variant thereof.
  • the second heavy chain comprises the heavy chain of SEQ ID NO: 182, or any variant thereof
  • the second light chain comprises the light chain of SEQ ID NO: 180, or any variant thereof.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 145 or any variant thereof, and the amino acid sequence SEQ ID NO: 142 or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 150 or any variant thereof, and the amino acid sequence SEQ ID NO: 148 or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence of SEQ ID NO: 154 or any variant thereof, and the amino acid sequence of SEQ ID NO: 152 or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 158 or any variant thereof, and the amino acid sequence SEQ ID NO: 156 or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 162, or any variant thereof, and the amino acid sequence SEQ ID NO: 160, or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 166 or any variant thereof, and the amino acid sequence SEQ ID NO: 164 or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof The second light chain variable region of the variant.
  • the first binding domain of the bispecific antibody comprises the first heavy chain variable region of the amino acid sequence SEQ ID NO: 170, or any variant thereof, and the amino acid sequence SEQ ID NO: 168, or the first heavy chain variable region thereof The first light chain variable region of any variant;
  • the second binding domain comprises the second heavy chain variable region of the amino acid sequence SEQ ID NO: 138 or any variant thereof, and the amino acid sequence SEQ ID NO: 106 or any thereof the second light chain variable region of the variant;
  • the first heavy chain comprises SEQ ID NO: 174
  • the first light chain of the bispecific antibody comprises SEQ ID NO: 172
  • the second heavy chain comprises SEQ ID NO: 182
  • the second light chain comprises SEQ ID NO: 180.
  • the first heavy chain comprises SEQ ID NO: 174
  • the first light chain of the bispecific antibody comprises SEQ ID NO: 176
  • the second heavy chain comprises SEQ ID NO: 182
  • the second light chain comprises SEQ ID NO: 180.
  • the first heavy chain comprises SEQ ID NO: 178
  • the first light chain of the bispecific antibody comprises SEQ ID NO: 172
  • the second heavy chain comprises SEQ ID NO: 182
  • the second light chain comprises SEQ ID NO: 180.
  • the first heavy chain comprises SEQ ID NO: 178
  • the first light chain of the bispecific antibody comprises SEQ ID NO: 176
  • the second heavy chain comprises SEQ ID NO: 182
  • the second light chain comprises SEQ ID NO: 180.
  • the present disclosure provides an antibody or antigen-binding portion thereof that binds BCMA, the antibody comprising the aforementioned first antigen-binding portion.
  • the antibody or antigen-binding portion thereof that binds BCMA is at least greater than 60%, 65%, 70%, 75%, 80%, 85%, 90% of the antibody or antigen-binding portion thereof of any of the preceding aspects , 95%, 96%, 97%, 98%, 99% or higher sequence identity.
  • the present disclosure provides nucleic acids encoding, or having at least greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, Nucleic acid molecules of 95%, 96%, 97%, 98%, 99% or higher sequence identity.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen binding portion is selected from the group consisting of the nucleotide sequences SEQ ID NOs: 11, 25, 35, 42, 49, 54, 64, 70, 80, 146, 151, 155, 159, 163, 167, 171 or any variant thereof; and/or the nucleic acid encoding the first light chain variable region of the first antigen-binding portion is selected from the group consisting of nucleotide sequences SEQ ID NO: 16, 21, 30, 39, 46, 52, 59, 68, 75, 82, 86, 91, 143, 149, 153, 157161, 165, 169 or any variation thereof.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 11; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 16.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 11; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:21.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 25; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:30.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 35; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:39.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 42; and the nucleic acid encoding the first light chain variable region is nucleotides Sequence SEQ ID NO:46.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 49; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:52.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 54; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:59.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 11; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:39.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 64; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:68.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 70; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:75.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 80; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:82.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 11; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:86.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 11; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO:91.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 146; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 143.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 151; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 149.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 155; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 153.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 159; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 157.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 163; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence SEQ ID NO: 163; Sequence SEQ ID NO: 161.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 167; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence Sequence SEQ ID NO: 165.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 171; and the nucleic acid encoding the first light chain variable region is the nucleotide sequence SEQ ID NO: 171; Sequence SEQ ID NO: 169.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion is selected from the group consisting of the nucleotide sequences of SEQ ID NO: 175, 179, or any variant thereof; and/or the first light chain of the first antigen-binding portion
  • the nucleic acid encoding the strand is selected from the nucleotide sequences of SEQ ID NO: 173, 177 or any variant thereof.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 175, and the nucleic acid encoding the first light chain of the first antigen-binding portion is nucleotides Sequence SEQ ID NO: 173.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 175, and the nucleic acid encoding the first light chain of the first antigen-binding portion is nucleotides Sequence SEQ ID NO: 177.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 179, and the nucleic acid encoding the first light chain of the first antigen-binding portion is nucleotides Sequence SEQ ID NO: 173.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion is the nucleotide sequence of SEQ ID NO: 179, and the nucleic acid encoding the first light chain of the first antigen-binding portion is nucleotides Sequence SEQ ID NO: 177.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen binding portion is selected from the group consisting of the nucleotide sequences SEQ ID NOs: 113, 118, 121, 124, 127, 130, 133, 137, 139, 141 or any variant thereof; and/or the nucleic acid encoding the second light chain variable region of the second antigen binding moiety is selected from the nucleotide sequences of SEQ ID NOs: 94, 99, 101, 105, 107, 110 or any thereof Variants.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 137; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 137; Sequence SEQ ID NO:94.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 139; Sequence SEQ ID NO:94.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 139; Sequence SEQ ID NO:99.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 139; Sequence SEQ ID NO: 101.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 113; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 113; Sequence SEQ ID NO: 107.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 137; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 137; Sequence SEQ ID NO: 107.
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence SEQ ID NO: 139; Sequence SEQ ID NO: 107.
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 183, or any variant thereof; and/or the encoding of the second light chain of the second antigen-binding portion
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 181 or any variant thereof.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 146; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 143;
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139;
  • the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 151; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 149;
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139;
  • the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 155; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 153; the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 159; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 157;
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139;
  • the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 163; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 161; the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 167; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 165;
  • the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139;
  • the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the first heavy chain variable region of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 171; and the encoding of the first light chain variable region
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 169; the nucleic acid encoding the second heavy chain variable region of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 139; and the nucleic acid encoding the second light chain variable region is the nucleotide sequence of SEQ ID NO: 107.
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 183, and the nucleic acid encoding the second light chain of the second antigen-binding portion is nucleotides Sequence SEQ ID NO: 181.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 175, and the nucleic acid encoding the first light chain of the first antigen-binding portion
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 173
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 183
  • the nucleic acid encoding the second light chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 181.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 175, and the nucleic acid encoding the first light chain of the first antigen-binding portion
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 177
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 183
  • the nucleic acid encoding the second light chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 181.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 179, and the nucleic acid encoding the first light chain of the first antigen-binding portion
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 173
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 183
  • the nucleic acid encoding the second light chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 181.
  • the nucleic acid encoding the first heavy chain of the first antigen-binding portion of the bispecific antibody is the nucleotide sequence of SEQ ID NO: 179, and the nucleic acid encoding the first light chain of the first antigen-binding portion
  • the nucleic acid is the nucleotide sequence of SEQ ID NO: 177
  • the nucleic acid encoding the second heavy chain of the second antigen-binding portion is the nucleotide sequence of SEQ ID NO: 183
  • the nucleic acid encoding the second light chain of the second antigen-binding portion is the nucleotide sequence SEQ ID NO: 181.
  • the present disclosure provides an antibody or antigen-binding portion thereof that binds BCMA, the antibody comprising the aforementioned first antigen-binding portion.
  • the present disclosure provides vectors comprising the aforementioned nucleic acids.
  • the present disclosure provides cells comprising the aforementioned nucleic acids or vectors.
  • compositions comprising the aforementioned bispecific antibodies or antigen-binding portions thereof, nucleic acids, vectors, and/or cells.
  • the present disclosure provides antibody-drug conjugates comprising the aforementioned bispecific antibodies, or antigen-binding portions thereof, covalently attached to a therapeutic moiety.
  • the therapeutic moiety is selected from cytotoxic moieties, chemotherapeutic agents, cytokines, immunosuppressive agents, immunostimulatory agents, lytic peptides or radioisotopes.
  • the antibodies of the present disclosure are useful as therapeutic or diagnostic tools in various diseases in which BCMA is unfavorably expressed or found.
  • the expression of BCMA in cells of a diseased tissue or organ is increased compared to the state in a healthy tissue or organ.
  • To increase means to increase by at least 10%, especially at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, at least 1000%, at least 10000% or even more.
  • expression is found only in diseased tissue, whereas expression in corresponding healthy tissue is suppressed.
  • diseases associated with BCMA include B cell diseases, eg, B cell disorders, such as plasma cell disorders and/or autoimmune diseases.
  • the disease condition is cancer.
  • the cancer is a B-cell associated cancer selected from the group consisting of multiple myeloma, malignant plasmacytoma, Hodgkin's lymphoma, nodular lymphocyte-predominant Hodgkin's lymphoma, Kahler's disease, and Myeloid leukemia, plasma cell leukemia, plasmacytoma, B-cell prolymphocytic leukemia, hairy cell leukemia, B-cell non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), chronic lymphocytic leukemia ( CLL), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), follicular lymphoma, Burkitt lymphoma, marginal zone lymphoma, mantle cell lymphoma, large cell lymphoma, precursor B- Lymphocytic lymphoma, myeloid leukemia, Waldenstrom's macro
  • M-proteins In plasma cell disorder, a single clone of plasma cells reproduces uncontrollably. As a result, this clone produces a large number of single (monoclonal) antibodies called M-proteins. In some cases, such as with monoclonal gammopathy, the antibody produced is incomplete, consisting only of light or heavy chains. These abnormal plasma cells and the antibodies they produce are usually limited to one type.
  • the plasma cell disorder is selected from the group consisting of: multiple myeloma, plasmacytoma, plasma cell leukemia, macroglobulinemia, amyloidosis, Waldenstrom's macroglobulinemia, solitary plasmacytoma of bone, extramedullary plasma cells tumor, sclerosing myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.
  • the disease condition is an autoimmune disorder, such as systemic lupus erythematosus or rheumatoid arthritis.
  • the therapeutic agent comprises an antibody that specifically binds an activating T cell antigen.
  • the therapeutic agent comprises an antibody that specifically binds CD3, particularly CD3 ⁇ .
  • Methods of treating diseases and symptoms with the bispecific antibodies of the present disclosure include the steps of administering to a mammal a therapeutically effective amount of an antibody or antigen-binding fragment or nucleic acid molecule or vector or cell or pharmaceutical composition of any of the foregoing aspects.
  • the present disclosure provides a method of treating or preventing a cancer disease comprising administering to a patient an antibody capable of binding BCMA, wherein the antibody is administered to provide a serum level of at least 40 ⁇ g/ml.
  • the antibody is administered to provide serum levels of at least 50 ⁇ g/ml, at least 150 ⁇ g/ml, at least 300 ⁇ g/ml, at least 400 ⁇ g/ml, or at least 500 ⁇ g/ml.
  • the antibody is administered to provide a serum level of no more than 800 ⁇ g/ml, 700 ⁇ g/ml, 600 ⁇ g/ml, 550 ⁇ g/ml or 500 ⁇ g/ml.
  • the provided serum level is 40 ⁇ g/ml to 700 ⁇ g/ml, preferably 40 ⁇ g/ml to 600 ⁇ g/ml, preferably 50 ⁇ g/ml to 500 ⁇ g/ml, such as 150 ⁇ g/ml to 500 ⁇ g/ml or 300 ⁇ g /ml to 500 ⁇ g/ml.
  • serum level as used in this specification means the concentration of the substance in question in serum.
  • serum levels are provided for at least 7 days or for at least 14 days.
  • the method comprises administering an antibody dose of at least 300 mg/m 2 , such as at least 600 mg/m 2 , and preferably at most 1500 mg/m 2 , at most 1200 mg/m 2 or at most 1000 mg/m 2 .
  • the present disclosure provides a method of treating or preventing a cancer disease, comprising administering to a patient an antibody capable of binding BCMA at at least 300 mg/m 2 , such as at least 600 mg/m 2 , and preferably at most 1500 mg/m 2 , the antibody is administered at a dose of up to 1200 mg/m 2 or up to 1000 mg/m 2 .
  • the present disclosure provides a method of treating or preventing a cancer disease comprising administering to a patient an antibody capable of binding BCMA, wherein at least 50%, preferably 60%, 70%, 80% or 90% of the patient has cancer
  • the cells are positive for BCMA and/or at least 40%, preferably 50% or 60% of the cancer cells of the patient are positive for surface expression of BCMA.
  • the present disclosure also provides a method of treating or preventing a cancer disease, the method comprising: a. identifying at least 50%, preferably 60%, 70%, 80% or 90% of BCMA positive cancer cells and/or at least 40% %, preferably 50% or 60% of the patient with cancer cells that are positive for surface expression of BCMA; and b. administering to the patient an antibody capable of binding BCMA.
  • at least 95% or at least 98% of the cancer cells of the patient are BCMA positive.
  • at least 70%, at least 80% or at least 90% of the cancer cells of the patient are positive for surface expression of BCMA.
  • the outcome of the treatment of the cancer disease is the achievement of stable disease.
  • disease stabilization is achieved for at least 2 months, at least 3 months, or at least 6 months.
  • the present disclosure provides a method of achieving stabilization of a cancer patient comprising administering to the patient an antibody capable of binding BCMA.
  • disease stabilization is achieved for at least 2 months, at least 3 months, or at least 6 months.
  • the antibody is administered in a single dose or multiple doses.
  • the present disclosure provides a method of treating or preventing a cancer disease comprising administering to a patient an antibody capable of binding BCMA, wherein the antibody is administered in multiple doses.
  • the antibody is administered in multiple doses according to the present disclosure, preferably at least 3 doses, at least 4 doses, at least 5 doses, at least 6 doses, at least 7 doses, at least 8 doses, at least 9 doses, or at least 9 doses
  • the antibody is administered in 10 doses and preferably up to 30 doses, 25 doses, 20 doses, 15 doses or 10 doses.
  • Doses of the antibody are preferably administered at intervals of at least 7 days, at least 10 days, at least 14 days, or at least 20 days.
  • Doses of antibody are preferably administered at intervals of 7 to 30 days, 10 to 20 days, and preferably about 14 days.
  • the antibody is administered so as to provide a serum level of at least 40 ⁇ g/ml. In various embodiments, the antibody is administered so as to provide serum levels of at least 50 ⁇ g/ml, at least 150 ⁇ g/ml, at least 300 ⁇ g/ml, at least 400 ⁇ g/ml, or at least 500 ⁇ g/ml. In various embodiments, the antibody is administered so as to provide serum levels of no more than 800 ⁇ g/ml, 700 ⁇ g/ml, 600 ⁇ g/ml, 550 ⁇ g/ml or 500 ⁇ g/ml.
  • the provided serum level is 40 ⁇ g/ml to 700 ⁇ g/ml, preferably 40 ⁇ g/ml to 600 ⁇ g/ml, preferably 50 ⁇ g/ml to 500 ⁇ g/ml, such as 150 ⁇ g/ml to 500 ⁇ g/ml or 300 ⁇ g /ml to 500 ⁇ g/ml.
  • serum levels are provided for at least 7 days or for at least 14 days.
  • the method comprises administering a dose of the antibody of at least 300 mg/m 2 , such as at least 600 mg/m 2 and preferably at most 1500 mg/m 2 , at most 1200 mg/m 2 or at most 1000 mg/m 2 .
  • the antibody is optionally conjugated to other drugs, such as labeled or cytotoxic conjugates.
  • kits comprising antibodies of the present disclosure, fragments, homologues, derivatives thereof, etc., eg, labeled or cytotoxic conjugates, as well as instructions for use of the antibodies, killing Conjugates to dead specific cell types and more.
  • the instructions may include instructions for using the antibody, conjugate, etc. in vitro, in vivo or ex vivo.
  • Antibodies can be in liquid form or solid, usually lyophilized.
  • the kit may contain other suitable reagents, such as buffers, reconstitution solutions, and other necessary components for the intended use. Packaged reagent combinations in predetermined quantities are contemplated along with instructions for their use, eg, for therapeutic use or for performing diagnostic assays.
  • the kit may include a substrate and cofactors required by the enzyme (eg, a substrate precursor that provides a detectable chromophore or fluorophore).
  • a substrate precursor that provides a detectable chromophore or fluorophore e.g., a substrate precursor that provides a detectable chromophore or fluorophore.
  • other additives such as stabilizers, buffers (eg, blocking buffers or lysis buffers), etc., may also be included.
  • the relative amounts of the various reagents can be varied to provide concentrates of reagent solutions, which provides user flexibility, space savings, reagent savings, and the like.
  • These reagents can also be provided in dry powder form, usually lyophilized, including excipients which, when dissolved, provide a solution of the reagents of appropriate concentrations.
  • antibodies of the present disclosure can also be used in immunoassays, purification methods, and other methods using immunoglobulins or fragments thereof. Such uses are well known in the art.
  • compositions comprising the anti-BCMA antibodies or fragments thereof of the present disclosure, the antibodies being conveniently combined with a pharmaceutically acceptable carrier, diluent or excipient, as is routine in the art.
  • the term "pharmaceutical composition” refers to a formulation of various preparations. Formulations containing a therapeutically effective amount of the multivalent antibody are in sterile liquid solutions, liquid suspensions, or lyophilized forms, optionally containing stabilizers or excipients.
  • the antibodies of the present disclosure can be used as compositions for administration alone, or can be used in combination with other active agents.
  • the humanized antibodies of the present disclosure are conjugated to a therapeutic moiety (ie, a drug).
  • Therapeutic moieties can be, for example, cytotoxins, chemotherapeutic agents, cytokines, immunosuppressive agents, immunostimulatory agents, lytic peptides, or radioisotopes.
  • conjugates are referred to herein as "antibody-drug conjugates" or "ADCs".
  • the antibody is conjugated to a cytotoxic moiety.
  • Cytotoxic moieties may, for example, be selected from the following: paclitaxel; cytochalasin B; gramicidin D; ethidium bromide; ipecine; mitomycin; etoposide; teniposide; vincristine; vinblastine ; Colchicine; Doxorubicin; Daunorubicin; F or its analogues or derivatives; Dolastatin 10 or 15 or its analogues; Irinotecan or its analogues; Mitoxantrone; corticosteroids; procaine; tetracaine; lidocaine; propranolol; puromycin; calicheamicin or its analogs or derivatives; antimetabolites such as methotrexate, 6-mercaptopurine , 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, sebadiazine, hydroxy
  • the antibody is conjugated to auristatin or a peptide analog, derivative or prodrug thereof.
  • Auristatin has been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cell division and has anticancer and antifungal activity.
  • auristatin E can be reacted with p-acetylbenzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively.
  • Other typical auristatin derivatives include AFP, MMAF (monomethyl auristatin F) and MMAE (monomethyl auristatin E).
  • Suitable auristatin and auristatin analogs, derivatives and prodrugs, as well as suitable linkers for conjugating auristatin to the Ab are described, for example, in US Pat. Nos. 5,635,483, 5,780,588 and 6,214,345 and International Patent Application Publication WO02088172 , WO2004010957, WO2005081711, WO2005084390, WO2006132670, WO03026577, WO200700860, WO207011968 and WO205082023.
  • the antibody is conjugated to pyrrolo[2,1-c][1,4]-benzodiazepine (PDB) or a peptide analog, derivative or prodrug thereof.
  • PDB pyrrolo[2,1-c][1,4]-benzodiazepine
  • Suitable PDBs and PDB derivatives and related techniques are described, for example, in Hartley J.A. et al., Cancer Res 2010; 70(17):6849-6858; Antonow D. et al., Cancer J 2008; 14(3):154-169; Howard P.W. et al, Bioorg Med Chem Lett 2009;19:6463-6466 and Sagnou et al, Bioorg Med Chem Lett 2000;10(18):2083-2086.
  • the antibody is conjugated to a cytotoxic moiety selected from the group consisting of anthracyclines, maytansines, calicheamicin, dukamycin, racheomycin (CC-1065), dolastatin 10.
  • a cytotoxic moiety selected from the group consisting of anthracyclines, maytansines, calicheamicin, dukamycin, racheomycin (CC-1065), dolastatin 10.
  • Dolastatin 15 irinotecan, monomethylauristatin E, monomethylauristatin F, PDB, or any analog, derivative or prodrug thereof.
  • the antibody is conjugated to an anthracycline or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to maytansine or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to calicheamicin or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to Dokamycin or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to Rachelmycin (CC-1065) or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to dolastatin 10 or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to dolastatin 15 or an analog, derivative or prodrug thereof.
  • the antibody is conjugated to monomethyl auristatin E or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to monomethylauristatin F or an analog, derivative or prodrug thereof. In some embodiments, the antibody is conjugated to a pyrrolo[2,1-c][1,4]-benzodiazepine or an analog, derivative, or prodrug thereof. In some embodiments, the antibody is conjugated to irinotecan or an analog, derivative or prodrug thereof.
  • the antibody is conjugated with a cytokine (eg, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL- 23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFN ⁇ , IFN ⁇ , IFN ⁇ , GM-CSF, CD40L, Flt3 ligand, stem cell factor, axigrastim and TNF ⁇ ) link.
  • a cytokine eg, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL- 23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFN ⁇ , IFN ⁇ , IFN ⁇ , GM-CSF, CD40L, Flt3 ligand, stem cell factor, axigrastim and TNF ⁇
  • the antibody is conjugated to a radioisotope or radioisotope-containing chelate.
  • the antibody can be conjugated to a chelator linker (eg, DOTA, DTPA, or tiracetam) that allows complexation of the antibody with the radioisotope.
  • Antibodies may also or alternatively contain or be conjugated to one or more radiolabeled amino acids or other radiolabeled molecules.
  • radioisotopes include3H , 14C , 15N , 35S , 90Y , 99Tc , 125I , 131I , 186Re , 213Bi , 225Ac , and227Th .
  • radioisotopes that emit beta or alpha particle radiation such as131I , 90Y , 211At , 212Bi , 67Cu , 186Re , 188Re and212Pb , can be used.
  • nucleic acid molecules are covalently linked to lysine or cysteine on the antibody through an N-hydroxysuccinimide ester or maleimide functional group, respectively.
  • Conjugation methods using engineered cysteines or incorporating unnatural amino acids have been reported to improve the homogeneity of the conjugates.
  • acyl-donor glutamine-containing tags eg Gin peptide-containing tags or Q-tags
  • polypeptide engineering eg by amino acid deletions, insertions, substitutions or mutations on polypeptides
  • Transglutaminase can then be covalently cross-linked with an amine-donating agent (eg, a small molecule comprising or linked to a reactive amine) to form a stable and homogeneous population of engineered Fc-containing polypeptide conjugates, wherein Amine donor agents are site-specifically coupled to Fc-containing polypeptides via an acyl-donor glutamine-containing tag or an accessible/exposed/reactive endogenous glutamine (WO2012059882).
  • an amine-donating agent eg, a small molecule comprising or linked to a reactive amine
  • the therapeutic agents according to the above-described embodiments will be administered with suitable pharmaceutically acceptable carriers, excipients, and other agents that are incorporated into the formulation to provide improved transfer, delivery, tolerability, and the like.
  • suitable pharmaceutically acceptable carriers, excipients, and other agents that are incorporated into the formulation to provide improved transfer, delivery, tolerability, and the like.
  • suitable formulations can be found in the pharmacopoeia known to all medicinal chemists: Remington's Pharmaceutical Sciences (15th edition, Mack Publishing Company, Easton, Pa. (1975)), especially Chapter 87 in Blaug, Seymour.
  • Such formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, lipid-containing (cationic or anionic) carriers (eg, Lipofectin TM ), DNA conjugates, anhydrous slurries, oil-in-water and water-in-oil emulsions, emulsion polyethylene glycols (polyethylene glycols of various molecular weights), semisolid gels, and semisolid mixtures containing polyethylene glycols. Any of the foregoing mixtures may be suitable for use in treatment or therapy according to the present disclosure, provided that the active ingredient in the formulation is not inactivated by the formulation and that the formulation is physiologically compatible and tolerated by the route of administration.
  • antibodies can be used as therapeutic agents. Such agents will typically be used to treat, alleviate and/or prevent a disease or pathology associated with aberrant BCMA expression, activity and/or signaling in a subject. Treatment regimens can be implemented using standard methods by identifying a subject, eg, a human patient having (or at risk or developing) a disease or disorder associated with aberrant BCMA expression, activity, and/or signaling, eg, a BCMA-related disorder.
  • An antibody preparation preferably one with high specificity and high affinity for its target antigen, is administered to a subject and will generally have an effect due to its binding to the target.
  • the administered antibody may abrogate or inhibit or interfere with the expression, activity and/or signaling function of the target (eg, BCMA).
  • Administered antibodies can eliminate or inhibit or prevent the target (eg, BCMA) from binding to the endogenous ligand to which it naturally binds.
  • target eg, BCMA
  • an antibody binds to a target and modulates, blocks, inhibits, reduces, antagonizes, neutralizes and/or otherwise interferes with BCMA expression, activity and/or signaling.
  • an antibody having heavy and light chain CDRs can be administered to a subject.
  • antibodies directed against BCMA can be used in methods known in the art related to the localization and/or quantification of BCMA (eg, for determining the level of BCMA and/or BCMA in an appropriate physiological sample, for diagnostic methods, for protein imaging, etc.).
  • an antibody specific for BCMA or a derivative, fragment, analog or homolog thereof, comprising an antigen-binding domain derived from an antibody is used as a pharmaceutically active compound (hereinafter referred to as "Therapeutic Agent").
  • BCMA polypeptides can be isolated by standard techniques such as immunoaffinity, chromatography or immunoprecipitation using antibodies specific for BCMA.
  • Antibodies to BCMA proteins (or fragments thereof) can be used to detect the proteins in biological samples.
  • BCMA can be detected in biological samples as part of a clinical testing procedure, eg, to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (ie, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase or acetylcholinesterase;
  • suitable prosthetic complexes include streptavidin/biotin and avidin/ Biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazine aminofluorescein, dansyl chloride, or phycoerythrin;
  • luminescent materials include Mino;
  • bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include125I, 131I , 35S , or3H .
  • antibodies according to the present disclosure can be used as reagents for detecting the presence of BCMA or protein fragments thereof in a sample.
  • the antibody comprises a detectable label.
  • the antibody is a polyclonal antibody, or more preferably a monoclonal antibody. Whole antibodies or fragments thereof (eg Fab, scFv or F(ab') 2 ) are used.
  • labeling in reference to an antibody is intended to include direct labeling of the antibody by conjugating (ie, physically linking) a detectable substance to the antibody, as well as indirect labeling of the antibody by reaction with another reagent that is directly labeled.
  • Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody, and end-labeling the antibody with biotin to enable detection with fluorescently-labeled streptavidin.
  • bio sample is intended to include tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells, and fluids present in a subject.
  • biological sample is used to include blood and fractions or components in blood, including serum, plasma, or lymph.
  • the detection methods of the above-described embodiments can be used to detect analyte mRNA, protein or genomic DNA in biological samples in vitro and in vivo.
  • in vitro detection techniques for analyte mRNA include Norhtern hybridization and in situ hybridization.
  • Analyte protein in vitro detection techniques include enzyme-linked immunosorbent assay (ELISA), Western blotting, immunoprecipitation, and immunofluorescence.
  • In vitro detection techniques for analyte genomic DNA include Southern hybridization. Procedures for performing immunoassays are described, for example, in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, JRCrowther (ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T.
  • in vivo detection techniques for analyte proteins include introducing into a subject a labeled anti-analyte protein antibody.
  • an antibody can be labeled with a radiolabel, and the presence and location of the radiolabel in a subject can then be detected by standard imaging techniques.
  • compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
  • the principles and considerations involved in preparing such compositions, as well as guidelines for selecting components, are well known in the art, see, for example, Remington's Pharmaceutical Sciences: The Science And Practice Of Pharmacy 19th Ed. (Edited by Alfonso R. Gennaro et al.) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, p. 4 volumes), 1991, M. Dekker, New York.
  • compositions typically comprise the antibody and a pharmaceutically acceptable carrier.
  • antibody fragments When antibody fragments are used, the smallest inhibitory fragment that specifically binds to the target protein binding domain may be preferred.
  • peptide molecules can be designed that retain the ability to bind target protein sequences. Such peptides can be chemically synthesized and/or produced by recombinant DNA techniques (see, eg, Marasco et al., Proc. Natl. Acad. Sci. USA, 90:7889-7893 (1993)).
  • the term "pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration .
  • Suitable pharmaceutically acceptable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard bibliography in the art, which is incorporated herein by reference.
  • Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Liposomes and non-aqueous vehicles, such as fixed oils, can also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. In addition to any conventional media or reagents that are incompatible with the antibody, its use in compositions is contemplated.
  • compositions of the above-described embodiments are formulated to be compatible with their intended route of administration.
  • routes of administration include parenteral, eg, intravenous, intradermal, subcutaneous, oral (eg, inhalation), transdermal (ie, topical), transmucosal, and rectal.
  • Solutions or suspensions for parenteral, intradermal or subcutaneous administration may include the following components: sterile injectable diluents such as water, saline solutions, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents; Antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate Or phosphate, and agents to adjust osmotic pressure, such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be packaged in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (herein water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • suitable pharmaceutically acceptable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that it is easy to inject. It must be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • Proper fluidity can be maintained, for example, by the use of coatings such as lecithin to maintain the desired particle size in the case of dispersions, and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents such as sugars, polyols (such as mannitol, sorbitol), sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the antibody in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by incorporating the antibody into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the methods of preparation are vacuum drying and freeze-drying to obtain a powder containing the active ingredient and any additional desired ingredient from a sterile-filtered solution of those previously enumerated. .
  • the compounds are delivered as an aerosol spray from a pressurized container or dispenser containing a gas of a suitable propellant, such as carbon dioxide, or a nebulizer.
  • a gas of a suitable propellant such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the permeation barrier are used in the formulation.
  • penetrants are generally known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • one or more antibodies can be formulated into an ointment, ointment, gel, or cream as generally known in the art.
  • the compounds can also be prepared for rectal delivery in the form of suppositories (eg, with conventional suppository bases such as cocoa butter or other glycerides) or retention enemas.
  • suppositories eg, with conventional suppository bases such as cocoa butter or other glycerides
  • retention enemas e.g., retention enemas.
  • the antibody may be prepared with a carrier that will prevent its rapid elimination from the body, such as a sustained/controlled release formulation, including implants and microencapsulated delivery systems.
  • a sustained/controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be apparent to those skilled in the art.
  • Dosage unit form refers to physically discrete units suitable as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier one or more antibodies.
  • the specifications for the dosage unit forms of the above-described embodiments are indicated by and are directly dependent on the unique characteristics of the antibody and the particular therapeutic effect to be achieved, and the limitations inherent in the art of formulation of such antibodies for the treatment of individuals.
  • compositions can be placed in a container, pack, or dispenser with instructions for administration.
  • compositions described herein may also contain more than one antibody, preferably those that have complementary activities but do not negatively affect each other, depending on the particular condition to be treated.
  • the composition may, for example, comprise an agent that enhances its function, such as a cytotoxic agent, a cytokine, a chemotherapeutic agent, or a growth inhibitory agent.
  • an agent that enhances its function such as a cytotoxic agent, a cytokine, a chemotherapeutic agent, or a growth inhibitory agent.
  • Such molecules are suitably combined in amounts effective for the intended purpose. For example, it can be combined in a kit, and can also be combined in use.
  • one or more antibodies may be administered in combination therapy, ie, with other agents such as therapeutic agents, which are useful in the treatment of pathological conditions or disorders, such as various forms of cancer, autoimmune disorders and inflammation sexually transmitted diseases) combined.
  • agents such as therapeutic agents, which are useful in the treatment of pathological conditions or disorders, such as various forms of cancer, autoimmune disorders and inflammation sexually transmitted diseases
  • the term "combination” as used herein refers to the administration of the agents substantially simultaneously, simultaneously or sequentially. If administered sequentially, at the start of administration of the second compound, the first of the two compounds is still preferably detected at an effective concentration at the treatment site. In one instance, “combination” can also be the simultaneous inclusion of an antibody of the present disclosure and other therapeutic agents in a kit.
  • a combination therapy can comprise one or more antibodies described herein with one or more additional therapeutic agents (eg, one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors) , enzyme inhibitors, and/or cytotoxins or cytostatics, as described in more detail below) are co-formulated and/or co-administered.
  • additional therapeutic agents eg, one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors
  • enzyme inhibitors e.g., enzyme inhibitors, and/or cytotoxins or cytostatics
  • administration of an anti-BCMA antibody and administration of a therapeutic agent can reduce the number of B cells in the subject.
  • the treatment regimen is effective to reduce cytokine release associated with administration of the T cell activating therapeutic in the subject compared to a corresponding treatment regimen without administration of an anti-BCMA antibody.
  • Human BCMA (Sino biological, HG10620-M) and rhesus monkey BCMA (Sino biological, CG90103-G, identical to the extracellular region sequence of cynomolgus monkey XP_005591343.1) were used as templates to amplify human BCMA (Met1-Asn53) Or rhesus monkey BCMA (Met1-Asn52), the C-terminal is fused with mouse IgG2a Fc, transfected into HEK293E cells, and expressed to obtain human or cynomolgus monkey BCMA-mFc bivalent recombinant protein (amino acid sequence such as SEQ ID NO.1-2 or fused with human IgG Fc (knob), using knob-into-hole technology, and co-transfected HEK293E cells with human IgG Fc (hole) to obtain human or cynomolgus monkey BCMA-hFc kih monovalent recombinant protein (
  • the Lenti vector and packaging plasmid (Genecoepia) containing the full-length sequence of human and cynomolgus monkey BCMA were co-transfected into HEK293T cells. After 48 hours of transfection, the culture supernatant containing pseudovirus was collected, and 10 ⁇ L was taken to infect 1 ⁇ 10 6 CHO cells. Different concentrations of puromycin were added to screen for resistance, and CHO-hBCMA (clone 2C2) and CHO-cynoBCMA (clone 1A2) stably transfected cells with high expression of human or cynomolgus monkey BCMA were finally isolated.
  • Figure 2 shows flow cytometric detection of human and monkey BCMA stable cells. Both human BCMA stable cells (CHO-hBCMA-2C2) and cynomolgus monkey BCMA stable cells (CHO-cynoBCMA-1A2) express high levels of BCMA.
  • CD3 ⁇ will be expressed
  • the recombinant plasmids of -Fc and CD3 ⁇ -Fc were mixed with 3 mg/mL PEI (Polysciences, #24765-2), co-transfected into HEK293E cells (medium OPM-293 CD03DPM), and collected after culturing for 7 days at 37°C, 120 rpm and 5% CO .
  • the supernatant of the medium was purified by Protein A affinity chromatography to obtain human or cynomolgus CD3 ⁇ -Fc recombinant protein, and the purity of SDS-PAGE was higher than 95% (Fig. 3).
  • BCMA-mFc recombinant protein or CHO-BCMA stably transfected cells were used as immunogens, respectively mixed with an equal volume of immune adjuvant (Titermax, Sigma-Aldrich), and 6-week-old female Balb/c mice (Beijing Weitonglihua) were taken. Perform footpad or subcutaneous immunization. Following the primary immunization, booster immunizations of the same dose were administered every two weeks, alternating with human and monkey antigen immunizations. After four immunizations, BCMA antibody titers greater than 1:10000 were detected in mouse serum.
  • mice spleen and some peripheral lymph nodes were harvested, total RNA was extracted, and antibody cDNA was obtained by reverse transcription with IgG-specific primers, and the light and heavy chain variable region fragments were amplified respectively to construct a phage Fab library , the number of transformed colonies (library capacity) was about 1.2 ⁇ 10 10 .
  • the BCMA antibody variable region sequence is as follows:
  • amino acid sequence of 3G11 heavy chain VH is shown in SEQ ID NO.10
  • its encoding nucleic acid is shown in SEQ ID NO.11
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • amino acid sequence of 3G11 light chain VK is shown in SEQ ID NO.15
  • its encoding nucleic acid is shown in SEQ ID NO.16
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.17, 18, 19 respectively.
  • amino acid sequence of 6G5 heavy chain VH is shown in SEQ ID NO.10
  • its encoding nucleic acid is shown in SEQ ID NO.11
  • its HCDR1, HCDR2 and HCDR3 are respectively shown in SEQ ID NO.12, 13, 14.
  • amino acid sequence of 6G5 light chain VK is shown in SEQ ID NO.20
  • its encoding nucleic acid is shown in SEQ ID NO.21
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.22, 23, and 19, respectively.
  • the amino acid sequence of 15G9 heavy chain VH is shown in SEQ ID NO.24, its encoding nucleic acid is shown in SEQ ID NO.25, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.26, 27, 28 respectively.
  • the amino acid sequence of 15G9 light chain VK is shown in SEQ ID NO.29, its encoding nucleic acid is shown in SEQ ID NO.30, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.31, 32, 33 respectively.
  • amino acid sequence of 15H10 heavy chain VH is shown in SEQ ID NO.34
  • its encoding nucleic acid is shown in SEQ ID NO.35
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 36, 37 respectively.
  • amino acid sequence of 15H10 light chain VK is shown in SEQ ID NO.38
  • its encoding nucleic acid is shown in SEQ ID NO.39
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.17, 40, 19 respectively.
  • the amino acid sequence of 16B9 heavy chain VH is shown in SEQ ID NO.41, its encoding nucleic acid is shown in SEQ ID NO.42, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 43, 44 respectively.
  • the amino acid sequence of 16B9 light chain VK is shown in SEQ ID NO.45, its encoding nucleic acid is shown in SEQ ID NO.46, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.47, 18, 19 respectively.
  • the amino acid sequence of 23F8 heavy chain VH is shown in SEQ ID NO.48, its encoding nucleic acid is shown in SEQ ID NO.49, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 50, 14 respectively.
  • the amino acid sequence of 23F8 light chain VK is shown in SEQ ID NO.51, its encoding nucleic acid is shown in SEQ ID NO.52, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.17, 40, 19 respectively.
  • the amino acid sequence of 23G9 heavy chain VH is shown in SEQ ID NO.53, its encoding nucleic acid is shown in SEQ ID NO.54, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.55, 56, 57 respectively.
  • the amino acid sequence of 23G9 light chain VK is shown in SEQ ID NO.58, its encoding nucleic acid is shown in SEQ ID NO.59, and its HCDR1, HCDR2 and HCDR3 are respectively shown in SEQ ID NO.60, 61, 62.
  • the amino acid sequence of 29A11 heavy chain VH is shown in SEQ ID NO.10, its encoding nucleic acid is shown in SEQ ID NO.11, and its HCDR1, HCDR2 and HCDR3 are respectively shown in SEQ ID NO.12, 13, 14.
  • the amino acid sequence of 29A11 light chain VK is shown in SEQ ID NO.38, its encoding nucleic acid is shown in SEQ ID NO.39, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.17, 40, 19 respectively.
  • amino acid sequence of 34G2 heavy chain VH is shown in SEQ ID NO.63
  • its encoding nucleic acid is shown in SEQ ID NO.64
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.65, 66, 14 respectively.
  • amino acid sequence of 34G2 light chain VK is shown in SEQ ID NO.67
  • its encoding nucleic acid is shown in SEQ ID NO.68
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.17, 40, 19 respectively.
  • amino acid sequence of 38E2 heavy chain VH is shown in SEQ ID NO.69
  • its encoding nucleic acid is shown in SEQ ID NO.70
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.71, 72, 73 respectively.
  • amino acid sequence of 38E2 light chain VK is shown in SEQ ID NO.74
  • its encoding nucleic acid is shown in SEQ ID NO.75
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.76, 77, 78 respectively.
  • amino acid sequence of 38D9 heavy chain VH is shown in SEQ ID NO.79
  • its encoding nucleic acid is shown in SEQ ID NO.80
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • amino acid sequence of 38D9 light chain VK is shown in SEQ ID NO.81, its encoding nucleic acid is shown in SEQ ID NO.82, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.83, 84, 19 respectively.
  • amino acid sequence of 38F9 heavy chain VH is shown in SEQ ID NO.10
  • its encoding nucleic acid is shown in SEQ ID NO.11
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • amino acid sequence of 38F9 light chain VK is shown in SEQ ID NO.85
  • its encoding nucleic acid is shown in SEQ ID NO.86
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.87, 88, 89 respectively.
  • amino acid sequence of 40C6 heavy chain VH is shown in SEQ ID NO.10
  • its encoding nucleic acid is shown in SEQ ID NO.11
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, and 14, respectively.
  • amino acid sequence of 40C6 light chain VK is shown in SEQ ID NO.90
  • its encoding nucleic acid is shown in SEQ ID NO.91
  • its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.92, 23, 19.
  • Murine hybridoma CD3 antibody (EMBO J.1985.4(2):337-344; J.Immunol.1986,137(4):1097-100; J.Exp.Med.1991,174:319-326; J. Immunol. 1991, 147(9):3047-52) recognizes human and cynomolgus monkey CD3 receptors, the sequence of which is as follows:
  • amino acid sequence of the anti-CD3 mouse monoclonal antibody light chain is shown in SEQ ID NO.184:
  • the heavy chain amino acid sequence of anti-CD3 mouse monoclonal antibody is shown in SEQ ID NO.185:
  • Anti-CD3 mouse monoclonal antibody was humanized, the human germline gene IMGT_hVL7-43 with the highest homology was selected for light chain CDR transplantation, human IGLJ3*02 was selected for FM4; human IMGT_hVH3-73 was selected for heavy chain CDR transplantation, and human FM4 was selected for transplantation IGHJ4*01. The design resulted in different heavy and light chain variants.
  • variable region of the light chain of the CD3 humanized antibody is as follows:
  • hVL1 The amino acid sequence of hVL1 is shown in SEQ ID NO.93, its encoding nucleic acid is shown in SEQ ID NO.94, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.95, 96, 97 respectively.
  • the amino acid sequence of hVL2 is shown as SEQ ID NO.98, its encoding nucleic acid is shown as SEQ ID NO.99, and its LCDR1, LCDR2 and LCDR3 are shown as SEQ ID NO.95, 96, 97 respectively.
  • the amino acid sequence of hVL3 is shown in SEQ ID NO.100, its encoding nucleic acid is shown in SEQ ID NO.101, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.102, 103, 97 respectively.
  • the amino acid sequence of hVL4 is shown in SEQ ID NO.104, its encoding nucleic acid is shown in SEQ ID NO.105, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.102, 103, 97 respectively.
  • the amino acid sequence of hVL5 is shown in SEQ ID NO.106, its encoding nucleic acid is shown in SEQ ID NO.107, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.95, 96, 108 respectively.
  • the amino acid sequence of hVL6 is shown in SEQ ID NO.109, its encoding nucleic acid is shown in SEQ ID NO.110, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.95, 111, 108 respectively.
  • the sequence of the heavy chain variable region of the CD3 humanized antibody is as follows:
  • hVH1 The amino acid sequence of hVH1 is shown in SEQ ID NO.112, its encoding nucleic acid is shown in SEQ ID NO.113, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.114, 115, 116, respectively.
  • the amino acid sequence of hVH2 is shown in SEQ ID NO.117, its encoding nucleic acid is shown in SEQ ID NO.118, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.119, 115, 116, respectively.
  • hVH3 The amino acid sequence of hVH3 is shown in SEQ ID NO.120, its encoding nucleic acid is shown in SEQ ID NO.121, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.119, 115, 122, respectively.
  • hVH4 The amino acid sequence of hVH4 is shown in SEQ ID NO.123, its encoding nucleic acid is shown in SEQ ID NO.124, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.119, 115, 125 respectively.
  • the amino acid sequence of hVH5 is shown in SEQ ID NO.126, its encoding nucleic acid is shown in SEQ ID NO.127, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.119, 115, 128, respectively.
  • hVH6 The amino acid sequence of hVH6 is shown in SEQ ID NO.129, its encoding nucleic acid is shown in SEQ ID NO.130, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.119, 115, 131 respectively.
  • amino acid sequence of hVH7 is shown in SEQ ID NO.132
  • its encoding nucleic acid is shown in SEQ ID NO.133
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.134, 135, and 116, respectively.
  • hVH8 The amino acid sequence of hVH8 is shown in SEQ ID NO.136, its encoding nucleic acid is shown in SEQ ID NO.137, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.114, 115, 116, respectively.
  • the amino acid sequence of hVH9 is shown in SEQ ID NO.138, its encoding nucleic acid is shown in SEQ ID NO.139, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.114, 115, 116, respectively.
  • the amino acid sequence of hVH10 is shown in SEQ ID NO.140, its encoding nucleic acid is shown in SEQ ID NO.141, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.114, 115, 116, respectively.
  • the light and heavy chain humanized variants were synthesized in full sequence respectively, cloned into a eukaryotic expression vector containing antibody lambda light chain constant region or human IgG4 heavy chain constant region CH1-CH3, and co-transfected HEK293E cells at 37°C After 5-6 days of culture at 120 rpm 5% CO 2 , the medium supernatant was collected and purified by a Protein A column.
  • CD3 antibodies Coated with human CD3 ⁇ protein overnight at 4°C. After blocking with 2% skim milk, CD3 antibodies of different dilutions were added to each well and incubated for 1 hour; the secondary antibody was added with HPR-labeled goat anti-human IgG Fc, after TMB solution developed color, the reaction was terminated with concentrated sulfuric acid and read at 450nm absorbance (results are shown in Figure 4).
  • Figure 4 shows the combination of anti-CD3 humanized antibodies (including aCD3-hVH8/VL1, aCD3-hVH9/VL1, aCD3-hVH9/VL2, aCD3-hVH9/VL3, aCD3-hVH1/VL5, aCD3- hVH8/VL5, aCD3-hVH9/VL5), CD3 humanized antibody binds CD3 ⁇ recombinant protein with high affinity.
  • CD3 humanized antibodies including aCD3-hVH8/VL1, aCD3-hVH9/VL1, aCD3-hVH9/VL2, aCD3-hVH9/VL3, aCD3-hVH1/VL5, aCD3- hVH8/VL5, aCD3-hVH9/VL5
  • Figure 5 shows a combination of anti-CD3 humanized antibodies that bind to Jurkat cells, wherein the CD3 humanized antibody hVH9/VL5 (aCD3-hVH9/VL5) binds Jurkat cells with moderate affinity.
  • the light chain variable region of humanized BCMA antibody was cloned into a eukaryotic expression vector containing the kappa light chain constant region, and the heavy chain variable region was cloned into a mutated human IgG4 constant region eukaryotic expression vector;
  • the light chain variable region of humanized CD3 antibody was cloned into a eukaryotic expression vector containing lambda light chain constant region and heavy chain hinge region and constant regions CH2 and CH3, and the heavy chain of CD3 antibody was cloned into a eukaryotic expression vector.
  • the variable region of the chain was cloned into a eukaryotic expression vector containing the human CH1 constant region.
  • BCMA-50 (synthesized according to US201213678247) was constructed with CD3 humanized antibody according to the above method to form a BCMA50-CD3 bispecific antibody as a reference, or a reference to express BCMA50 ⁇ CD3 (BiTE).
  • the amino acid sequence of h38E2 light chain VK is shown in SEQ ID NO.142, its encoding nucleic acid is shown in SEQ ID NO.143, and its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.144, 77, 78.
  • amino acid sequence of h38E2 heavy chain VH is shown in SEQ ID NO.145
  • its encoding nucleic acid is shown in SEQ ID NO.146
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.71, 147, 73 respectively.
  • amino acid sequence of h23F8 light chain VK is shown in SEQ ID NO.148
  • its encoding nucleic acid is shown in SEQ ID NO.149
  • its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.17, 40, 19.
  • amino acid sequence of h23F8 heavy chain VH is shown in SEQ ID NO.150
  • its encoding nucleic acid is shown in SEQ ID NO.151
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 50, 14 respectively.
  • the amino acid sequence of h40C6 light chain VK is shown in SEQ ID NO.152, its encoding nucleic acid is shown in SEQ ID NO.153, and its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.92, 23, 19.
  • h40C6 heavy chain VH The amino acid sequence of h40C6 heavy chain VH is shown in SEQ ID NO.154, its encoding nucleic acid is shown in SEQ ID NO.155, and its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • the amino acid sequence of h38D9 light chain VK is shown in SEQ ID NO.156, its encoding nucleic acid is shown in SEQ ID NO.157, and its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.83, 84, 19 respectively.
  • amino acid sequence of h38D9 heavy chain VH is shown in SEQ ID NO.158
  • its encoding nucleic acid is shown in SEQ ID NO.159
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • amino acid sequence of h29A11 light chain VK is shown in SEQ ID NO.160
  • its encoding nucleic acid is shown in SEQ ID NO.161
  • its LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO.17, 40, 19 respectively.
  • amino acid sequence of h29A11 heavy chain VH is shown in SEQ ID NO.162
  • its encoding nucleic acid is shown in SEQ ID NO.163
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 13, 14 respectively.
  • amino acid sequence of h15H10 light chain VK is shown in SEQ ID NO.164
  • its encoding nucleic acid is shown in SEQ ID NO.165
  • its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.17, 40, 19.
  • amino acid sequence of h15H10 heavy chain VH is shown in SEQ ID NO.166
  • its encoding nucleic acid is shown in SEQ ID NO.167
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.12, 36, 37 respectively.
  • amino acid sequence of h34G2 light chain VK is shown in SEQ ID NO.168
  • its encoding nucleic acid is shown in SEQ ID NO.169
  • its LCDR1, LCDR2 and LCDR3 are respectively shown in SEQ ID NO.17, 40, 19.
  • amino acid sequence of h34G2 heavy chain VH is shown in SEQ ID NO.170
  • its encoding nucleic acid is shown in SEQ ID NO.171
  • its HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NO.65, 66, 14 respectively.
  • T cell-dependent cytotoxicity assay (TDCC)
  • Detection antibodies (CD25-PE, CD4-APC, CD69-FITC and CD8-APC) were incubated on ice for 20 minutes. After the incubation, add 200 ⁇ L of 4% calf blood to each well to wash 3 times, discard the supernatant, add 60 ⁇ L/well of propidium iodide (PI) solution (1:200 dilution), and incubate on ice for 5 minutes. A cytometer (BD FACS celesta) was used for detection. The formula for calculating the kill rate is as follows:
  • the killing activities of the bispecific antibody combinations are shown in Table 6.
  • the clone 29A11 with higher killing efficiency and the clone 6G5 with homology to it were selected for humanization sequence optimization.
  • the heavy chain variable region was from mouse IGHV9-3, and the light chain variable region was from mouse IGKV3-12.
  • the heavy chain CDRs were transplanted into human germline genes IGHV7-4-1*02 and IGVK_7_3 respectively, and the designed humanized BCMA antibody sequences were synthesized.
  • charge variants (V ⁇ BCMA : Gln 42 Lys; VH BCMA : Gln 39 Glu; V ⁇ CD3 : Gln 40 Glu; VH CD3 : Gln 39 Lys) were introduced into the BCMA antigen arm and the humanized CD3 antibody arm containing ⁇ light chain. ) to construct a novel BCMA-CD3 ⁇ humanized bispecific antibody with native IgG configuration (Table 7).
  • the Fc portion of the bispecific antibody adopts the human IgG4 knob-into-hole structure to achieve heterodimer pairing (Atwell et al., 1997), and by mutating Ser 228 Pro, Leu 235 Glu and Pro 329 Ala, the hinge region is stabilized and Attenuates interactions with Fc ⁇ receptors and C1q.
  • the BCMA ⁇ CD3 ⁇ bispecific antibody binds BCMA+ tumor cells NCI-H929 and RPMI-8226 with high affinity.
  • Jurkat cells in logarithmic growth phase were taken, 200 ⁇ g/mL mouse IgG (Jackson ImmunoResearch, 115-005-03) was added, and the cells were ice-bathed for 30 minutes.
  • the cells were adjusted to 5 ⁇ 10 5 cells/mL with 4% calf serum, 100 ⁇ L per well was added to a 96-well U-plate, centrifuged at 300 g to remove the supernatant, and 100 ⁇ L of serially diluted antibodies (initial concentration 1800 nM, 3 times) were added to each well. dilution, 10 gradients) and incubated at 4°C for 60 minutes.
  • PBMCs were isolated by Ficoll-Paque Plu (GE, 17-1440-03). PBMC were adjusted to 5 ⁇ 10 5 cells/mL with 4% calf serum (Hyclone, SH30626.06), 100 ⁇ L/well was added to a 96-well U-shaped plate, the supernatant was discarded by centrifugation, and 100 ⁇ L of serially diluted antibody was added to each well. (initial concentration 1800nM, 3-fold dilution, 10 gradients), incubated at 4°C for 60 minutes.
  • the test results are shown in Figure 9 and Table 13.
  • the BCMA ⁇ CD3 ⁇ bispecific antibody recognizes human peripheral blood CD4+T and CD8+T cells, and the affinity with human T cells is about 60-97nM, which is weaker than the BCMA antigen arm and the BCMA receptor.
  • the binding capacity is favorable for the preferential enrichment of bispecific antibodies to tumor cells.
  • FIGS. 10A and 10B show the killing of NCI-H929 cells and the activation of T cells by BCMA ⁇ CD3 ⁇ bispecific antibodies, respectively.
  • Figures 11A and 11B show the killing of RPMI-8226 cells and the activation of T cells by BCMA ⁇ CD3 ⁇ bispecific antibodies, respectively.
  • both BCMA ⁇ CD3 ⁇ bispecific antibodies can mediate effective killing of T cells, and the killing activity is comparable to that of the control antibody.
  • the luciferase reporter plasmid pGL4.30[luc2P/NFAT-RE/Hygro] was transfected into Jurkat cells, and 200 ⁇ g/ml hygromycin B was added for screening to obtain Jurkat-NFAT luc stably transfected reporter cells.
  • Jurkat-NFAT-luc reporter cells and target cells RPMI-8226 in logarithmic growth phase were taken, the supernatant was discarded by centrifugation, and resuspended to 2 ⁇ 10 6 cells/ml.
  • His-Tag antibody was coupled to the CM5 chip through amino groups to capture Fc ⁇ RI, Fc ⁇ RIIA H131 and Fc ⁇ RIIIA V158 recombinant proteins with His6 tags respectively.
  • the capture time was 40 seconds and the flow rate was 10 ⁇ L/min.
  • the antibody (initial concentration 37.5 ⁇ g/mL, 2-fold dilution) flowed through the chip at a flow rate of 30 ⁇ L/min, the binding time was 120 seconds, the dissociation time was 200 seconds, and the affinity constant was obtained by fitting with Biacore evaluation software.
  • the test results are shown in Figure 14.
  • the BCMA ⁇ CD3 ⁇ bispecific antibody did not bind to the activated receptors Fc ⁇ RI, Fc ⁇ RIIA H131 and Fc ⁇ RIIIA V158 ; the wild-type IgG4 and control antibodies were bound to Fc ⁇ RI, Fc ⁇ RIIA H131 or Fc ⁇ RIIIA V158 , respectively.
  • 1 ⁇ g/mL human BCMA recombinant antigen was prepared with pH9.6 carbonate buffer, added to maxisorp 96-well plate, and coated overnight at 4°C. After blocking with 5% nonfat milk/PBS for 1 hour at room temperature, 50 ⁇ L of antibody (4-fold dilution from 30 ⁇ g/mL, 10 dilutions in total) was added to each well, and incubated for 30 minutes at room temperature. 50 ⁇ L of biotin-labeled human APRIL recombinant protein (Novoprotein, CU89) at a concentration of 240 ng/mL was added, and the incubation was continued for 30 minutes.
  • biotin-labeled human APRIL recombinant protein Novoprotein, CU89
  • mice 6-8 week old female B-NGD mice (Biositu Biotechnology Co., Ltd.) were selected, subcutaneously inoculated with 2 ⁇ 10 6 NCI-H929 cells (mixed with Matrigel 1:1), and randomly divided into groups when the tumor grew to 60 mm 3 , respectively 3.0 mg/kg in the administration group, 0.6 mg/kg in the administration group, 0.12 mg/kg in the administration group and KLH ⁇ CD3 3 mg/kg in the negative control group. Each mouse was injected with 1 ⁇ 10 7 PBMC cells through the tail vein, and the first mouse administration was started 3 days later, and the administration interval was once every 5 days, with a total of 2 administrations. The tumor volume and body weight of the mice were monitored every 2 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本公开涉及一种T细胞衔接器治疗剂的开发和应用。该T细胞衔接器为一种T细胞双特异性抗体，该双特异性抗体包含结合到靶细胞表面上的BCMA的第一结合结构域和结合到T细胞表面上的CD3的第二结合结构域。该双特异性抗体耐受良好，可有效阻断BCMA与受体APRIL的结合，无体重减轻等不良反应。

Description

一种T细胞衔接器治疗剂的开发和应用 技术领域
本公开涉及一种T细胞衔接器治疗剂的开发和应用，特别是结合BCMA和CD3的双特异性抗体及其应用。
背景技术
B细胞成熟抗原(B-cell maturation antigen，BCMA)，是一种肿瘤坏死因子受体超家族成员，广泛表达于骨髓瘤细胞表面，正常组织中仅在浆细胞表达，而在初始B细胞、CD34+造血干细胞和其他正常组织中都不表达。BCMA缺陷小鼠具有正常的B细胞发育和体液免疫反应，多发性骨髓瘤患者样本中，配体APRIL(A Proliferation Inducing Ligand)与BCMA结合后，可刺激骨髓瘤细胞生长和增殖，同时阻止肿瘤细胞发生凋亡。由于恶性浆细胞上的表达量显著高于正常浆细胞，BCMA已成为一个重要的免疫治疗靶点。
在血液***恶性肿瘤中，多发性骨髓瘤是第二大常见病种，多发于中老年人。患者骨髓中积聚恶性增殖的浆细胞，可导致骨髓衰竭和免疫功能缺失，同时常伴多发性溶骨性损害、高钙血症、贫血、肾脏损害。尽管近年来，新的药物包括蛋白酶体抑制剂、免疫调节剂和靶向抗体等，显著延长了患者的生存期，但几乎所有患者仍会复发。正在开发的新疗法如CAR-T细胞(chimeric antigen receptor T-cells)由于制备过程复杂，治疗费用高，且复发率较高；抗体药物偶联物(antibody drug conjugate，ADC)由于偶联毒素的安全原因，临床剂量仅局限于低剂量；在前研发的BCMA双特异抗体，尽管临床显示出相当好的疗效，但剂量升高也伴随副作用加大，可能引起强烈的细胞因子风暴综合征，并危及患者生命。因此，该领域仍需开发新的更加安全有效的药物。
T细胞双特异抗体(或称T细胞衔接器)，是一种人为构建的特殊抗体分子，可通过其一端识别靶细胞表面抗原(抗原臂)，通过另一端结合T细胞CD3受体(CD3臂)。利用靶向CD3ε链的抗体，以一种类似于TCR/肽/HLA的方式，使T细胞上的CD3发生聚集，从而活化T细胞并杀伤肿瘤。BCMA×CD3双特异性分子是靶向骨髓瘤细胞上表达的BCMA和T细胞上存在的CD3ε链(CD3e)的T细胞双特异性(TCB)抗体。BCMA×CD3双特异性分子的作用机制包含同时结合BCMA+骨髓瘤细胞和CD3+T细胞，引起T细胞活化和T细胞介导的细胞杀伤作用。
正常免疫应答过程中，TCR以低亲和力(约1-100μM)结合感染或突变细胞上的外源肽-人白细胞抗原复合物(HLA)，通过CD3将活化信号传导到核内，激活转录因子及其下游蛋白(细胞因子、颗粒酶、穿孔素等)的表达，其中TCR复合物产生的信号强度将决定T细胞的命运。信号传导复合物的ε、γ、δ以及ζ亚基彼此缔合以形成CD3ε-γ异源二聚体、CD3ε-δ异源二聚体以及CD3ζ-ζ同源二聚体。而早期开发的CD3双特异抗体，多基于OKT3、L2K、UCHT1和TR66等少数鼠源抗体，亲和力较高。在临床研究中发现，CD3抗体的亲和力过强将导致T细胞过度活化，并释放大量细胞因子，形成细胞因子风暴综合征；同时，高亲和力也会导致双特异抗体在二级淋巴器官的富集，减低在肿瘤组织的暴露。抗体Fc部分与Fcγ受体的结合能力是另一个对影响药物安全的重要因素，由于Fcγ受体在多种正常组织表达，双特异抗体通过Fc与细胞膜上的Fcγ受体结合后，可导致另一端结合的CD3受体因Fcγ受体聚集而交联活化，从而产生严重的脱靶毒性，例如：早期上市的catumaxomab由于Fc段与肝脏Kupffer细胞表达的Fcγ受体结合，引发了快速的细胞因子释放。通过使用Fcγ受体结合能力较弱的人IgG2亚型或IgG4亚型，或者进一步在CH2相应位点进行氨基酸替换，如：Armour等将IgG1和IgG4的第233-236位点(EU序列编号)替换成IgG2相应序列，减少了和Fcγ受体的结合(Armour KL et al,Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities,Eur J Immunol.1999 Aug；29(8):2613-24)，Newman等在IgG4引入突变Ser228Pro和Leu235Glu，稳定IgG4结构同时减少与Fcγ受体的结合(Newman R.et al,Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+)T cells in chimpanzees,Clin Immunol.2001 Feb；98(2):164-74,)，Idusogie等发现将Asp270、Lys322、Pro329或Pro331分别替换成Ala，可减少IgG1与补体C1q的结合(Idusogie EE et al,Mapping of the C1q Binding Site on Rituxan,a Chimeric Antibody with a Human IgG1 Fc,J Immunol April 15,2000,164(8)4178-4184)等。
发明内容
为了解决现有技术中存在的问题，本公开提供了一种新的与BCMA蛋白具有高亲和力的BCMA抗体。并且，本公开还提供了BCMA抗体与CD3抗体形成的新型BCMA-CD3κλ双特异抗体。BCMA-CD3κλ双特异抗体采用全长IgG构型，通过引入电荷及亲和力优化，使κλ双特异抗体优先定位到BCMA+肿瘤组织，低浓度下即可募集活化T细胞，对靶细胞产生有效杀伤，无靶细胞存在时不激活T细胞；同时，κλ双特异抗体不与FcγRI、FcγRIIA和FcγRIIIA等受体结合，减低了产生细胞因子风暴的风险。在免疫重建小鼠模型中证实，这种新型BCMA-CD3κλ双特异抗体可有效抑制肿瘤生长，疗效优于同类抗体。
在一方面，本公开提供了一种结合BCMA的抗体或其抗原结合部分。
在一方面，本公开提供了一种双特异性抗体或其抗原结合部分。
在一方面，本公开提供了编码如前述的双特异性抗体或其抗原结合部分的核酸。
在一方面，本公开提供了包含前述的核酸的载体。
在一方面，本公开提供了包含前述的核酸或载体的细胞。
根据前述的抗体或其抗原结合部分，其中前述抗体或其抗原结合部分是人源化的。
在一方面，本公开提供了包含如前述的抗体或其抗原结合部分或其编码核酸和药学上可接受的载体的药物组合物或试剂盒。
在一方面，本公开提供了包含共价附着至治疗部分的前述的抗体或其抗原结合部分、双特异性或多特异性分子的抗体-药物偶联物。
在一方面，本公开提供了治疗与BCMA相关病症的方法，其包括下述步骤：向哺乳动物施用治疗有效量的前述的抗体或其抗原结合片段、核酸、载体、细胞和/或药物组合物。
在一方面，本公开提供了前述的抗体或其抗原结合片段、核酸、载体、细胞和/或药物组合物在制备用于治疗哺乳动物中与BCMA相关病症的药物或试剂盒中的用途。
本公开的抗体可以用于多种应用，包括检测BCMA蛋白，诊断、治疗或预防与BCMA相关的疾病。
附图说明
图1示出了人、食蟹猴BCMA-mFc双价重组蛋白和BCMA-hFc kih单价重组蛋白的SDS-PAGE结果。
图2示出了流式细胞检测人和食蟹猴BCMA稳转细胞，人BCMA稳转细胞(CHO-hBCMA-2C2)和食蟹猴BCMA稳转细胞(CHO-cynoBCMA-1A2)均表达高水平的BCMA。
图3示出了CD3εγ-Fc重组蛋白的SDS-PAGE结果。
图4示出了人源化CD3抗体与CD3εγ-Fc重组蛋白的结合。
图5示出了人源化CD3抗体与Jurkat细胞的结合。
图6示出了BCMA×CD3κλ双特异抗体与BCMA稳转细胞的结合。
图7示出了BCMA×CD3κλ双特异抗体高亲和力结合BCMA+肿瘤细胞。
图8示出了BCMA×CD3κλ双特异抗体与Jurkat细胞的结合。
图9示出了BCMA×CD3κλ双特异抗体与人外周血T细胞的结合
图10示出了BCMA×CD3κλ双特异抗体对NCI-H929细胞的杀伤和对T细胞的活化，其中，图10A显示对NCI-H929细胞的杀伤，图10B显示对T细胞的活化。
图11示出了BCMA×CD3κλ双特异抗体对RPMI-8226细胞的杀伤和对T细胞的活化，其中，图11A显示对RPMI-8226细胞的杀伤，图11B显示对T细胞的活化。
图12示出了BCMA×CD3κλ双特异抗体对T细胞信号通路的活化。
图13示出了BCMA×CD3κλ双特异抗体对外周血T细胞的活化。
图14示出了BCMA×CD3κλ双特异抗体与活化型FcγR受体的结合。
图15示出了BCMA×CD3κλ双特异抗体对BCMA与受体APRIL结合的阻断。
图16示出了BCMA×CD3κλ双特异抗体对免疫缺陷型小鼠皮下NCI-H929移植瘤模型的抑制作用。
具体实施方式
I.定义
在本公开中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的蛋白质和核酸化学、分子生物学、细胞和组织培养、微生物学、免疫学相关术语和实验室操作步骤均为相应领域内广泛使用的术语和常规步骤。同时，为了更好地理解本公开，下面提供相关术语的定义和解释。
如本文中使用的，术语“BCMA”可以指共同指代存在于动物中并且优选地存在于人体中的BCMA本身及其任何变体、同种型和旁系同源物的概念。
术语“人BCMA”是指人来源的BCMA，并且可以优选具有但不限于Genbank登录号AB052772.1的氨基酸序列。
术语“抗BCMA抗体”和“结合BCMA的抗体”指能够以足够亲和力结合BCMA，使得该抗体作为诊断剂和/或治疗剂在靶向BCMA中是有用的抗体。在一个实施方案中，抗BCMA抗体对无关非BCMA蛋白的结合程度小于该抗体对BCMA的结合的约10％，如通过例如放射免疫测定法(RIA)测量的。在某些实施方案中，结合BCMA的抗体具有≤1μM，≤100nM，≤10nM，≤1nM，≤0.1nM，≤0.01nM，或≤0.001nM(例如10 -8M或更低，例如10 -8M至10 -13M，例如10 -9M至10 -13M)的解离常数(K d)。在某些实施方案中，抗BCMA抗体结合在来自不同物种的BCMA间保守的BCMA表位。
“CD3”指来自任何脊椎动物来源，包括哺乳动物，诸如灵长动物(例如人)，非人灵长动物(例如食蟹猴)和啮齿动物(例如小鼠和大鼠)的任何天然CD3，除非另外指明。该术语涵盖“全长”未加工的CD3以及源自细胞中加工的任何形式的CD3。该术语还涵盖CD3的天然发生变体，例如剪接变体或等位变体。在一个实施方案中，CD3是人CD3，特别是人CD3的厄普西隆亚基(CD3ε)。人CD3ε的氨基酸序列显示于UniProt(www.uniprot.org)登录号P07766(版本144)，或NCBI(www.ncbi.nlm.nih.gov/)RefSeq NP_000724.1。食蟹猴[Macaca fascicularis]CD3ε的氨基酸序列显示于NCBI GenBank no.BAB71849.1。
术语“细胞表面”的使用是根据其在本领域的正常含义，因此包括可通过与蛋白和其它分子结合而接近的细胞外部。
如本文使用的和除非另作说明，术语“约”或“大约”是指在给定值或范围的加或减10％之内。在需要整数的情况下，该术语是指在给定值或范围的加或减10％之内、向上或向下舍入到最接近的整数。
就抗体链多肽序列而言，短语“基本相同”可理解为表现出与参照多肽序列至少60％、65％、70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更多的序列同一性的抗体链。就核酸序列而言，该术语可理解为表现出与参照核酸序列至少大于60％、65％、70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更高的序列同一性的核苷酸序列。
序列“相同性”或“同一性”具有本领域公认的含义，并且可以利用公开的技术计算两个核酸或多肽分子或区域之间序列相同性的百分比。可以沿着多核苷酸或多肽的全长或者沿着该分子的区域测量序列相同性。虽然存在许多测量两个多核苷酸或多肽之间的相同性的方法，但是术语“相同性”是技术人员公知的(Carrillo,H.&Lipman,D.,SIAM J Applied Math 48:1073(1988))。
“取代型”变体是天然序列中至少一个氨基酸残基被除去并被不同的氨基酸***其相同位置的变体。所述取代可为单个的，其中该分子中仅有一个氨基酸被取代；或可为多个的，其中该相同分子有两个或更多的氨基酸被取代。多个取代可位于连续的位点。同样，一个氨基酸可被多个残基取代，其中这样的变体包括取代和***二者。“***型”变体是一个或多个氨基酸被***到紧邻一段天然序列某个特定位置处的氨基酸的变体。紧邻氨基酸意指与该氨基酸的α-羧基或α-氨基官能团连接。“缺失型”变体是天然氨基酸序列中一个或多个氨基酸被除去的变体。通常情况下，缺失型变体在其分子的特定区域内有一个或两个氨基酸被缺失。
就抗体的可变结构域而言，术语“可变”系指抗体之间有广泛序列差异的相关分子的某些部分，且被用于针对其特异靶的特定抗体的特异识别和结合。但是，可变性在抗体的整个可变结构域内不是均匀分布的。可变性集中在被称为互补决定区域(CDRs；即CDR1、CDR2和CDR3)或超变区的三个区段，它们均位于轻链和重链的可变结构域内。可变结构域内保守程度更高的部分被称为构架(FR)区或构架序列。天然重链和轻链的每个可变结构域均包括四个FR区，其主要采用β-折叠构型，它们籍三个CDRs连接起来，CDRs形成环，所述环连接β-折叠结构并在某些情形下形成部分的β-折叠结构。每条链的CDRs通常被FR区在邻近连接起来，并且借助于来自其它链的CDR，有助于抗体靶结合位点(表位或决定簇)的形成。正如本文所使用，免疫球蛋白氨基酸残基的编号是依据Kabat等人的免疫球蛋白氨基酸残基编号***而进行的，除非另有说明。一个CDR可具有特异结合关联表位的能力。
如本文所用，抗体的“抗体片段”或“抗原结合片段”指全长抗体的任何部分，其少于全长，但是至少包含结合抗原的所述抗体的部分可变区(例如一个或多个CDR和/或一个或多个抗体结合位点)，并且因此保留结合特异性以及所述全长抗体的至少部分特异性结合能力。因此，抗原结合片段指包含与衍生抗体片段的抗体结合相同抗原的抗原结合部分的抗体片段。抗体片段包括通过酶促处理全长抗体所产生的抗体衍生物，以及合成产生的衍生物，例如重组产生的衍生物。抗体包括抗体片段。抗体片段的实例包括但不限于Fab、Fab'、F(ab') 2、单链Fv(scFv)、Fv、dsFv、双抗体、Fd和Fd'片段以及其他片段，包括修饰的片段。所述片段可以包括连接在一起的多条链，例如通过二硫键和/或通过肽接头。抗体片段一般包含至少或约50个氨基酸，并且典型至少或约200个氨基酸。抗原结合片段包括任何抗体片段，其在被***抗体框架(例如通过置换相应区域)时获得免疫特异性地结合(即表现出至少或至少约10 7-10 8M -1的Ka)抗原的抗体。“功能片段”或“抗BCMA抗体的类似物”是可防止或实质降低所述受体结合配体或启动信号转导的能力的片段或类似物。正如本文所使用，功能片段一般与“抗体片段”含义相同，且就抗体而论，可指能防止或实质降低所述受体结合配体或启动信号转导的能力的片段，例如Fv、Fab、F(ab') 2等等。“Fv”片段由一条重链的可变结构域和一条轻链的可变结构域籍非共价结合方式而形成的二聚体(V H-V L二聚体)组成。在该构型中，每个可变结构域的三个CDRs相互作用，以确定V H-V L二聚体表面上的靶结合位点，与完整抗体的情况一样。所述六个CDRs共同赋予完整抗体的靶结合特异性。但是，即使是单个可变结构域(或仅包括3个靶特异的CDRs的Fv的一半)，仍可具有识别和结合靶的能力。
如本文中所用，术语“双特异性”(Bispecific antibody，BsAb)指抗体和/或抗原结合分子能够特异性结合两种不同的抗原性决定簇，通常，双特异性抗体和/或抗原结合分子包含两种抗原结合位点，其中每种特异于不同的抗原性决定簇。在某些实施方案中，所述双特异性抗体和/或抗原结合分子能够同时结合两种抗原决定簇，特别是在两种不同的细胞上表达的两种抗原性决定簇。
如本文所用，“单克隆抗体”指相同抗体的群体，表示单克隆抗体群体中的每个单独的抗体分子与其他抗体分子相同。这种特性与抗体的多克隆群体的特性相反，所述抗体的多克隆群体包含具有多种不同序列的抗体。单克隆抗体可以通过许多公知的方法来制备(Smith et al.(2004)J.Clin.Pathol.57,912-917；和Nelson et al.,J Clin Pathol(2000),53,111-117)。例如，单克隆抗体可以通过永生化B细胞来制备，例如通过与骨髓瘤细胞融合以产生杂交瘤细胞系或者通过用诸如EBV的病毒感染B细胞。重组技术还可以用来在体外通过用携带编码抗体的核苷酸的人工序列的质粒转化宿主细胞来从宿主细胞的克隆群体制备抗体。
如本文中所用，术语“杂交瘤”或“杂交瘤细胞”指由融合产抗体的淋巴细胞和不产抗体的癌细胞而产生的细胞或细胞系(通常为骨髓瘤或淋巴瘤细胞)。如本领域普通技术人员所知的，杂交瘤可增殖并持续供应产生特定单克隆抗体。用于产生杂交瘤的方法为本领域已知的。当提及术语“杂交瘤”或“杂交瘤细胞”时，其还包括杂交瘤的亚克隆和后代细胞。
如本文所用，全长抗体是具有两条全长重链(例如VH-CH1-CH2-CH3或VH-CH1-CH2-CH3-CH4)和两条全长轻链(VL-CL)和铰链区的抗体，例如通过抗体分泌B细胞天然产生的抗体以及合成产生的具有相同结构域的抗体。
术语“嵌合抗体”是指这样的抗体，其中可变区序列源自一个物种，恒定区序列源自另一物种，如其中可变区序列源自小鼠抗体及恒定区序列源自人抗体的抗体。
“人源化”抗体是指非人(例如小鼠)抗体形式，其是嵌合的免疫球蛋白、免疫球蛋白链或者其片段(如Fv、Fab、Fab'、F(ab') 2或者抗体的其它抗原结合亚序列)，含有源自非人免疫球蛋白的最小序列。优选地，人源化抗体是人免 疫球蛋白(接受者抗体)，其中接受者抗体的互补决定区(CDR)的残基由来自具有希望的特异性、亲和性和能力的非人物种(供体抗体)如小鼠、大鼠或者兔的CDR残基置换。
此外，在人源化中，还可能对VH和/或VL的CDR1、CDR2和/或CDR3区内的氨基酸残基进行突变，由此改善抗体的一或多种结合特性(例如亲和性)。可进行例如PCR介导的突变引入突变，其对抗体结合或其它功能特性的影响可利用本文所述的体外或体内测试评估。通常，引入保守性突变。此类突变可为氨基酸取代、添加或缺失。另外，CDR内的突变通常不超过一个或两个。因此，本公开所述人源化抗体还涵盖CDR内包含1或2两个氨基酸突变的抗体。
如本文所用，术语“CDR”指互补决定区(complementarity-determining region)，已知抗体分子的每个重链和轻链具有3个CDR。CDR也称作高变区，且存在于抗体的每个重链和轻链的可变区中，在CDR的一级结构中具有非常高的变异性位点。本说明书中，重链的CDR由来自重链的氨基端序列的氨基端的CDR1、CDR2、CDR3表示，轻链的CDR由来自轻链的氨基端序列的氨基端的CDR1、CDR2、CDR3表示。这些位点在三级结构中彼此临近，并决定抗体所结合的抗原的特异性。
如本文所用，术语“表位”指抗体的互补位结合的抗原上的任何抗原决定簇。表位决定簇通常包含分子的化学活性表面分型，例如氨基酸或糖侧链，并且通常具有特定的三维结构特征以及特定的电荷特征。
如本文所用，关于抗体或其抗原结合片段的“特异性结合”或“免疫特异性地结合”在本文中可交换使用，并且指抗体或抗原结合片段通过抗体和抗原的抗体结合位点之间的非共价相互作用与同种抗原形成一个或多个非共价键的能力。所述抗原可以是分离的抗原或存在于肿瘤细胞。通常，免疫特异性地结合(或特异性结合)抗原的抗体是以约或1×10 7M -1或1×10 8M -1或更大的亲和常数Ka(或者1×10 -7M或1×10 -8M或更低的解离常数(Kd))结合所述抗原。亲和常数可以通过抗体反应的标准动力学方法来测定，例如，免疫测定、表面等离子共振(SPR)(Rich and Myszka(2000)Curr.Opin.Biotechnol 11:54；Englebienne(1998)Analyst.123:1599)、等温滴定量热法(ITC)或本领域已知的其他动力学相互作用测定；还参见描述用于计算抗体的结合亲和力的示例性SPR和ITC方法的美国专利第7，229，619号)。用于实时检测和监测结合速率的仪器和方法是已知的，并且可商购(参见，BiaCore 2000,Biacore AB,Upsala,Sweden and GE Healthcare Life Sciences；Malmqvist(2000)Biochem.Soc.Trans.27:335)。
如本文所用，术语“多核苷酸”和“核酸分子”指包含至少两个连接的核苷酸或核苷酸衍生物的寡聚体或聚合物，包括通常通过磷酸二酯键连接在一起的脱氧核糖核酸(DNA)和核糖核酸(RNA)。如本文所使用，术语“核酸分子”意欲包括DNA分子及RNA分子。核酸分子可为单链或双链，且可为cDNA。
如本文所用，分离的核酸分子是从存在于核酸分子的天然来源中的其他核酸分子分离的核酸分子。诸如cDNA分子的“分离的”核酸分子可以在通过重组技术制备时基本上不含其他细胞物质或培养基，或者在化学合成时基本上不含化学前体或其他化学成分。本文所提供的示例性分离的核酸分子包括编码所提供的抗体或抗原结合片段的分离的核酸分子。
如本文所用，关于核酸序列、区域、元件或结构域的“可操作地连接”表示核酸区域互相功能相关。例如，启动子可以可操作地连接至编码多肽的核酸，从而所述启动子调控或介导所述核酸的转录。
亦提供本文所述序列表中所述序列的“保守序列修饰”，即不消除由核苷酸序列编码或含有氨基酸序列的抗体与抗原的结合的核苷酸及氨基酸序列修饰。这些保守序列修饰包括保守核苷酸及氨基酸取代以及核苷酸及氨基酸添加及缺失。例如，可通过本领域已知的标准技术(例如定点诱变及PCR介导的诱变)将修饰引入本文所述的序列表中。保守序列修饰包括保守氨基酸取代，其中氨基酸残基被替换为具有类似侧链的氨基酸残基。具有类似侧链的氨基酸残基的家族是本领域中已有定义的。这些家族包括具有碱性侧链的氨基酸(例如赖氨酸、精氨酸、组氨酸)、具有酸性侧链的氨基酸(例如天冬氨酸、谷氨酸)、具有不带电极性侧链的氨基酸(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸)、具有非极性侧链的氨基酸(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)、具有β分枝侧链的氨基酸(例如苏氨酸、缬氨酸、异亮氨酸)及具有芳香族侧链的氨基酸(例如酪氨酸、苯丙氨酸、色氨酸、组氨酸)。因此，抗BCMA抗体中的预测的非必需氨基酸残基优选被来自同一侧链家族的另一氨基酸残基替代。鉴定不消除抗原结合的核苷酸及氨基酸保守取代的方法为本领域所熟知(例如，参见Brummell et al.,Biochem.32:1180-1187(1993)；Kobayashi et al.,Protein Eng.12(10):879-884(1999)；Burks et al.,Proc.Natl.Acad.Sci.USA 94:412-417(1997))。
作为另一选择，在另一实施方案中，可通过例如饱和诱变沿抗BCMA抗体编码序列的全部或一部分随机引入突变，且可针对改良的结合活性筛选所得经修饰抗BCMA抗体。
如本文所用，“表达”指通过多核苷酸的转录和翻译产生多肽的过程。多肽的表达水平可以利用本领域已知的任何方法来评价，包括例如测定从宿主细胞产生的多肽的量的方法。这类方法可以包括但不限于通过ELISA定量细胞裂解物中的多肽，凝胶电泳之后考马斯蓝染色，Lowry蛋白测定以及Bradford蛋白测定。
如本文所用，“宿主细胞”是用于接受、保持、复制和扩增载体的细胞。宿主细胞还可以用来表达载体所编码的多肽。当宿主细胞***时，载体中所含的核酸复制，从而扩增核酸。宿主细胞可以是真核细胞或原核细胞。合适的宿主细胞包括但不限于CHO细胞、各种COS细胞、HeLa细胞、HEK细胞例如HEK 293细胞。
如本文所用，“载体”是可复制的核酸，当载体转化入适当的宿主细胞时，可以从该载体表达一种或多种异源蛋白。关于载体包括那些通常通过限制酶切消化和连接可以将编码多肽或其片段的核酸引入其中的载体。关于载体还包括那些包含编码多肽的核酸的载体。载体用来将编码多肽的核酸引入宿主细胞，用于扩增核酸或者用于表达/展示核酸所编码的多肽。载体通常保持游离，但是可以设计为使基因或其部分整合入基因组的染色体。还考虑人工染色体的载体，例如酵母人工载体和哺乳动物人工染色体。这类媒介物的选择和用途是本领域技术人员公知的。
如本文所用，载体还包括“病毒载体”或“病毒的载体”。病毒的载体是工程化的病毒，其可操作地连接至外源基因以将外源基因转移(作为媒介物或穿梭(shuttle))入细胞。
如本文所用，“表达载体”包括能够表达DNA的载体，所述DNA与诸如启动子区的能够影响这类DNA片段表达的调控序列可操作地连接。这类额外的片段可以包括启动子和终止子序列，并且任选地可以包括一个或多个复制起点、一个或多个选择标记、增强子、多腺苷酸化信号等。表达载体一般来源于质粒或病毒DNA，或者可以包含这两者的元件。因此，表达载体指重组DNA或RNA构建体，例如质粒、噬菌体、重组病毒或其他载体，当引入适当的宿主细胞时，导致克隆DNA的表达。适当的表达载体是本领域技术人员公知的，并且包括在真核细胞和/或原核细胞中可复制的表达载体以及保持游离的表达载体或者整合入宿主细胞基因组的表达载体。
如本文所用，“治疗”患有疾病或疾病状况的个体表示所述个体的症状部分或全部缓解，或者在治疗后保持不变。因此，治疗包括预防、治疗和/或治愈。预防指防止潜在疾病和/或防止症状恶化或疾病发展。治疗还包括所提供的任何抗体或其抗原结合片段以及本文所提供的组合物的任何药学用途。
如本文所用，“疗效”表示由个体的治疗所导致的效果，其改变、通常改良或改善疾病或疾病状况的症状，或者治愈疾病或疾病状况。
如本文所用，“治疗有效量”或“治疗有效剂量”指施用于对象之后至少足以产生疗效的物质、化合物、材料或包含化合物的组合物的量。因此，其为防止、治愈、改善、阻滞或部分阻滞疾病或病症的症状所必需的量。
如本文所用，“预防有效量”或“预防有效剂量”指在施用于对象时会具有预期的预防效果的物质、化合物、材料或包含化合物的组合物的量，例如，防止或延迟疾病或症状的发生或复发，减少疾病或症状发生或复发的可能性。完全预防有效剂量不必通过施用一个剂量发生，并且可以仅在施用一系列剂量之后发生。因此，预防有效量可以在一次或多次施用中施用。
如本文中所使用的，术语“患者”是指哺乳动物，例如人。
II.具体实施方案详述
在一方面，本公开提供了一种双特异性抗体或其抗原结合部分，其包含：
(a)结合到靶细胞表面上的BCMA抗原的第一抗原结合部分或其抗原结合片段，第一抗原结合部分包含第一重链和第一轻链，第一抗原结合部分包含与第一抗原结合的第一结合结构域，其中，第一结合结构域包含选自氨基酸序列SEQ ID NO:12、13、14、26、27、28、36、37、43、44、50、55、56、57、65、66、71、72、73、147或其任何变体的重链CDR，和/或选自氨基酸序列SEQ ID NO:17、18、19、22、23、31、32、33、40、47、60、61、62、76、77、78、83、84、87、88、89、92、144或任何变体的轻链CDR；和
(b)结合到T细胞表面上的CD3抗原的第二抗原结合部分或其抗原结合片段，第二抗原结合部分包含第二重链和第二轻链，第二抗原结合部分包含与第二抗原结合的第二结合结构域。
根据前一方面的抗体或其抗原结合部分，第一结合结构域包含选自氨基酸序列SEQ ID NO:12、26、55、65、71或其任何变体的重链CDR1，选自氨基酸序列SEQ ID NO:13、27、36、43、50、56、66、72、147或其任何变体的重链CDR2，选自氨基酸序列SEQ ID NO:14、28、37、44、57、73或其任何变体的重链CDR3；和/或第一结合结构域包含选自氨基酸序列SEQ ID NO:17、22、31、47、60、76、83、87、92、144或其任何变体的轻链CDR1，选自氨基酸序列SEQ ID NO:18、23、32、40、61、77、84、88或其任何变体的轻链CDR2，选自氨基酸序列SEQ ID NO:19、33、62、78、89或其任何变体的轻链CDR3。
根据前述任一方面的抗体或其抗原结合部分，第一结合结构域的重链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:26、27、28的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、36、37的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、43、44的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、50、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:55、56、57的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:65、66、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:71、72、73的第一重链CDR1、CDR2及CDR3序列；氨基酸序列SEQ ID NO:71、147、73的第一重链CDR1、CDR2及CDR3序列；和第一结合结构域的轻链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:17、18、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:22、23、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:31、32、33的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:47、18、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:60、61、62的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:76、77、78的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:83、84、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:87、88、89的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:92、23、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:144、77、78的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、18、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:22、23、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:26、27、28的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:31、32、33的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、36、37的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、43、44的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:47、18、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、50、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:55、56、57的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:60、61、62的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:65、66、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:71、72、73的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:76、77、78的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:83、84、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:87、88、89的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:92、23、19的第一轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:71、147、73的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:144、77、78的第一轻链CDR1、CDR2及CDR3序列。
根据前述任一方面的抗体或其抗原结合部分，第一结合结构域包含选自氨基酸序列SEQ ID NO:10、24、34、41、48、53、63、69、79、145、150、154、158、162、166、170或其任何变体的第一重链可变区，和/或包含选自氨基酸序列SEQ ID NO:15、20、29、38、45、51、58、67、74、81、85、90、142、148、152、156、160、164、168或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:15或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:20或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:24或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:29或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:34或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:38或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:41或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:45或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:48或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:51或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:53或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:58或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:38或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:63或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:67或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:69或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:74或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:79或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:81或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:85或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:90或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:145或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:142或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:150或其任何变体的第一重链可变区，和氨 基酸序列SEQ ID NO:148或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:154或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:152或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:158或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:156或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:162或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:160或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:166或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:164或其任何变体的第一轻链可变区。
在一些实施方案中，第一结合结构域包含氨基酸序列SEQ ID NO:170或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:168或其任何变体的第一轻链可变区。
根据前述任一方面的抗体或其抗原结合部分，第二结合结构域包含选自氨基酸序列SEQ ID NO:114、115、116、119、122、125、128、131、134、135或其任何变体的重链CDR；和/或选自氨基酸序列SEQ ID NO:95、96、97、102、103、108、111或其任何变体的轻链CDR。
在一些实施方案中，第二结合结构域包含选自氨基酸序列SEQ ID NO:114、119、134或其任何变体的第二重链CDR1，选自氨基酸序列SEQ ID NO:115、135或其任何变体的第二重链CDR2，选自氨基酸序列SEQ ID NO:116、122、125、128、131或其任何变体的第二重链CDR3；和/或选自氨基酸序列SEQ ID NO:95、102或其任何变体的第二轻链CDR1，选自氨基酸序列SEQ ID NO:96、103、111或其任何变体的第二轻链CDR2，选自氨基酸序列SEQ ID NO:91、108或其任何变体的第二轻链CDR3。
在一些实施方案中，第二结合结构域的重链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、116的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、122的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、125的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、128的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、131的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:134、135、116的第二重链CDR1、CDR2及CDR3序列；和第二结合结构域的轻链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:95、96、97的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:102、103、97的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:95、96、108的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:95、111、108的第二轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、96、97的第二轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:102、103、97的第二轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、96、108的第二轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、111、108的第二轻链CDR1、CDR2及CDR3序列。
在一些实施方案中，第二结合结构域包含选自氨基酸序列SEQ ID NO:112、117、120、123、126、129、132、136、138、140或其任何变体的第二重链可变区，和/或包含选自氨基酸序列SEQ ID NO:93、98、100、104、106、109或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:136或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:93或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:93或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:98或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:100或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:112或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:136或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些实施方案中，第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
根据前述任一方面的抗体或其抗原结合部分，第一抗原结合部分的第一轻链为κ型轻链，第二抗原结合部分的 第二轻链为λ型轻链，
在一些实施方案中，第二抗原结合部分的第二轻链可变区具有Gln 40Glu突变(Vλ CD3:Gln 40Glu)；第二抗原结合部分的第二重链可变区具有Gln 39Lys突变(VH CD3:Gln 39Lys)。
在一些实施方案中，第一抗原结合部分的第一轻链可变区具有Gln 42Lys突变(Vκ BCMA:Gln 42Lys)在一些实施方案中，第一抗原结合部分的第一重链可变区具有Gln 39Glu突变(VH BCMA:Gln 39Glu)。
在一些实施方案中，双特异抗体的第一抗原结合部分和第二抗原结合部分的Fc部分采用knob-into-hole结构。在一些优选的实施方案中，Fc部分采用人IgG4knob-into-hole结构。
在一些实施方案中，第一重链包含选自SEQ ID NO:174、178或其任何变体的重链，第一轻链包含选自SEQ ID NO:172、176或其任何变体的轻链。
在一些优选的实施方案中，第一重链包含选自SEQ ID NO:174或其任何变体的重链，第一轻链包含选自SEQ ID NO:172或其任何变体的轻链。
在一些优选的实施方案中，第一重链包含选自SEQ ID NO:174或其任何变体的重链，第一轻链包含选自SEQ ID NO:176或其任何变体的轻链。
在一些优选的实施方案中，第一重链包含选自SEQ ID NO:178或其任何变体的重链，第一轻链包含选自SEQ ID NO:172或其任何变体的轻链。
在一些优选的实施方案中，第一重链包含选自SEQ ID NO:178或其任何变体的重链，第一轻链包含选自SEQ ID NO:176或其任何变体的轻链。
在一些实施方案中，第二重链包含SEQ ID NO:182或其任何变体的重链，第二轻链包含SEQ ID NO:180或其任何变体的轻链。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:145或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:142或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:150或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:148或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:154或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:152或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:158或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:156或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:162或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:160或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:166或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:164或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
在一些优选的实施方案中，双特异性抗体的第一结合结构域包含氨基酸序列SEQ ID NO:170或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:168或其任何变体的第一轻链可变区；第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
在一个具体实施方案中，第一重链包含SEQ ID NO:174，双特异性抗体的第一轻链包含SEQ ID NO:172；第二重链包含SEQ ID NO:182，第二轻链包含SEQ ID NO:180。
在一个具体实施方案中，第一重链包含SEQ ID NO:174，双特异性抗体的第一轻链包含SEQ ID NO:176；第二重链包含SEQ ID NO:182，第二轻链包含SEQ ID NO:180。
在一个具体实施方案中，第一重链包含SEQ ID NO:178，双特异性抗体的第一轻链包含SEQ ID NO:172；第二重链包含SEQ ID NO:182，第二轻链包含SEQ ID NO:180。
在一个具体实施方案中，第一重链包含SEQ ID NO:178，双特异性抗体的第一轻链包含SEQ ID NO:176；第二重链包含SEQ ID NO:182，第二轻链包含SEQ ID NO:180。
在一方面，本公开提供了一种结合BCMA的抗体或其抗原结合部分，抗体包含前述第一抗原结合部分。
在一些实施方案中，结合BCMA的抗体或其抗原结合部分与前述任一方面的抗体或其抗原结合部分具有至少大于60％、65％、70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更高的序列同一性。
在一方面，本公开提供了编码如前述任一方面的抗体或其抗原结合部分的核酸，或与其具有至少大于60％、65％、70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更高的序列同一性的核酸分子。
在一些实施方案中，第一抗原结合部分的第一重链可变区的编码核酸选自核苷酸序列SEQ ID NO:11、25、35、42、49、54、64、70、80、146、151、155、159、163、167、171或其任何变体；和/或第一抗原结合部分的第一轻链可变区的编码核酸选自核苷酸序列SEQ ID NO:16、21、30、39、46、52、59、68、75、82、86、91、143、149、153、157161、165、169或其任何变体。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:16。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:21。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:25；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:30。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:35；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:39。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:42；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:46。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:49；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:52。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:54；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:59。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:39。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:64；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:68。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:70；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:75。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:80；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:82。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:86。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:91。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:146；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:143。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:151；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:149。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:155；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:153。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:159；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:157。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:163；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:161。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:167；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:165。
在一些优选的实施方案中，第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:171；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:169。
在一些实施方案中，第一抗原结合部分的第一重链的编码核酸选自核苷酸序列SEQ ID NO:175、179或其任何变体；和/或第一抗原结合部分的第一轻链的编码核酸选自核苷酸序列SEQ ID NO:173、177或其任何变体。
在一些优选的实施方案中，第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173。
在一些优选的实施方案中，第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177。
在一些优选的实施方案中，第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173。
在一些优选的实施方案中，第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和第一抗 原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177。
在一些实施方案中，第二抗原结合部分的第二重链可变区的编码核酸选自核苷酸序列SEQ ID NO:113、118、121、124、127、130、133、137、139、141或其任何变体；和/或第二抗原结合部分的第二轻链可变区的编码核酸选自核苷酸序列SEQ ID NO:94、99、101、105、107、110或其任何变体。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:137；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:94。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:94。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:99。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:101。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:113；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:137；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些实施方案中，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183或其任何变体；和/或第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181或其任何变体。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:146；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:143；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:151；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:149；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:155；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:153；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:159；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:157；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:163；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:161；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:167；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:165；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:171；和第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:169；第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107。
在一些优选的实施方案中，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
在一些优选的实施方案中，双特异性抗体的第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177，第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
在一方面，本公开提供了一种结合BCMA的抗体或其抗原结合部分，抗体包含前述第一抗原结合部分。
在一方面，本公开提供了包含前述核酸的载体。
在一方面，本公开提供了包含前述核酸或载体的细胞。
在一方面，本公开提供了包含前述双特异性抗体或其抗原结合部分、核酸、载体和/或细胞的组合物。
在一方面，本公开提供了包含共价附着至治疗部分的前述双特异性抗体或其抗原结合部分的抗体-药物偶联物。
优选地，治疗部分选自细胞毒性部分、化疗剂、细胞因子、免疫抑制剂、免疫刺激剂、裂解肽或放射性同位素。
本公开的抗体在各种BCMA被不利地表达或发现的疾病中可用作治疗或诊断工具。
在一个与BCMA相关的疾病实施方案中，BCMA在患病组织或器官的细胞中的表达与在健康组织或器官中的状态相比有所增加。增加是指增加至少10％、特别是至少20％、至少50％、至少100％、至少200％、至少500％、至少1000％、至少10000％或甚至更多。在一个实施方案中，表达仅在患病组织中发现，而在相应健康组织中的表达受阻抑。根据本公开，与BCMA相关的疾病包括B细胞疾病，例如B细胞障碍，如浆细胞障碍和/或自体免疫疾病。
在一些实施方案中，疾病状况是癌症。在一些实施方案中，癌症是B-细胞相关癌症，其选自多发性骨髓瘤、恶性浆细胞瘤、霍奇金淋巴瘤、结节性淋巴细胞为主的霍奇金淋巴瘤、Kahler’s病和骨髓性白血病、浆细胞白血病、浆细胞瘤、B-细胞幼淋巴细胞白血病、毛细胞白血病、B-细胞非霍奇金淋巴瘤(NHL)、急性髓性白血病(AML)、慢性淋巴细胞白血病(CLL)、急性淋巴细胞白血病(ALL)、慢性髓性白血病(CML)、滤泡性淋巴瘤、伯基特淋巴瘤、边缘区淋巴瘤、套细胞淋巴瘤、大细胞淋巴瘤、前体B-淋巴细胞淋巴瘤、髓性白血病、瓦尔登斯特伦巨球蛋白血症、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、边缘区淋巴瘤、粘膜相关淋巴组织淋巴瘤、小细胞淋巴细胞性淋巴瘤、套细胞淋巴瘤、伯基特淋巴瘤、原发性纵隔(胸腺)大B细胞淋巴瘤、淋巴浆细胞淋巴瘤、瓦尔登斯特伦巨球蛋白血症、***边缘区B细胞淋巴瘤、脾边缘区淋巴瘤、血管内大B-细胞淋巴瘤、原发性渗出性淋巴瘤、淋巴瘤样肉芽肿病、富含T细胞/组织细胞的大B-细胞淋巴瘤、原发性中枢神经***淋巴瘤、原发性皮肤弥漫性大B-细胞淋巴瘤(腿型)、老年人EBV阳性弥漫性大B-细胞淋巴瘤、炎症相关的弥漫性大B-细胞淋巴瘤、血管内大B-细胞淋巴瘤、ALK阳性大B-细胞淋巴瘤、浆母细胞淋巴瘤、HHV8相关的多中心Castleman病中产生的大B-细胞淋巴瘤、未分类的具有弥漫性大B-细胞淋巴瘤和伯基特淋巴瘤中间特征的B-细胞淋巴瘤、未分类的具有弥漫性大B-细胞淋巴瘤和经典霍奇金淋巴瘤中间特征的B-细胞淋巴瘤以及其他B-细胞相关淋巴瘤。
在浆细胞障碍中，一个浆细胞克隆不受控制地繁殖。结果，该克隆产生大量称为M-蛋白的单一(单克隆)抗体。在一些情况下，例如患有单克隆丙种球蛋白病，产生的抗体是不完整的，其仅由轻链或重链组成。这些异常浆细胞及其产生的抗体通常限于一种类型。优选地，浆细胞障碍选自：多发性骨髓瘤、浆细胞瘤、浆细胞白血病、巨球蛋白血症、淀粉样变性、华氏巨球蛋白血症、孤立性骨浆细胞瘤、髓外浆细胞瘤、骨硬化性骨髓瘤、重链病、意义不明确的单克隆丙种球蛋白病以及郁积型多发性骨髓瘤。
在一些实施方案中，疾病状况是自身免疫性病症，如***性红斑性狼疮或类风湿性关节炎。
在一些实施方案中，该治疗剂包含特异性结合活化性T细胞抗原的抗体。
在一个实施方案中，该治疗剂包含特异性结合CD3，特别是CD3ε的抗体。
用本公开的双特异性抗体治疗的疾病和症状方法包括下述步骤：向哺乳动物施用治疗有效量的前述任一方面的抗体或其抗原结合片段或核酸分子或载体或细胞或药物组合物。
在一些实施方案中，本公开提供治疗或预防癌症疾病的方法，其包括向患者施用能够结合BCMA的抗体，其中施用抗体以提供至少40μg/ml的血清水平。在不同实施方案中，施用抗体以提供至少50μg/ml、至少150μg/ml、至少300μg/ml、至少400μg/ml或至少500μg/ml的血清水平。在不同实施方案中，施用抗体以提供不超过800μg/ml、700μg/ml、600μg/ml、550μg/ml或500μg/ml的血清水平。在一个实施方案中，所提供的血清水平为40μg/ml至700μg/ml，优选为40μg/ml至600μg/ml，优选为50μg/ml至500μg/ml，如150μg/ml至500μg/ml或者300μg/ml至500μg/ml。如本说明书中使用的术语“血清水平”，其意指所讨论的物质在血清中的浓度。在一个实施方案中，提供血清水平至少7天或至少14天。在一个实施方案中，所述方法包括施用至少300mg/m 2的抗体剂量，如至少600mg/m 2，且优选至多1500mg/m 2，至多1200mg/m 2或至多1000mg/m 2。
在一些实施方案中，本公开提供治疗或预防癌症疾病的方法，其包括向患者施用能够结合BCMA的抗体，其中以至少300mg/m 2，如至少600mg/m 2，且优选至多1500mg/m 2，至多1200mg/m 2或至多1000mg/m 2的剂量施用抗体。
在一些实施方案中，本公开提供治疗或预防癌症疾病的方法，其包括向患者施用能够结合BCMA的抗体，其中患者的至少50％，优选为60％、70％、80％或90％的癌细胞为BCMA阳性和/或患者的至少40％，优选为50％或60％的癌细胞为BCMA的表面表达阳性。在该方面，本公开还提供治疗或预防癌症疾病的方法，方法包括：a.鉴定显示至少50％，优选为60％、70％、80％或90％的BCMA阳性癌细胞和/或至少40％，优选为50％或60％的癌细胞的患者，癌细胞为BCMA的表面表达阳性；以及b.向患者施用能够结合BCMA的抗体。在一个实施方案中，患者的至少95％或至少98％的癌细胞为BCMA阳性的。在一个实施方案中，患者的至少70％、至少80％或至少90％的癌细胞为BCMA的表面表达阳性。
在本文所述的任何方面的方法的一个实施方案中，癌症疾病的治疗结果是实现病情稳定。在一个实施方案中，病情稳定实现至少2个月、至少3个月或至少6个月。
在一些实施方案中，本公开提供实现癌症患者的病情稳定的方法，其包括向患者施用能够结合BCMA的抗体。在一个实施方案中，病情稳定实现至少2个月、至少3个月或至少6个月。
在本文所述的任何方面的方法的一个实施方案中，以单剂量或多剂量施用抗体。
在一些实施方案中，本公开提供治疗或预防癌症疾病的方法，其包括向患者施用能够结合BCMA的抗体，其中以多剂量施用抗体。
如果根据本公开以多次剂量施用抗体，则优选以至少3次剂量、至少4次剂量、至少5次剂量、至少6次剂量、至少7次剂量、至少8次剂量、至少9次剂量或至少10次剂量且优选至多30次剂量、25次剂量、20次剂量、15次剂量或10次剂量施用抗体。优选以至少7天、至少10天、至少14天或至少20天的时间间隔施用抗体的剂量。优选以7至30天、10至20天且优选为约14天的时间间隔施用抗体的剂量。
在一个实施方案中，施用抗体以便提供至少40μg/ml的血清水平。在不同实施方案中，施用抗体以便提供至少50μg/ml、至少150μg/ml、至少300μg/ml、至少400μg/ml或至少500μg/ml的血清水平。在不同实施方案中，施用抗体以便提供不超过800μg/ml、700μg/ml、600μg/ml、550μg/ml或500μg/ml的血清水平。在一个实施方案中，所提供的血清水平为40μg/ml至700μg/ml，优选为40μg/ml至600μg/ml，优选为50μg/ml至500μg/ml，如150μg/ml至500μg/ml或300μg/ml至500μg/ml。在一个实施方案中，提供血清水平至少7天或至少14天。在一个实施方案中，所述方法包括施用至少300mg/m 2，如至少600mg/m 2且优选至多1500mg/m 2、至多1200mg/m 2或至多1000mg/m 2的抗体的剂量。
前述任一方面的抗体或其抗原结合片段或核酸分子或载体或细胞或药物组合物在制备用于治疗哺乳动物中BCMA相关病症的药物中的用途。
根据前述任一方面，任选地，抗体偶联其他药物，例如带标记或具有细胞毒性的缀合物。
在一方面，本公开还包括试剂盒，例如试剂盒包括本公开的抗体、其片段、同源物、其衍生物等，例如带标记或具有细胞毒性的缀合物，以及抗体使用说明书、杀死特定类型细胞的缀合物等等。该说明书可包括在体外、体内或离体使用抗体、缀合物等的指导。抗体可以是液体形式或固体，通常是冻干的。该试剂盒可包含其它适宜的试剂，如缓冲液、重构溶液以及为了预定用途的其它必要成分。考虑了以预定量包装好的试剂组合与用于其用途的说明书，用途例如用于治疗用途或用于进行诊断测定。当抗体是带标记的时，例如用酶标记的，那么该试剂盒可包括底物和酶所需的辅因子(例如提供可检测生色团或荧光团的底物前体)。此外，其它添加剂，如稳定剂、缓冲液(例如封闭缓冲液或裂解缓冲液)等也可包括在内。多种试剂的相对量可以改变而提供试剂溶液的浓缩物，这就提供了用户灵活性、节省空间、节省试剂等。这些试剂也可以干粉形式提供，通常是冻干形式，包括赋形剂，它在溶解时可提供具有适当浓度的试剂溶液。
前述任一方面的抗体或其功能片段或核酸分子或载体或细胞或药物组合物或试剂盒在制备用于抑制BCMA结合的试剂中的用途。
此外，本公开的抗体还可用于免疫测定、纯化方法以及其它用到免疫球蛋白或其片段的方法。此类用途在本领域为人所熟知。
相应地，本公开还提供包含本公开的抗BCMA的抗体或其片段的组合物，抗体方便地和药学上可接受的载体、稀释剂或赋形剂组合，这是本领域的常规做法。
本公开所使用的术语“药物组合物”系指多种制备物的制剂。含有治疗有效量的多价抗体的制剂为无菌液体溶液、液体悬浮剂或冻干形式，任选地包含稳定剂或赋形剂。
本公开的抗体可以作为单独施用的组合物使用，或可与其它活性剂联合使用。
在一些实施方案中，本公开的人源化抗体与治疗部分(即药物)偶联。治疗部分可以是例如细胞毒素、化疗剂、细胞因子、免疫抑制剂、免疫刺激剂、裂解肽或放射性同位素。此类偶联物在本文中称为“抗体-药物偶联物”或“ADC”。
在一些实施方案中，抗体与细胞毒性部分偶联。细胞毒性部分可以例如选自以下：紫杉醇；细胞松弛素B；短杆菌肽D；溴化乙锭；吐根碱；丝裂霉素；依托泊苷；替尼泊苷；长春新碱；长春碱；秋水仙碱；多柔比星；柔红霉素；二羟基蒽二酮；微管蛋白抑制剂如美登素或其类似物或衍生物；抗有丝***剂如单甲基奥瑞他汀E或F或其类似物或衍生物；海兔毒素10或15或其类似物；伊立替康或其类似物；米托蒽醌；光辉霉素；放线菌素D；1-脱氢睾酮；糖皮质激素；普鲁卡因；丁卡因；利多卡因；***；嘌呤霉素；卡奇霉素或其类似物或衍生物；抗代谢药，如甲氨喋呤、6巯基嘌呤、6硫鸟嘌呤、阿糖胞苷、氟达拉滨、5氟尿嘧啶、癸二嗪、羟基脲、天冬酰胺酶、吉西他滨或克拉屈滨；烷化剂，如二氯甲基二乙胺、硫代嘌呤、苯丁酸氮芥、美法仑、卡莫司汀(BSNU)、洛莫司汀(CCNU)、环磷酰胺、白消安、二溴甘露醇、链脲佐菌素、达卡巴嗪(DTIC)、丙卡巴嗪、丝裂霉素C；铂类衍生物，如顺铂或卡铂；多卡霉素A、多卡霉素SA、雷切霉素(CC-1065)或其类似物或衍生物；抗生素，如放线菌素、博来霉素、柔红霉素、多柔比星、伊达比星、光霉素、丝裂霉素、米托蒽醌、普力霉素、安定霉素(AMC)；吡咯并[2,1-c][1,4]-苯并二氮杂卓(PDB)；白喉毒素及相关分子如白喉A链及其活性片段和杂合分子、蓖麻毒素如蓖麻毒素A或去糖基化蓖麻毒素A链毒素、霍乱毒素、志贺样毒素如SLT I、SLT II、SLT IIV、LT毒素、C3毒素、志贺毒素、百日咳毒素、破伤风毒素、大豆Bowman-Birk蛋白酶抑制剂、假单胞菌外毒素、阿罗林、皂草素、蒴莲根毒素、胶凝蛋白、相思豆毒素A链、蒴莲根毒素A链、α-sarcin、油桐(Aleurites fordii)蛋白、石竹素蛋白、美洲商陆蛋白如PAPI、PAPII和PAP-S、苦瓜(momordica charantia)抑制剂、泻果素、巴豆毒素、肥阜草(sapaonaria officinalis)抑制剂、白树毒素、丝裂霉素、局限曲菌素、酚霉素和依诺霉素毒素；核糖核酸酶(RNase)；DNase I、葡萄球菌内毒素A；商陆抗病毒蛋白；白喉毒素和假单胞菌内毒素。
在一些实施方案中，抗体与奥瑞他汀或其肽类似物、衍生物或前药偶联。已经表明，奥瑞他汀干扰微管动力学、GTP水解以及核和细胞***并具有抗癌和抗真菌活性。例如，奥瑞他汀E可以与对乙酰基苯甲酸或苯甲酰基戊酸反应，分别产生AEB和AEVB。其他典型的奥瑞他汀衍生物包括AFP、MMAF(单甲基奥瑞他汀F)和MMAE(单甲基 奥瑞他汀E)。合适的奥瑞他汀和奥瑞他汀的类似物、衍生物和前药，以及用于将奥瑞他汀与Ab偶联的合适接头描述于例如美国专利号5,635,483、5,780,588和6,214,345以及国际专利申请公开WO02088172、WO2004010957、WO2005081711、WO2005084390、WO2006132670、WO03026577、WO200700860、WO207011968和WO205082023。
在一些实施方案中，抗体与吡咯并[2,1-c][1,4]-苯并二氮杂卓(PDB)或其肽类似物、衍生物或前药偶联。合适的PDB以及PDB衍生物和相关技术描述于例如Hartley J.A.等,Cancer Res 2010；70(17):6849-6858；Antonow D.等,Cancer J 2008；14(3):154-169；Howard P.W.等,Bioorg Med Chem Lett 2009；19:6463-6466和Sagnou等,Bioorg Med Chem Lett 2000；10(18):2083-2086。
在一些实施方案中，抗体与选自以下的细胞毒性部分偶联：蒽环类抗生素、美登素、卡奇霉素、多卡霉素、雷切霉素(CC-1065)、海兔毒素10、海兔毒素15、伊立替康、单甲基奥瑞他汀E、单甲基奥瑞他汀F、PDB，或它们任何的类似物、衍生物或前药。
在一些实施方案中，抗体与蒽环类抗生素或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与美登素或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与卡奇霉素或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与多卡霉素或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与雷切霉素(CC-1065)或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与海兔霉素10或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与海兔霉素15或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与单甲基奥瑞他汀E或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与单甲基奥瑞他汀F或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与吡咯并[2,1-c][1,4]-苯并二氮杂卓或其类似物、衍生物或前药偶联。在一些实施方案中，抗体与伊立替康或其类似物、衍生物或前药偶联。
在一些实施方案中，抗体与细胞因子(例如IL-2、IL-4、IL-6、IL-7、IL-10、IL-12、IL-13、IL-15、IL-18、IL-23、IL-24、IL-27、IL-28a、IL-28b、IL-29、KGF、IFNα、IFNβ、IFNγ、GM-CSF、CD40L、Flt3配体、干细胞因子、安西司亭和TNFα)偶联。
在一些实施方案中，抗体与放射性同位素或含放射性同位素的螯合物偶联。例如，抗体可以与允许抗体与放射性同位素络合的螯合剂接头(例如DOTA、DTPA或噻西坦)偶联。抗体还可以或可选地包含一个或多个放射性标记的氨基酸或其他放射性标记的分子或与之偶联。放射性同位素的非限制性实例包括 3H、 14C、 15N、 35S、 90Y、 99Tc、 125I、 131I、 186Re、 213Bi、 225Ac和 227Th。为了治疗目的，可以使用发射β或α颗粒辐射的放射性同位素，例如 131I、 90Y、 211At、 212Bi、 67Cu、 186Re、 188Re和 212Pb。
将分子与抗体偶联的技术是本领域熟知的。通常，核酸分子分别通过N-羟基琥珀酰亚胺酯或马来酰亚胺官能团与抗体上的赖氨酸或半胱氨酸共价连接。据报道，使用工程化半胱氨酸或整合非天然氨基酸的偶联方法可改进偶联物的同质性。特别地，本领域技术人员还可以预期用含酰基供体谷氨酰胺的标签(例如含有Gin肽的标签或Q-标签)或通过多肽工程(例如通过多肽上的氨基酸缺失、***、取代或突变)产生反应性的内源性谷氨酰胺工程化的含Fc多肽。然后，转谷氨酰胺酶可与胺供体剂(例如，包含或连接于反应性胺的小分子)共价交联，以形成稳定且均质的工程化含Fc多肽偶联物群，其中胺供体剂通过含酰基供体谷氨酰胺标签或可接近/暴露/反应性的内源性谷氨酰胺位点特异性地与含Fc多肽偶联(WO2012059882)。
应当理解，根据上述实施方案的治疗剂将与合适的药学上可接受的载体、赋形剂、以及其它被掺入制剂中以提供改善的转移、递送、耐受性等的试剂一同施用。大量适当的制剂可见于所有药物化学工作者已知的药典中：Remington's Pharmaceutical Sciences(第15版，Mack Publishing Company，Easton，Pa.(1975))，特别是其中Blaug、Seymour的第87章。这些制剂包括例如粉末、糊剂、膏剂、凝胶剂、蜡、油、脂质、含脂质(阳离子或阴离子)载体(例如Lipofectin TM)、DNA缀合物、无水吸浆、水包油和油包水乳液、乳液聚乙二醇(各种分子量的聚乙二醇)、半固态凝胶以及含有聚乙二醇的半固态混合物。任何前述混合物均可适用于根据本公开的治疗或疗法，条件是制剂中的活性成分不被制剂灭活并且制剂在生理学上是相容的并耐受给药途径。
在一个实施方案中，可将抗体用作治疗剂。此类试剂将通常用于治疗、缓解和/或预防受试者的与异常BCMA表达、活性和/或信号传导相关的疾病或病理。可使用标准方法通过鉴定受试者，例如患有(或处于风险或发展)与异常BCMA表达、活性和/或信号传导相关的疾病或障碍，例如BCMA相关病症的人患者来实施治疗方案。将抗体制剂，优选对其靶抗原有高特异性和高亲和性的抗体制剂施用给受试者并且将通常因其与靶标结合而产生效应。施用的抗体可消除或抑制或妨碍靶标(例如BCMA)的表达、活性和/或信号传导功能。施用的抗体可消除或抑制或妨碍靶标(例如BCMA)与其所天然结合的内源性的配体结合。例如，抗体与靶标结合并调节、阻断、抑制、减少、拮抗、中和/或以其它方式妨碍BCMA表达、活性和/或信号传导。在一些实施方案中，为治疗与异常BCMA表达相关的疾病或障碍，可将具有重链和轻链CDR的抗体施用给受试者。
在另一个实施方案中，针对BCMA的抗体可用于本领域中已知的与BCMA定位和/或定量相关的方法(例如，用于测定适当生理样品中的BCMA和/或BCMA的水平，用于诊断方法，用于蛋白成像等等)。在一个给定实施方案中，对BCMA或其衍生物、片段、类似物或同系物具有特异性的、包含源于抗体的抗原结合结构域的抗体，被用作药物学活性化合物(下文称为“治疗剂”)。
在另一个实施方案中，可通过标准技术例如免疫亲和、色谱或免疫沉淀，使用对BCMA具有特异性的抗体来分离BCMA多肽。针对BCMA蛋白质的抗体(或其片段)可用于检测生物样品中的蛋白质。在一些实施方案中，在生物样品中可检测BCMA作为临床测试过程的一部分，例如，用于确定给定治疗方案的功效。将抗体偶联(即物理连接)到可检测物质可有利于检测。可检测物质的示例包括各种酶、辅基、荧光材料、发光材料、生物发光材料和放射性材料。合适的酶的示例包括辣根过氧化物酶、碱性磷酸酶、β-半乳糖苷酶或乙酰胆碱酯酶；合适的辅基 复合物的示例包括链霉亲和素/生物素和亲和素/生物素；合适的荧光材料的示例包括伞形酮、荧光素、异硫氰酸荧光素、罗丹明、二氯三嗪氨荧光素、丹磺酰氯或藻红蛋白；发光材料的一个示例包括鲁米诺；生物发光材料的示例包括荧光素酶、荧光素和水母蛋白，并且合适放射性材料的示例包括 125I、 131I、 35S或 3H。
在另一个实施方案中，根据本公开的抗体可用作检测样品中BCMA或其蛋白质片段存在的试剂。在一些实施方案中，抗体包含可检测标记。抗体为多克隆抗体，或更优选单克隆抗体。使用完整的抗体或其片段(例如Fab、scFv或F(ab') 2)。关于抗体的术语“标记”旨在包括通过将可检测物质偶联(即物理连接)到该抗体来直接标记该抗体，以及通过与直接标记的另一种试剂反应来间接标记该抗体。间接标记的示例包括使用荧光标记的第二抗体检测第一抗体，以及用生物素进行末端标记抗体，以便能够用荧光标记的链霉亲和素进行检测。术语“生物样品”旨在包括从受试者分离的组织、细胞和生物学流体，以及受试者体内存在的组织、细胞和流体。因此，使用的术语“生物样品”包括血液和血液中的级分或组分，包括血清、血浆、或淋巴液。换言之，上述实施方案的检测方法可用于在体外及体内检测生物样品中的分析物mRNA、蛋白质或基因组DNA。例如，分析物mRNA体外检测技术包括Norhtern杂交和原位杂交。分析物蛋白质体外检测技术包括酶联免疫吸附测定(ELISA)、Western印迹、免疫沉淀、以及免疫荧光。分析物基因组DNA体外检测技术包括Southern杂交。用于进行免疫测定的过程描述于例如“ELISA:Theory and Practice:Methods in Molecular Biology”，第42卷，J.R.Crowther(编辑)Human Press，Totowa，N.J.，1995；“Immunoassay”，E.Diamandis和T.Christopoulus，Academic Press，Inc.，San Diego，Calif.，1996；以及“Practice and Theory of Enzyme Immunoassays”，P.Tijssen，Elsevier Science Publishers，Amsterdam，1985。此外，分析物蛋白质的体内检测技术包括向受试者体内导入标记的抗分析物蛋白抗体。例如，可以用放射性标记标记抗体，然后可以通过标准成像技术检测受试者体内该放射性标记物的存在和位置。
可将本文所述抗体和其衍生物、片段、类似物和同系物掺入适于施用的药物组合物中。制备此类组合物所涉及的原理和考虑事项以及选择组分的指南在本领域中是熟知的，例如参见Remington's Pharmaceutical Sciences:The Science And Practice Of Pharmacy第19版(Alfonso R.Gennaro等人编辑)Mack Pub.Co.，Easton，Pa.:1995；Drug Absorption Enhancement:Concepts，Possibilities，Limitations，And Trends，Harwood Academic Publishers，Langhorne，Pa.，1994；以及Peptide And Protein Drug Delivery(Advances In Parenteral Sciences，第4卷)，1991，M.Dekker，New York。
此类组合物通常包含抗体和药学上可接受的载体。当使用抗体片段时，与靶蛋白结合结构域特异性结合的最小抑制片段可为优选的。例如，基于抗体的可变区序列，可以设计保留结合靶蛋白质序列能力的肽分子。此类肽可化学合成和/或通过重组DNA技术产生(参见例如Marasco等人，Proc.Natl.Acad.Sci.USA，90:7889-7893(1993))。
如本文所用，术语“药学上可接受的载体”旨在包括与药物给药相容的任何和所有溶剂、分散介质、包衣、抗细菌剂和抗真菌剂、等渗剂和吸收延缓剂等。合适的药学上可接受的载体描述于最新版的Remington's Pharmaceutical Sciences中，这是本领域的标准参考书目，其以引用方式并入本文。此类载体或稀释剂的优选示例包括但不限于水、盐水、林格氏溶液、葡萄糖溶液和5％的人血清白蛋白。也可以使用脂质体和非水性载体，例如固定化油。将此类介质和试剂用于药物活性物质是本领域熟知的。除去任何常规的介质或试剂与抗体不相容之外，设想其在组合物中的用途。
将上述实施方案的药物组合物配制成与其预期施用途径相容。给药途径的示例包括肠胃外，例如静脉内、皮内、皮下、经口(例如吸入)、经皮(即局部的)、经粘膜和直肠给药。用于肠胃外、皮内或皮下施用的溶液或悬浮液可包括以下组分：注射用无菌稀释剂例如水、盐溶液、固定油、聚乙二醇类、甘油、丙二醇或其它合成溶剂；抗细菌剂，例如苄醇或对羟基苯甲酸甲酯；抗氧化剂，例如抗坏血酸或亚硫酸氢钠；螯合剂，例如乙二胺四乙酸(EDTA)；缓冲剂，例如乙酸盐、柠檬酸盐或磷酸盐、以及调节渗透压的试剂，例如氯化钠或右旋糖。pH可用酸或碱进行调节，例如盐酸或氢氧化钠。可将肠胃外制剂包装在安瓿、一次性注射器或玻璃或塑料制多剂量小瓶内。
适于注射用途的药物组合物包括无菌水性溶液(在此是水溶性的)或分散体以及用于即时制备无菌注射液或分散体的无菌粉末。对于静脉内施用，合适的药学上可接受的载体包括生理盐水、抑菌水、Cremophor EL TM(BASF，Parsippany，N.J.)或磷酸盐缓冲盐水(PBS)。在所有情况下，组合物必须是无菌的并且应当为流动性达到易于注射的程度。其在制造和储存条件下必须是稳定的并且必须能防止微生物例如细菌和真菌的污染作用。载体可以是含有例如水、乙醇、多元醇(例如，甘油、丙二醇和液体聚乙二醇等)的溶剂或分散介质，及其适宜的混合物。例如通过利用涂层例如卵磷脂，在分散体情况下维持所需颗粒尺寸，以及利用表面活性剂，可以保持适宜的流动性。对微生物作用的防止可以通过各种抗细菌剂和抗真菌剂例如对羟基苯甲酸酯、氯代丁醇、苯酚、抗坏血酸、硫柳汞等来实现。在许多情况下，将优选在组合物中包含等渗剂，例如糖、多元醇(诸如甘露糖醇、山梨醇)、氯化钠。注射用组合物的延长吸收可通过在组合物中包含延缓吸收的试剂例如单硬脂酸铝和明胶来达到。
根据需要，可以通过将抗体以所需量掺入具有上文所列成分中的一种或组合(按需要)的合适溶剂中来制备无菌注射溶液，然后过滤消毒。一般来讲，通过将抗体掺入含有碱性分散介质和上文所列那些中的所需其它成分的无菌载体中来制备分散体。就用于制备无菌注射溶液的无菌粉末而言，制备方法是获得粉末的真空干燥和冷冻干燥，该粉末包含活性成分和任何另外的期望成分，它们来自前述的这些成分的无菌过滤溶液。
对于吸入给药，从包含合适推进剂如二氧化碳等气体的加压容器或分配器或者喷雾器以气溶胶喷雾形式递送化合物。
还可以通过经粘膜或透皮方式全身给药。对于经粘膜或透皮给药，在制剂中使用适于渗透屏障的渗透剂。此类渗透剂通常在本领域是通常所知的，并且包括如用于经粘膜给药的去污剂、胆盐和夫西地酸衍生物。经粘膜给药可以通过使用喷鼻剂或栓剂来实现。对于透皮给药，可将一种或多种抗体配制成如本领域通常所知的膏剂、软膏、凝 胶、或霜膏。
还可将化合物以栓剂(例如，具有常规栓剂基质，如可可脂或其它甘油酯)或滞留性灌肠剂形式进行制备以用于经直肠递送。
在一个实施方案中，抗体可用防止其不被身体迅速消除的载体制备，例如缓释/控释制剂，包括植入体和微胶囊化递送体系。可使用可生物降解、可生物相容的聚合物，例如乙烯-乙酸乙烯酯、聚酐、聚乙醇酸、胶原、聚原酸酯和聚乳酸。用于制备此类制剂的方法对于本领域技术人员而言是显而易见的。
尤其有利的是以剂量单位形式配制肠胃外组合物以易于施用和剂量的一致性。如本文所用，剂量单位形式是指用于待治疗的受试者，适合作为单位剂量的物理上可分离的单位；每个单位含有经计算与所需药物载体结合产生期望治疗效果的预定量的一种或多种抗体。上述实施方案的剂量单位形式的规格由以下指示并直接取决于：抗体的独特特征和待实现的具体治疗效果，和用于治疗个体的此类抗体的调配领域中固有的局限性。
药物组合物可与给药说明书一起放于容器、包装、或分配器中。
本文所述制剂还可根据要治疗的具体情况而包含多于一种抗体，优选具有互补活性但对彼此无负面影响的那些。另选地或除此之外，组合物可例如包含增强其功能的试剂，诸如细胞毒素试剂、细胞因子、化学治疗剂、或生长抑制剂。此类分子以对预期目的有效的量适当地联合存在。例如，可以在试剂盒中联合存在，也可以在使用中联合存在。
在一个实施方案中，一种或多种抗体可在联合治疗中施用，即与其它试剂例如治疗剂(其可用于治疗病理学病症或障碍，例如各种形式的癌症、自身免疫性障碍和炎性疾病)联合。术语“联合”在本文中是指将试剂基本上同步地，同时地或顺次地给予。如果顺次给予，则在开始施用第二种化合物时，两种化合物中的第一种仍优选在治疗位点处以有效浓度被检测到。在一种情况下，“联合”也可以是在试剂盒中同时包含本公开的抗体和其他治疗剂。
例如，联合治疗可包含本文所述一种或多种抗体与一种或多种附加治疗剂(例如一种或多种细胞因子和生长因子抑制剂、免疫抑制剂、抗炎剂、代谢抑制剂、酶抑制剂、和/或细胞毒素或细胞生长抑制剂，如下更详述的)共同配制和/或共同施用。此类联合治疗可有利地利用较低剂量的施用的治疗剂，因而避免了与各种单一疗法相关的可能毒性或并发症。
在一个实施方案中，抗BCMA抗体的施用和治疗剂的施用可以降低该受试者中的B细胞的数目。
在一个实施方案中，与相应的不施用抗BCMA抗体的治疗方案相比该治疗方案有效降低该受试者中与该T细胞活化性治疗剂的施用相关的细胞因子释放。
为了达到清楚和简洁描述的目的，本文中作为相同的或分开的一些实施方案的一部分来描述特征，然而，将要理解的是，本公开的范围可包括具有所描述的所有或一些特征的组合的一些实施方案。
实施例
实施例1抗原表达和稳转细胞的构建
分别以人BCMA(Sino biological，HG10620-M)和恒河猴BCMA(Sino biological，CG90103-G，与食蟹猴XP_005591343.1胞外区序列相同)为模板，扩增人BCMA(Met1-Asn53)或恒河猴BCMA(Met1-Asn52)，C端与小鼠IgG2a Fc融合，转染HEK293E细胞，表达得到人或食蟹猴BCMA-mFc双价重组蛋白(氨基酸序列如SEQ ID NO.1-2所示)；或与人IgG Fc(knob)融合，利用knob-into-hole技术，和人IgG Fc(hole)共转染HEK293E细胞，得到人或食蟹猴BCMA-hFc kih单价重组蛋白(氨基酸序列如SEQ ID NO.3-5所示)。图1示出了人、食蟹猴BCMA-mFc双价重组蛋白和BCMA-hFc kih单价重组蛋白的SDS-PAGE结果。
将含有人和食蟹猴BCMA全长序列的Lenti载体和包装质粒(Genecoepia)，共转染HEK293T细胞，转染48小时后收集含有假病毒的培养上清，取10μL感染1×10 6CHO细胞，加入不同浓度的嘌呤霉素(puromycin)进行抗性筛选，最终分离得到高表达人或食蟹猴BCMA的稳转细胞CHO-hBCMA(克隆2C2)和CHO-cynoBCMA(克隆1A2)。图2示出了流式细胞检测人和猴BCMA稳转细胞，人BCMA稳转细胞(CHO-hBCMA-2C2)和食蟹猴BCMA稳转细胞(CHO-cynoBCMA-1A2)均表达高水平的BCMA。
构建人或食蟹猴CD3εγ异源二聚体：合成人CD3γ(UniProt P09693，Gln23-Asn116)和CD3ε(UniProt P07766，Gln23-Asp126)胞外区核苷酸序列，C端分别与人IgG Fc hole或Fc knob融合，表达形成人CD3εγ-Fc异源二聚体(人CD3γIgG Fc(hole)的氨基酸序列如SEQ ID NO.6所示，人CD3εIgG Fc(knob)的氨基酸序列如SEQ ID NO.7所示)；同样合成食蟹猴CD3γ(UniProt Q95LI7，Gln23-Asn110)和CD3ε(UniProt Q95LI5，Gln22-Asp117)，C端与食蟹猴IgG Fc hole或Fc knob融合，表达形成食蟹猴CD3εγ-Fc异源二聚体(食蟹猴CD3γIgG Fc(hole)的氨基酸序列如SEQ ID NO.8所示，食蟹猴CD3γIgG Fc(knob)的氨基酸序列如SEQ ID NO.9所示。将表达CD3γ-Fc和CD3ε-Fc的重组质粒与3mg/mL PEI(Polysciences，#24765-2)混合，共转染HEK293E细胞(培养基OPM-293 CD03DPM)，37℃120rpm 5％CO 2培养7天后，收集培养基上清液，经Protein A亲和层析纯化，得到人或食蟹猴CD3εγ-Fc重组蛋白，SDS-PAGE纯度高于95％(图3)。
实施例2、动物免疫和BCMA抗体的制备
以BCMA-mFc重组蛋白或CHO-BCMA稳转细胞为免疫原，分别与等体积免疫佐剂(Titermax，Sigma-Aldrich)混合，取6周龄雌性Balb/c小鼠(北京维通利华)进行足垫或皮下免疫。在初次免疫以后，每两周进行一次相同剂量的加强免疫，并交替进行人和猴的抗原免疫。四次免疫后，检测到小鼠血清中BCMA抗体滴度大于1:10000。进行抗原尾静脉冲击免疫3天后，收取小鼠脾脏和部分外周***，提取总RNA，通过IgG特异引物反转录得到抗 体cDNA，分别扩增其中轻、重链可变区片段，构建噬菌体Fab文库，转化菌落数(库容量)约为1.2×10 10。
1、噬菌体抗体文库的筛选
采用经典的淘选方式，将1mL BCMA免疫文库噬菌体与3.5mL 2％BSA/PBS溶液混合后，加入包被人或食蟹猴BCMA重组蛋白的Maxisorp Immunotube(Nunc)，结合1小时后，用PBS-吐温(0.5％v/v)和PBS进行多轮洗涤以除去非特异或低亲和力结合的噬菌体，用100mM三乙胺洗脱高亲和力结合的噬菌体，中和后感染TG1细胞。经二轮筛选后，挑取单克隆接种至96孔U型板，加入1mM IPTG诱导表达，取含有Fab的诱导上清进行ELISA检测筛选，初筛得到265个阳性克隆。
重新诱导表达后，将10μg/ml的生物素化标记的人BCMA重组蛋白固定在SA探针上，结合时间200s，解离时间300s，检测与Fab的亲和力(Octet，Fortebio)。选取其中59个亲和力较高的克隆，利用人、食蟹猴BCMA-CHO稳转细胞检测与细胞膜表面受体的结合，其中52个克隆可交叉识别人和食蟹猴BCMA-CHO稳转细胞。
2、Biacore测定抗体的亲和力
选择部分高亲和力抗体克隆，提取质粒并转化TG1细胞，0.1mM IPTG 30℃诱导表达过夜，从细菌的周质腔抽提重组表达的Fab，通过Ni-NTA亲和层析纯化得到Fab抗体。Biacore亲和力测定采用Protein A芯片(GE healthcare)，设定捕获人BCMA-hFc重组蛋白(0.5μg/mL)为200RU，基线平稳后，将梯度稀释的抗体Fab(从10μg/mL起，2倍稀释7个梯度)，以30μL/min的流速流过芯片，结合时间350秒，解离时间600秒。通过Biacore T200 evaluation软件以Langmuir 1:1 kinetics模型，拟合得到动力学常数。BCMA抗体亲和力测定结果见表1。
表1、BCMA抗体的亲和力
Figure PCTCN2021135121-appb-000001
BCMA抗体可变区序列如下：
表2、BCMA鼠源抗体的可变区序列
Figure PCTCN2021135121-appb-000002
3G11
3G11重链VH的氨基酸序列如SEQ ID NO.10所示，其编码核酸如SEQ ID NO.11所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000003
核酸序列
Figure PCTCN2021135121-appb-000004
3G11轻链VK的氨基酸序列如SEQ ID NO.15所示，其编码核酸如SEQ ID NO.16所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.17、18、19所示。
Figure PCTCN2021135121-appb-000005
核酸序列
Figure PCTCN2021135121-appb-000006
6G5
6G5重链VH的氨基酸序列如SEQ ID NO.10所示，其编码核酸如SEQ ID NO.11所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000007
核酸序列
Figure PCTCN2021135121-appb-000008
6G5轻链VK的氨基酸序列如SEQ ID NO.20所示，其编码核酸如SEQ ID NO.21所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.22、23、19所示。
Figure PCTCN2021135121-appb-000009
核酸序列
Figure PCTCN2021135121-appb-000010
15G9
15G9重链VH的氨基酸序列如SEQ ID NO.24所示，其编码核酸如SEQ ID NO.25所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.26、27、28所示。
Figure PCTCN2021135121-appb-000011
核酸序列
Figure PCTCN2021135121-appb-000012
15G9轻链VK的氨基酸序列如SEQ ID NO.29所示，其编码核酸如SEQ ID NO.30所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.31、32、33所示。
Figure PCTCN2021135121-appb-000013
核酸序列
Figure PCTCN2021135121-appb-000014
Figure PCTCN2021135121-appb-000015
15H10
15H10重链VH的氨基酸序列如SEQ ID NO.34所示，其编码核酸如SEQ ID NO.35所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、36、37所示。
Figure PCTCN2021135121-appb-000016
核酸序列
Figure PCTCN2021135121-appb-000017
15H10轻链VK的氨基酸序列如SEQ ID NO.38所示，其编码核酸如SEQ ID NO.39所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000018
核酸序列
Figure PCTCN2021135121-appb-000019
16B9
16B9重链VH的氨基酸序列如SEQ ID NO.41所示，其编码核酸如SEQ ID NO.42所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、43、44所示。
Figure PCTCN2021135121-appb-000020
核酸序列
Figure PCTCN2021135121-appb-000021
16B9轻链VK的氨基酸序列如SEQ ID NO.45所示，其编码核酸如SEQ ID NO.46所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.47、18、19所示。
Figure PCTCN2021135121-appb-000022
核酸序列
Figure PCTCN2021135121-appb-000023
23F8
23F8重链VH的氨基酸序列如SEQ ID NO.48所示，其编码核酸如SEQ ID NO.49所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、50、14所示。
Figure PCTCN2021135121-appb-000024
核酸序列
Figure PCTCN2021135121-appb-000025
Figure PCTCN2021135121-appb-000026
23F8轻链VK的氨基酸序列如SEQ ID NO.51所示，其编码核酸如SEQ ID NO.52所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000027
核酸序列
Figure PCTCN2021135121-appb-000028
23G9
23G9重链VH的氨基酸序列如SEQ ID NO.53所示，其编码核酸如SEQ ID NO.54所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.55、56、57所示。
Figure PCTCN2021135121-appb-000029
核酸序列
Figure PCTCN2021135121-appb-000030
23G9轻链VK的氨基酸序列如SEQ ID NO.58所示，其编码核酸如SEQ ID NO.59所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.60、61、62所示。
Figure PCTCN2021135121-appb-000031
核酸序列
Figure PCTCN2021135121-appb-000032
29A11
29A11重链VH的氨基酸序列如SEQ ID NO.10所示，其编码核酸如SEQ ID NO.11所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000033
核酸序列
Figure PCTCN2021135121-appb-000034
29A11轻链VK的氨基酸序列如SEQ ID NO.38所示，其编码核酸如SEQ ID NO.39所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000035
核酸序列
Figure PCTCN2021135121-appb-000036
Figure PCTCN2021135121-appb-000037
34G2
34G2重链VH的氨基酸序列如SEQ ID NO.63所示，其编码核酸如SEQ ID NO.64所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.65、66、14所示。
Figure PCTCN2021135121-appb-000038
核酸序列
Figure PCTCN2021135121-appb-000039
34G2轻链VK的氨基酸序列如SEQ ID NO.67所示，其编码核酸如SEQ ID NO.68所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000040
核酸序列
Figure PCTCN2021135121-appb-000041
38E2
38E2重链VH的氨基酸序列如SEQ ID NO.69所示，其编码核酸如SEQ ID NO.70所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.71、72、73所示。
Figure PCTCN2021135121-appb-000042
核酸序列
Figure PCTCN2021135121-appb-000043
38E2轻链VK的氨基酸序列如SEQ ID NO.74所示，其编码核酸如SEQ ID NO.75所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.76、77、78所示。
Figure PCTCN2021135121-appb-000044
核酸序列
Figure PCTCN2021135121-appb-000045
38D9
38D9重链VH的氨基酸序列如SEQ ID NO.79所示，其编码核酸如SEQ ID NO.80所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000046
核酸序列
Figure PCTCN2021135121-appb-000047
Figure PCTCN2021135121-appb-000048
38D9轻链VK的氨基酸序列如SEQ ID NO.81所示，其编码核酸如SEQ ID NO.82所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.83、84、19所示。
Figure PCTCN2021135121-appb-000049
核酸序列
Figure PCTCN2021135121-appb-000050
38F9
38F9重链VH的氨基酸序列如SEQ ID NO.10所示，其编码核酸如SEQ ID NO.11所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000051
核酸序列
Figure PCTCN2021135121-appb-000052
38F9轻链VK的氨基酸序列如SEQ ID NO.85所示，其编码核酸如SEQ ID NO.86所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.87、88、89所示。
Figure PCTCN2021135121-appb-000053
核酸序列
Figure PCTCN2021135121-appb-000054
40C6
40C6重链VH的氨基酸序列如SEQ ID NO.10所示，其编码核酸如SEQ ID NO.11所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000055
核酸序列
Figure PCTCN2021135121-appb-000056
40C6轻链VK的氨基酸序列如SEQ ID NO.90所示，其编码核酸如SEQ ID NO.91所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.92、23、19所示。
Figure PCTCN2021135121-appb-000057
核酸序列
Figure PCTCN2021135121-appb-000058
Figure PCTCN2021135121-appb-000059
实施例3、BCMA×CD3双特异抗体的构建
1、CD3人源化抗体
鼠源杂交瘤CD3抗体(EMBO J.1985.4(2):337-344；J.Immunol.1986,137(4):1097-100；J.Exp.Med.1991,174:319-326；J.Immunol.1991,147(9):3047-52)识别人和食蟹猴CD3受体，其序列如下：
抗CD3鼠单抗轻链氨基酸序列如SEQ ID NO.184所示：
Figure PCTCN2021135121-appb-000060
抗CD3鼠单抗重链氨基酸序列如SEQ ID NO.185所示：
Figure PCTCN2021135121-appb-000061
将抗CD3鼠单抗人源化，选择同源性最高的人胚系基因IMGT_hVL7-43进行轻链CDR移植，FM4选用人IGLJ3*02；选择人IMGT_hVH3-73进行重链CDR移植，FM4选用人IGHJ4*01。设计共得到不同的重链变体和轻链变体。
CD3人源化抗体轻链可变区的序列如下：
表3、CD3人源化抗体的轻链可变区序列
Figure PCTCN2021135121-appb-000062
hVL1的氨基酸序列如SEQ ID NO.93所示，其编码核酸如SEQ ID NO.94所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.95、96、97所示。
Figure PCTCN2021135121-appb-000063
hVL2的氨基酸序列如SEQ ID NO.98所示，其编码核酸如SEQ ID NO.99所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.95、96、97所示。
Figure PCTCN2021135121-appb-000064
hVL3的氨基酸序列如SEQ ID NO.100所示，其编码核酸如SEQ ID NO.101所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.102、103、97所示。
Figure PCTCN2021135121-appb-000065
hVL4的氨基酸序列如SEQ ID NO.104所示，其编码核酸如SEQ ID NO.105所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.102、103、97所示。
Figure PCTCN2021135121-appb-000066
hVL5的氨基酸序列如SEQ ID NO.106所示，其编码核酸如SEQ ID NO.107所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.95、96、108所示。
Figure PCTCN2021135121-appb-000067
hVL6的氨基酸序列如SEQ ID NO.109所示，其编码核酸如SEQ ID NO.110所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.95、111、108所示。
Figure PCTCN2021135121-appb-000068
CD3人源化抗体重链可变区的序列如下：
表4、CD3人源化抗体的重链可变区序列
Figure PCTCN2021135121-appb-000069
Figure PCTCN2021135121-appb-000070
hVH1的氨基酸序列如SEQ ID NO.112所示，其编码核酸如SEQ ID NO.113所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.114、115、116所示。
Figure PCTCN2021135121-appb-000071
hVH2的氨基酸序列如SEQ ID NO.117所示，其编码核酸如SEQ ID NO.118所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.119、115、116所示。
Figure PCTCN2021135121-appb-000072
hVH3的氨基酸序列如SEQ ID NO.120所示，其编码核酸如SEQ ID NO.121所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.119、115、122所示。
Figure PCTCN2021135121-appb-000073
hVH4的氨基酸序列如SEQ ID NO.123所示，其编码核酸如SEQ ID NO.124所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.119、115、125所示。
Figure PCTCN2021135121-appb-000074
hVH5的氨基酸序列如SEQ ID NO.126所示，其编码核酸如SEQ ID NO.127所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.119、115、128所示。
Figure PCTCN2021135121-appb-000075
hVH6的氨基酸序列如SEQ ID NO.129所示，其编码核酸如SEQ ID NO.130所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.119、115、131所示。
Figure PCTCN2021135121-appb-000076
hVH7的氨基酸序列如SEQ ID NO.132所示，其编码核酸如SEQ ID NO.133所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.134、135、116所示。
Figure PCTCN2021135121-appb-000077
hVH8的氨基酸序列如SEQ ID NO.136所示，其编码核酸如SEQ ID NO.137所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.114、115、116所示。
Figure PCTCN2021135121-appb-000078
hVH9的氨基酸序列如SEQ ID NO.138所示，其编码核酸如SEQ ID NO.139所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.114、115、116所示。
Figure PCTCN2021135121-appb-000079
hVH10的氨基酸序列如SEQ ID NO.140所示，其编码核酸如SEQ ID NO.141所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.114、115、116所示。
Figure PCTCN2021135121-appb-000080
将轻、重链人源化变体分别进行全序列合成后，克隆到含有抗体lambda轻链恒定区或人IgG4重链恒定区CH1-CH3的真核表达载体，共转染HEK293E细胞，37℃120rpm 5％CO 2培养5-6天后，收集培养基上清液，通过Protein A层析柱进行纯化。
2、ELISA亲和力测定
包被人CD3εγ蛋白，4℃过夜。2％脱脂牛奶封闭后，每孔加入不同稀释倍数的CD3抗体，孵育1小时；二抗加入HPR标记的山羊抗人IgG Fc，TMB溶液显色后，以浓硫酸终止反应并在450nm处读出吸光度(结果如图4所示)。
图4显示与人CD3εγ蛋白结合的抗CD3人源化抗体组合(包括aCD3-hVH8/VL1、aCD3-hVH9/VL1、aCD3-hVH9/VL2、aCD3-hVH9/VL3、aCD3-hVH1/VL5、aCD3-hVH8/VL5、aCD3-hVH9/VL5)，CD3人源化抗体高亲和力结合CD3εγ重组蛋白。
3、Jurkat T细胞亲和力测定
取对数生长期的Jurkat细胞，3％BSA封闭30分钟，以每孔5×10 4细胞加入96孔U型板，离心弃上清，每孔加入50μL梯度稀释的抗体(抗体浓度从30μg/mL起，3倍稀释5个梯度)，4℃孵育1小时。洗去一抗后，加入二抗1:300稀释的Alexa Fluro647标记的山羊抗人IgG Fc(Jackson ImmunoResearch，109-606-170)，4℃孵育45分钟，洗涤后每孔重悬于50μL PBS进行FACS(iQue，Intellicyt)检测(结果如图5所示)。
图5显示与Jurkat细胞结合的抗CD3人源化抗体组合，其中CD3人源化抗体hVH9/VL5(aCD3-hVH9/VL5)以中度亲和力结合Jurkat细胞。
4、BCMA抗体与CD3抗体的组合筛选
选择部分亲和力较高的BCMA克隆，分别与同源性最高的人胚系基因进行CDR移植，得到BCMA人源化抗体h38E2、h23F8、h40C6、h38D9、h29A11、h15H10和h34G2(表5)。参考Schaefer W等(PNAS,2011)，对人源化BCMA抗体与CD3抗体aCD3-hVH9/VL5(轻链可变区氨基酸序列如SEQ ID NO.106所示，重链可变区氨基酸序列如SEQ ID NO.138所示)的组合进行筛选：将人源化BCMA抗体的轻链可变区克隆到含有kappa轻链恒定区的真核表达载体，将重链可变区克隆到含有突变的人IgG4恒定区真核表达载体；将人源化CD3抗体的轻链可变区克隆到含有lambda轻链恒定区以及重链铰链区和恒定区CH2、CH3的真核表达载体，将CD3抗体的重链可变区克隆到含有人CH1恒定区的真核表达载体，将编码轻、重链基因的4种质粒按1：1：1：1比率混合，转染HEK293E细胞，表达5-6天后收取培养上清，Protein A一步纯化后，SEC-HPLC显示单体含量>55％，用于相对活性评价。将BCMA-50(按US201213678247合成)按上述方法，与CD3人源化抗体构建成BCMA50-CD3双特异抗体作为参照，或参考文献表达BCMA50×CD3(BiTE)。
表5、人源化BCMA抗体可变区序列
Figure PCTCN2021135121-appb-000081
h38E2
h38E2轻链VK的氨基酸序列如SEQ ID NO.142所示，其编码核酸如SEQ ID NO.143所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.144、77、78所示。
Figure PCTCN2021135121-appb-000082
核酸序列
Figure PCTCN2021135121-appb-000083
h38E2重链VH的氨基酸序列如SEQ ID NO.145所示，其编码核酸如SEQ ID NO.146所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.71、147、73所示。
Figure PCTCN2021135121-appb-000084
核酸序列
Figure PCTCN2021135121-appb-000085
h23F8
h23F8轻链VK的氨基酸序列如SEQ ID NO.148所示，其编码核酸如SEQ ID NO.149所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000086
Figure PCTCN2021135121-appb-000087
核酸序列
Figure PCTCN2021135121-appb-000088
h23F8重链VH的氨基酸序列如SEQ ID NO.150所示，其编码核酸如SEQ ID NO.151所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、50、14所示。
Figure PCTCN2021135121-appb-000089
核酸序列
Figure PCTCN2021135121-appb-000090
h40C6
h40C6轻链VK的氨基酸序列如SEQ ID NO.152所示，其编码核酸如SEQ ID NO.153所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.92、23、19所示。
Figure PCTCN2021135121-appb-000091
核酸序列
Figure PCTCN2021135121-appb-000092
h40C6重链VH的氨基酸序列如SEQ ID NO.154所示，其编码核酸如SEQ ID NO.155所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000093
核酸序列
Figure PCTCN2021135121-appb-000094
h38D9
h38D9轻链VK的氨基酸序列如SEQ ID NO.156所示，其编码核酸如SEQ ID NO.157所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.83、84、19所示。
Figure PCTCN2021135121-appb-000095
核酸序列
Figure PCTCN2021135121-appb-000096
h38D9重链VH的氨基酸序列如SEQ ID NO.158所示，其编码核酸如SEQ ID NO.159所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000097
核酸序列
Figure PCTCN2021135121-appb-000098
h29A11
h29A11轻链VK的氨基酸序列如SEQ ID NO.160所示，其编码核酸如SEQ ID NO.161所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000099
核酸序列
Figure PCTCN2021135121-appb-000100
h29A11重链VH的氨基酸序列如SEQ ID NO.162所示，其编码核酸如SEQ ID NO.163所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、13、14所示。
Figure PCTCN2021135121-appb-000101
核酸序列
Figure PCTCN2021135121-appb-000102
h15H10
h15H10轻链VK的氨基酸序列如SEQ ID NO.164所示，其编码核酸如SEQ ID NO.165所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000103
核酸序列
Figure PCTCN2021135121-appb-000104
h15H10重链VH的氨基酸序列如SEQ ID NO.166所示，其编码核酸如SEQ ID NO.167所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.12、36、37所示。
Figure PCTCN2021135121-appb-000105
核酸序列
Figure PCTCN2021135121-appb-000106
h34G2
h34G2轻链VK的氨基酸序列如SEQ ID NO.168所示，其编码核酸如SEQ ID NO.169所示，其LCDR1、LCDR2和LCDR3分别如SEQ ID NO.17、40、19所示。
Figure PCTCN2021135121-appb-000107
核酸序列
Figure PCTCN2021135121-appb-000108
h34G2重链VH的氨基酸序列如SEQ ID NO.170所示，其编码核酸如SEQ ID NO.171所示，其HCDR1、HCDR2和HCDR3分别如SEQ ID NO.65、66、14所示。
Figure PCTCN2021135121-appb-000109
核酸序列
Figure PCTCN2021135121-appb-000110
5、T细胞依赖的细胞毒实验(TDCC)
取新鲜分离得到的PBMC和处于对数生长期的RPMI-8226细胞混合(效应/靶细胞＝10:1)，每孔加入50μL梯度稀释的抗体(起始浓度40μg/mL，10倍稀释，7个梯度)，5％CO 2 37℃培养24小时。培养结束后，1000rpm离心3分钟，取上清检测LDH释放，将50μL上清转移至黑色酶标板，加入50μL/孔LDH检测底物，10分钟后终止反应并检测(Biotek Synergy HT)，按下述公式计算杀伤率；弃去上清后，将孔内剩余细胞用4％小牛血清洗2次后，加入100μg/mL人IgG封闭10分钟，加入T细胞早期活化标记CD69和后期标记CD25检测抗体(CD25-PE，CD4-APC，CD69-FITC和CD8-APC)，冰上孵育20分钟。孵育结束后，每孔加入200μL 4％小牛血清洗3次，弃上清，加入60μL/孔碘化丙啶(PI)溶液(1：200稀释)，置于冰上孵育5分钟，用流式细胞仪(BD FACS celesta)进行检测。杀伤率计算公式如下：
Figure PCTCN2021135121-appb-000111
双特异抗体组合的杀伤活性见表6。
表6、双特异抗体的杀伤活性
Figure PCTCN2021135121-appb-000112
6、构建BCMA×CD3κλ人源化双特异抗体
选择杀伤效率较高的克隆29A11及与之序列同源的克隆6G5进行人源化序列优化，其重链可变区来自鼠IGHV9-3，轻链可变区来自鼠IGKV3-12，将轻、重链CDR移植分别移植到人胚系基因IGHV7-4-1*02和IGVK_7_3，合成设计得到的人源化BCMA抗体序列。同时，在BCMA抗原臂和含λ轻链的人源化CD3抗体臂引入电荷变异体(Vκ BCMA:Gln 42Lys；VH BCMA:Gln 39Glu；Vλ CD3:Gln 40Glu；VH CD3:Gln 39Lys)，构建具有天然IgG构型的新型BCMA-CD3κλ人源化双特异抗体(表7)。双特异抗体的Fc部分采用人IgG4knob-into-hole结构，以实现异源二聚体配对(Atwell等，1997)，并且通过突变Ser 228Pro、Leu 235Glu和Pro 329Ala，保持铰链区稳定并减弱与Fcγ受体和C1q的相互作用。
将编码相应抗体片段的质粒，按κ轻链：λ轻链：重链1：重链2＝2:2:1:1的比率混合，与3mg/mL PEI混合后，共同转染CHO-S细胞，在500mL CD CHO AGT培养基(Gibco#12490-001)37℃5％CO 2 150rpm培养，分别在瞬转第2、4和6天，加入4％CHO Feed C+补料(Gibco#A25031-05)。当细胞活率降至85％左右，收获发酵液，过滤后经Protein A亲和层析初步纯化，SEC-HPLC单体含量显示高于92％；经Capto S ImpAct离子交换层析，通过50-300mM NaCl/磷酸盐pH6.0梯度洗脱，合并洗脱峰，单体含量进一步提高至98-99％以上(表8)。
表7、BCMA×CD3κλ双特异抗体
Figure PCTCN2021135121-appb-000113
Figure PCTCN2021135121-appb-000114
Figure PCTCN2021135121-appb-000115
表8、BCMA×CD3κλ双特异抗体的纯度
Figure PCTCN2021135121-appb-000116
实施例4、BCMA×CD3κλ双特异抗体的结合活性
分别通过检测与BCMA重组蛋白、过表达稳转细胞或BCMA+肿瘤细胞的结合，确定双特异抗体BCMA抗原臂的亲和力，通过检测CD3重组抗原、Jurkat细胞或新鲜分离的外周血T细胞的结合，确定双特异抗体CD3臂的亲和力。
1、BCMA×CD3κλ双特异抗体与抗原的亲和力测定
将10μg/mL人或食蟹猴BCMA或CD3εγ重组抗原通过氨基偶联结合到CM5芯片(GE healthcare)，控制抗原结合量约200RU。基线平稳后，将梯度稀释的抗体(从10μg/mL起，2倍稀释7个梯度)，以30μL/min的流速流过 芯片，结合时间350秒，解离时间600秒。用Biacore T200 evaluation软件以1:1结合模型，拟合得到动力学常数。亲和力测定结果见表9。
表9、BCMA×CD3κλ双特异性抗体与BCMA和CD3重组抗原的亲和力
KD(nM) 人BCMA 食蟹猴BCMA 人CD3εγ 食蟹猴CD3εγ
BCMA×CD3κλ003 1.3 0.16 31 43
BCMA×CD3κλ004 1.0 0.12 32 43
BCMA×CD3κλ005 1.1 0.09 28 20
BCMA×CD3κλ006 1.2 0.10 27 33
2、BCMA×CD3κλ双特异抗体与BCMA稳转细胞的结合
取对数生长期实施例1制备的CHO-人BCMA和CHO-食蟹猴BCMA稳转细胞，用4％小牛血清(Hyclone，SH30626.06)调整细胞至5×10 5个细胞/ml，加入100μl/孔细胞悬液至96孔U型板，300g离心5分钟，弃上清，每孔加入100μL梯度稀释的抗体(起始浓度1800nM，3倍稀释，10个梯度)，4℃孵育60分钟。二抗加入50μL/孔Alexa Fluro647标记的山羊抗人IgG Fc(1:300稀释)，冰上孵育20分钟，洗1次后加入50μL/孔PI溶液(1:300)，孵育5分钟，用流式细胞仪进行检测。图6和表10显示，BCMA×CD3κλ双特异抗体高亲和力结合人、食蟹猴BCMA稳转细胞。
表10、BCMA×CD3κλ双特异性抗体和BCMA稳转细胞的结合
EC 50(nM) 人BCMA-CHO 食蟹猴BCMA-CHO
BCMA×CD3κλ003 16 3
BCMA×CD3κλ004 22 3
BCMA×CD3κλ005 24 3
BCMA×CD3κλ006 16 3
KLH×CD3 - -
3、BCMA×CD3κλ双特异抗体与BCMA +肿瘤细胞的结合
取对数生长期的NCI-H929和RPMI-8226细胞，加入200μg/mL鼠IgG(Jackson ImmunoResearch，115-005-03)，冰浴封闭30分钟，用4％小牛血清调整细胞至5×10 5个细胞/mL，每孔100μL加入96孔U型板，300g离心5分钟，弃上清，每孔加入100μL梯度稀释的抗体(起始浓度1800nM，3倍稀释，10个梯度)，4℃孵育60分钟。洗去一抗，加入50μL/孔Alexa Fluro647标记的山羊抗人IgG Fc(1:300稀释)，冰上孵育20分钟，洗1次后加入50μL/孔PI，孵育5分钟，用流式细胞仪进行检测。检测结果见图7和表11，BCMA×CD3κλ双特异抗体高亲和力结合BCMA+肿瘤细胞NCI-H929和RPMI-8226。
表11、BCMA×CD3κλ双特异性抗体和BCMA+肿瘤细胞的结合
EC 50(nM) NCI-H929 RPMI-8226
BCMA×CD3κλ003 34 34
BCMA×CD3κλ004 36 39
BCMA×CD3κλ005 33 38
BCMA×CD3κλ006 32 19
KLH×CD3 - -
4、BCMA×CD3κλ双特异抗体与Jurkat细胞的结合
取对数生长期的Jurkat细胞，加入200μg/mL鼠IgG(Jackson ImmunoResearch，115-005-03)，冰浴30分钟。用4％小牛血清调整细胞至5×10 5个细胞/mL，每孔100μL加入96孔U型板，300g离心去上清，每孔加入100μL梯度稀释的抗体(起始浓度1800nM，3倍稀释，10个梯度)，4℃孵育60分钟。二抗加入50μL/孔Alexa Fluro647标记的山羊抗人IgG Fc(1:300稀释)，冰上孵育20分钟，洗1次后加入50μL/孔PI，孵育5分钟，用流式细胞仪(BD C6)进行检测。检测结果如图8和表12，BCMA×CD3κλ双特异抗体以中度亲和力结合人白血病T细胞系Jurkat细胞。
表12、BCMA×CD3κλ双特异抗体与Jurkat细胞的结合
EC 50(nM) Jurkat
BCMA×CD3κλ003 66
BCMA×CD3κλ004 61
BCMA×CD3κλ005 51
BCMA×CD3κλ006 56
KLH×CD3 76
5、BCMA×CD3κλ双特异抗体与外周血T细胞的结合
取新鲜人或食蟹猴外周血，通过Ficoll-Paque Plu(GE，17-1440-03)分离得到PBMC。将PBMC用4％小牛血清(Hyclone，SH30626.06)调整细胞至5×10 5个细胞/mL，100μL/孔加入96孔U型板，离心弃上清，每孔加入100μL梯度稀释的抗体(起始浓度1800nM，3倍稀释，10个梯度)，4℃孵育60分钟。二抗加入50μL/孔Alexa Fluro647标记的山羊抗人IgG Fc(1:300稀释)，冰浴20分钟，洗1次后加入50μL/孔PI，孵育5分钟，用流式细胞仪(BD C6)进行检测。对照抗体REGN5458参照US20200024356合成并制备。
检测结果见图9和表13所示，BCMA×CD3κλ双特异抗体识别人外周血CD4+T和CD8+T细胞，与人T细胞亲和力约60-97nM，均弱于BCMA抗原臂与BCMA受体的结合力，有利于双特异抗体优先富集到肿瘤细胞。
表13、BCMA×CD3κλ双特异性抗体与外周血T细胞的结合
EC 50(nM) CD4+T cell CD8+T cell
BCMA×CD3κλ003 87 97
BCMA×CD3κλ004 77 84
BCMA×CD3κλ005 66 60
BCMA×CD3κλ006 91 93
KLH×CD3 57 62
实施例5、BCMA×CD3κλ双特异抗体介导的TDCC
取新鲜分离得到的PBMC分别与处于对数生长期的靶细胞NCI-H929和RPMI-8226细胞混合，效应/靶细胞＝8:1，每孔加入50μL梯度稀释的抗体(抗体浓度从66.7nM起，10倍稀释，7个梯度)，5％CO 2 37℃培养24小时。培养结束后，将50μL上清转移至新的黑色酶标板，加入50μL/孔LDH检测底物，10分钟后终止反应并检测LDH释放；孔内剩余细胞用4％小牛血清洗2次后，加入100μg/mL人IgG孵育10分钟，再加入T细胞活化检测抗体(CD25-PE，CD4-APC，CD69-FITC和CD8-APC)，冰上孵育20分钟。洗涤弃上清，加入60μL/孔PI，置于冰上孵育5分钟，用流式细胞仪进行检测。图10A、10B分别显示BCMA×CD3κλ双特异抗体对NCI-H929细胞的杀伤和对T细胞的活化。图11A、11B分别显示BCMA×CD3κλ双特异抗体对RPMI-8226细胞的杀伤和对T细胞的活化。对于BCMA表达水平不同的肿瘤细胞NCI-H929和RPMI-8226，BCMA×CD3κλ双特异抗体均可介导T细胞产生有效杀伤，杀伤活性与对照抗体相当。
实施例6、BCMA×CD3κλ双特异抗体对T细胞活化通路的激活
将荧光素酶报告质粒pGL4.30[luc2P/NFAT-RE/Hygro](Promega，E8481)转染Jurkat细胞，添加200μg/ml潮霉素B进行筛选，获得Jurkat-NFAT luc稳转报告细胞。取对数生长期的Jurkat-NFAT-luc报告细胞和靶细胞RPMI-8226，离心弃上清，重悬至2×10 6个细胞/ml。50μl/孔接种靶细胞至96孔板，300g离心5分钟弃上清，50μl/孔接种Jurkat-NFAT-luc报告细胞至96孔板，每孔加入50μL梯度稀释的BCMA×CD3κλ双特异抗体或对照抗体KLH×CD3(起始浓度20μg/ml，10倍稀释，10个梯度)，5％CO 2，37℃培养6小时。培养结束后，按照ONE-Glo Luciferase Assay System说明书，每孔加入100μL检测试剂，室温放置3分钟，于酶标仪(Biotek Synergy HT)检测。检测结果见图12，BCMA×CD3κλ双特异抗体以RPMI-8226肿瘤细胞为靶细胞时，可激活T细胞的NFAT信号通路；无靶细胞时，不激活NFAT信号通路。
实施例7、BCMA×CD3κλ双特异抗体对PBMC的非特异激活
取新鲜分离得到的PBMC，每孔加入50μL梯度稀释的抗体(抗体浓度从66.7nM起，10倍稀释，7个梯度)，5％CO 2 37℃培养24小时。培养结束后，将50μL上清转移至新的黑色酶标板，加入50μL/孔LDH检测底物，10分钟后终止反应并检测LDH释放；孔内剩余细胞用4％小牛血清洗2次后，加入100μg/mL人IgG孵育10分钟，再加入T细胞活化检测抗体(CD25-PE，CD4-APC，CD69-FITC和CD8-APC)，冰上孵育20分钟。洗涤弃上清，加入60μL/孔PI，置于冰上孵育5分钟，用流式细胞仪进行检测。检测结果见图13，在缺乏靶细胞的条件下，BCMA×CD3κλ双特异抗体对外周血T细胞无激活作用，与阴性对照KLH×CD3相当。
实施例8、BCMA×CD3κλ双特异抗体与Fc受体的结合
将50μg/ml His-Tag抗体通过氨基偶联到CM5芯片，分别捕获带有His6标签的FcγRI、FcγRIIA H131和FcγRIIIA V158重组蛋白，捕获时间40秒，流速10μL/min，基线平稳后，将梯度稀释的抗体(起始浓度37.5μg/mL，2倍稀释)以30μL/min的流速流过芯片，结合时间120秒，解离时间200秒，用Biacore evaluation软件拟合得到亲和力常数。检测结果见图14，BCMA×CD3κλ双特异抗体与活化受体FcγRI、FcγRIIA H131和FcγRIIIA V158均无结合；野生型IgG4和对照抗体分别与FcγRI、FcγRIIA H131或FcγRIIIA V158有结合。
实施例9、BCMA×CD3κλ双特异抗体对BCMA受体与配体结合的阻断
用pH9.6碳酸缓冲液配制1μg/mL人BCMA重组抗原，加入maxisorp96孔板，4℃包被过夜。5％脱脂牛奶/PBS室温封闭1小时后，每孔加入50μL抗体(从30μg/mL起4倍稀释，共稀释10个梯度)，室温孵育30分钟。加入50μL浓度240ng/mL的生物素标记人APRIL重组蛋白(Novoprotein，CU89)，继续孵育30分钟。0.05％PBST(PBS+0.05％Tween-20)和PBS各洗3遍后，每孔加入100μL SA-HRP(1:8000稀释)，室温孵育45分钟。再以0.05％PBST和PBS各洗3遍，每孔加入100μL TMB显色液，10分钟后每孔加入50μL浓硫酸终止反应，酶标仪读数OD450nm，使用Graphpad软件进行三参数拟合曲线。检测结果见图15，BCMA×CD3κλ双特异抗体可有效阻断BCMA与受体APRIL的结合。
实施例10、免疫重建小鼠皮下NCI-H929移植瘤模型
选择6～8周雌性B-NGD小鼠(百奥赛图生物科技有限公司)，皮下接种2×10 6NCI-H929细胞(与Matrigel 1:1混合)，待肿瘤长至60mm 3时，随机分组，分别为给药组3.0mg/kg、给药组0.6mg/kg、给药组0.12mg/kg和阴性对照组KLH×CD3 3mg/kg。每只小鼠尾静脉注射1×10 7个PBMC细胞，3天后开始第一次小鼠给药，给药间隔为5天一次，共给药2次。每2天监测一次小鼠肿瘤体积及小鼠体重，实验结束后断颈处死小鼠，取瘤称重并记录。结果见图16，BCMA×CD3κλ双特异抗体的体内药效呈现剂量相关性，低剂量、中剂量和高剂量抑瘤率分别为55％、95％和108％(BCMA×CD3κλ005)以及46％、94％和108％(BCMA×CD3κλ006)，疗效显著优于对照抗体。荷瘤小鼠对以上剂量耐受良好，无体重减轻等不良反应。

Claims (16)

  1. 一种双特异性抗体或其抗原结合部分，其包含：
    (a)结合到靶细胞表面上的BCMA抗原的第一抗原结合部分或其抗原结合片段，所述第一抗原结合部分包含第一重链和第一轻链，所述第一抗原结合部分包含与第一抗原结合的第一结合结构域，其中，所述第一结合结构域包含选自氨基酸序列SEQ ID NO:12、13、14、26、27、28、36、37、43、44、50、55、56、57、65、66、71、72、73、147或其任何变体的重链CDR，和/或选自氨基酸序列SEQ ID NO:17、18、19、22、23、31、32、33、40、47、60、61、62、76、77、78、83、84、87、88、89、92、144或任何变体的轻链CDR；和
    (b)结合到T细胞表面上的CD3抗原的第二抗原结合部分或其抗原结合片段，所述第二抗原结合部分包含第二重链和第二轻链，所述第二抗原结合部分包含与第二抗原结合的第二结合结构域。
  2. 根据权利要求1的双特异性抗体或其抗原结合部分，其中，所述第一结合结构域包含选自氨基酸序列SEQ ID NO:12、26、55、65、71或其任何变体的重链CDR1，选自氨基酸序列SEQ ID NO:13、27、36、43、50、56、66、72、147或其任何变体的重链CDR2，选自氨基酸序列SEQ ID NO:14、28、37、44、57、73或其任何变体的重链CDR3；和/或所述第一结合结构域包含选自氨基酸序列SEQ ID NO:17、22、31、47、60、76、83、87、92、144或其任何变体的轻链CDR1，选自氨基酸序列SEQ ID NO:18、23、32、40、61、77、84、88或其任何变体的轻链CDR2，选自氨基酸序列SEQ ID NO:19、33、62、78、89或其任何变体的轻链CDR3。
  3. 根据权利要求1或2所述的双特异性抗体或其抗原结合部分，其中，
    所述第一结合结构域的重链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:26、27、28的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、36、37的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、43、44的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:12、50、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:55、56、57的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:65、66、14的第一重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:71、72、73的第一重链CDR1、CDR2及CDR3序列；氨基酸序列SEQ ID NO:71、147、73的第一重链CDR1、CDR2及CDR3序列；和所述第一结合结构域的轻链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:17、18、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:22、23、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:31、32、33的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:47、18、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:60、61、62的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:76、77、78的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:83、84、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:87、88、89的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:92、23、19的第一轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:144、77、78的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、18、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:22、23、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:26、27、28的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:31、32、33的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、36、37的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、43、44的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:47、18、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、50、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:55、56、57的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:60、61、62的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:65、66、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:17、40、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:71、72、73的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:76、77、78的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:83、84、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序 列，和包含氨基酸序列SEQ ID NO:87、88、89的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:12、13、14的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:92、23、19的第一轻链CDR1、CDR2及CDR3序列；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:71、147、73的第一重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:144、77、78的第一轻链CDR1、CDR2及CDR3序列。
  4. 根据权利要求1-3任一项所述的双特异性抗体或其抗原结合部分，其中，所述第一结合结构域包含选自氨基酸序列SEQ ID NO:10、24、34、41、48、53、63、69、79、145、150、154、158、162、166、170或其任何变体的第一重链可变区，和/或包含选自氨基酸序列SEQ ID NO:15、20、29、38、45、51、58、67、74、81、85、90、142、148、152、156、160、164、168或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:15或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:20或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:24或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:29或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:34或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:38或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:41或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:45或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:48或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:51或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:53或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:58或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:38或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:63或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:67或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:69或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:74或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:79或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:81或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:85或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:10或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:90或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:145或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:142或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:150或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:148或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:154或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:152或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:158或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:156或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:162或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:160或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:166或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:164或其任何变体的第一轻链可变区；
    优选地，所述第一结合结构域包含氨基酸序列SEQ ID NO:170或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:168或其任何变体的第一轻链可变区。
  5. 根据权利要求1-4任一项所述的双特异性抗体或其抗原结合部分，其中，所述第二结合结构域包含选自氨基酸序列SEQ ID NO:114、115、116、119、122、125、128、131、134、135或其任何变体的重链CDR；和/或选自氨基酸序列SEQ ID NO:95、96、97、102、103、108、111或其任何变体的轻链CDR；
    优选地，所述第二结合结构域包含选自氨基酸序列SEQ ID NO:114、119、134或其任何变体的第二重链CDR1，选自氨基酸序列SEQ ID NO:115、135或其任何变体的第二重链CDR2，选自氨基酸序列SEQ ID NO:116、122、125、128、131或其任何变体的第二重链CDR3；和/或选自氨基酸序列SEQ ID NO:95、102或其任何变体的第二轻链CDR1，选自氨基酸序列SEQ ID NO:96、103、111或其任何变体的第二轻链CDR2，选自氨基酸序列SEQ ID NO:91、108或其任何变体的第二轻链CDR3；
    优选地，所述第二结合结构域的重链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、116的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、122的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、125的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、128的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:119、115、131的第二重链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:134、135、116的第二重链CDR1、CDR2及CDR3序列；和所述第二结合结构域的轻链CDR1、CDR2及CDR3序列选自：氨基酸序列SEQ ID NO:95、96、97的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:102、103、97的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:95、96、108的第二轻链CDR1、CDR2及CDR3序列，氨基酸序列SEQ ID NO:95、111、108的第二轻链CDR1、CDR2及CDR3序列；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、96、97的第二轻链CDR1、CDR2及CDR3序列；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:102、103、97的第二轻链CDR1、CDR2及CDR3序列；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、96、108的第二轻链CDR1、CDR2及CDR3序列；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:114、115、116的第二重链CDR1、CDR2及CDR3序列，和包含氨基酸序列SEQ ID NO:95、111、108的第二轻链CDR1、CDR2及CDR3序列；
    优选地，所述第二结合结构域包含选自氨基酸序列SEQ ID NO:112、117、120、123、126、129、132、136、138、140或其任何变体的第二重链可变区，和/或包含选自氨基酸序列SEQ ID NO:93、98、100、104、106、109或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:136或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:93或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:93或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:98或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:100或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:112或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:136或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    更优选地，所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区。
  6. 根据权利要求1-5任一项所述的双特异性抗体或其抗原结合部分，其中，所述第一抗原结合部分的所述第一轻链为κ型轻链，所述第二抗原结合部分的所述第二轻链为λ型轻链，
    优选地，所述第二抗原结合部分的第二轻链可变区具有Gln 40Glu突变(Vλ CD3:Gln 40Glu)；所述第二抗原结合部分的第二重链可变区具有Gln 39Lys突变(VH CD3:Gln 39Lys)；
    所述第一抗原结合部分的第一轻链可变区具有Gln 42Lys突变(Vκ BCMA:Gln 42Lys)；更优选地，所述第一抗原结合部分的第一重链可变区具有Gln 39Glu突变(VH BCMA:Gln 39Glu)；
    优选地，所述双特异抗体的第一抗原结合部分和第二抗原结合部分的Fc部分采用knob-into-hole结构；优选地，采用人IgG4 knob-into-hole结构。
  7. 根据权利要求1-6任一项所述的双特异性抗体或其抗原结合部分，其中，所述第一重链包含选自SEQ ID NO:174、178或其任何变体的重链，所述第一轻链包含选自SEQ ID NO:172、176或其任何变体的轻链；
    优选地，所述第一重链包含选自SEQ ID NO:174或其任何变体的重链，所述第一轻链包含选自SEQ ID NO:172或其任何变体的轻链；
    优选地，所述第一重链包含选自SEQ ID NO:174或其任何变体的重链，所述第一轻链包含选自SEQ ID NO:176或其任何变体的轻链；
    优选地，所述第一重链包含选自SEQ ID NO:178或其任何变体的重链，所述第一轻链包含选自SEQ ID NO:172或其任何变体的轻链；
    优选地，所述第一重链包含选自SEQ ID NO:178或其任何变体的重链，所述第一轻链包含选自SEQ ID NO:176或其任何变体的轻链。
  8. 根据权利要求1-7任一项所述的双特异性抗体或其抗原结合部分，其中，所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述第二重链包含SEQ ID NO:182或其任何变体的重链，所述第二轻链包含SEQ ID NO:180或其任何变体的轻链；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:145或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:142或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:150或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:148或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:154或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:152或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:158或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:156或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:162或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:160或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:166或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:164或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    优选地，所述双特异性抗体的所述第一结合结构域包含氨基酸序列SEQ ID NO:170或其任何变体的第一重链可变区，和氨基酸序列SEQ ID NO:168或其任何变体的第一轻链可变区；所述第二结合结构域包含氨基酸序列SEQ ID NO:138或其任何变体的第二重链可变区，和氨基酸序列SEQ ID NO:106或其任何变体的第二轻链可变区；
    更优选地，所述双特异性抗体的所述第一重链包含SEQ ID NO:174或其任何变体的重链，第一轻链包含SEQ ID NO:172或其任何变体的轻链；所述第二重链包含SEQ ID NO:182或其任何变体的重链，所述第二轻链包含SEQ ID NO:180或其任何变体的轻链；
    更优选地，所述双特异性抗体的所述第一重链包含SEQ ID NO:174或其任何变体的重链，第一轻链包含SEQ ID NO:176或其任何变体的轻链；所述第二重链包含SEQ ID NO:182或其任何变体的重链，所述第二轻链包含SEQ ID NO:180或其任何变体的轻链；
    更优选地，所述双特异性抗体的所述第一重链包含SEQ ID NO:178或其任何变体的重链，第一轻链包含SEQ ID NO:172或其任何变体的轻链；所述第二重链包含SEQ ID NO:182或其任何变体的重链，所述第二轻链包含SEQ ID NO:180或其任何变体的轻链；
    更优选地，所述双特异性抗体的所述第一重链包含SEQ ID NO:178或其任何变体的重链，第一轻链包含SEQ ID NO:176或其任何变体的轻链；所述第二重链包含SEQ ID NO:182或其任何变体的重链，所述第二轻链包含SEQ ID NO:180或其任何变体的轻链。
  9. 一种结合BCMA的抗体或其抗原结合部分，所述抗体包含权利要求1-8中任一项所述的第一抗原结合部分。
  10. 编码根据1-8任一项所述的双特异性抗体或其抗原结合部分或权利要求9所述的结合BCMA的抗体或其抗原结合部分的核酸；
    优选地，所述第一抗原结合部分的第一重链可变区的编码核酸选自核苷酸序列SEQ ID NO:11、25、35、42、49、54、64、70、80、146、151、155、159、163、167、171或其任何变体；和/或所述第一抗原结合部分的第一轻链可变区的编码核酸选自核苷酸序列SEQ ID NO:16、21、30、39、46、52、59、68、75、82、86、91、143、149、153、157、161、165、169或其任何变体；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:16；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:21；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:25；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:30；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:35；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:39；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:42；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:46；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:49；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:52；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:54；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:59；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:39；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:64；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:68；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:70；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:75；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:80；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:82；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:86；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:11；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:91；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:146；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:143；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:151；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:149；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:155；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:153；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:159；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:157；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:163；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:161；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:167；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:165；
    更优选地，所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:171；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:169；
    优选地，所述第一抗原结合部分的第一重链的编码核酸选自核苷酸序列SEQ ID NO:175、179或其任何变体；和/或所述第一抗原结合部分的第一轻链的编码核酸选自核苷酸序列SEQ ID NO:173、177或其任何变体；
    更优选地，所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173；
    更优选地，所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177；
    更优选地，所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173；
    更优选地，所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177；
    优选地，所述第二抗原结合部分的第二重链可变区的编码核酸选自核苷酸序列SEQ ID NO:113、118、121、124、127、130、133、137、139、141或其任何变体；和/或所述第二抗原结合部分的第二轻链可变区的编码核酸选自核苷酸序列SEQ ID NO:94、99、101、105、107、110或其任何变体；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:137；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:94；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:94；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:99；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:101；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:113；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:137；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    优选地，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183或其任何变体；和/或所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181或其任何变体；
    更优选地，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:146；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:143；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:151；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:149；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:155；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:153；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:159；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:157；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:163；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:161；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:167；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:165；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链可变区的编码核酸为核苷酸序列SEQ ID NO:171；和所述第一轻链可变区的编码核酸为核苷酸序列SEQ ID NO:169；所述第二抗原结合部分的第二重链可变区的编码核酸为核苷酸序列SEQ ID NO:139；和所述第二轻链可变区的编码核酸为核苷酸序列SEQ ID NO:107；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:175，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:173，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181；
    更优选地，所述双特异性抗体的所述第一抗原结合部分的第一重链的编码核酸为核苷酸序列SEQ ID NO:179，和所述第一抗原结合部分的第一轻链的编码核酸为核苷酸序列SEQ ID NO:177，所述第二抗原结合部分的第二重链的编码核酸为核苷酸序列SEQ ID NO:183，和所述第二抗原结合部分的第二轻链的编码核酸为核苷酸序列SEQ ID NO:181。
  11. 含有权利要求10所述核酸的载体。
  12. 含有权利要求9所述的核酸或权利要求11所述载体的细胞。
  13. 一种组合物，其包含权利要求1-8任一项所述的双特异性抗体或其抗原结合部分、权利要求9所述的结合BCMA的抗体或其抗原结合部分、权利要求10所述的核酸、权利要求11所述的载体和/或权利要求12所述的细胞。
  14. 一种抗体-药物偶联物，其包含共价附着至治疗部分的权利要求1-8任一项所述的双特异性抗体或其抗原结合部分或权利要求9所述的结合BCMA的抗体或其抗原结合部分；
    优选地，所述治疗部分选自细胞毒性部分、化疗剂、细胞因子、免疫抑制剂、免疫刺激剂、裂解肽或放射性同位素；
    优选地，所述细胞毒性部分选自以下：紫杉醇；细胞松弛素B；短杆菌肽D；溴化乙锭；吐根碱；丝裂霉素；依托泊苷；替尼泊苷；长春新碱；长春碱；秋水仙碱；多柔比星；柔红霉素；二羟基蒽二酮；微管蛋白抑制剂如美登素或其类似物或衍生物；抗有丝***剂如单甲基奥瑞他汀E或F或其类似物或衍生物；海兔毒素10或15或其类似物；伊立替康或其类似物；米托蒽醌；光辉霉素；放线菌素D；1-脱氢睾酮；糖皮质激素；普鲁卡因；丁卡因；利多卡因；***；嘌呤霉素；卡奇霉素或其类似物或衍生物；抗代谢药，如甲氨喋呤、6巯基嘌呤、6硫鸟嘌呤、阿糖胞苷、氟达拉滨、5氟尿嘧啶、癸二嗪、羟基脲、天冬酰胺酶、吉西他滨或克拉屈滨；烷化剂，如二氯甲基二乙胺、硫代嘌呤、苯丁酸氮芥、美法仑、卡莫司汀(BSNU)、洛莫司汀(CCNU)、环磷酰胺、白消安、二溴甘露醇、链脲佐菌素、达卡巴嗪(DTIC)、丙卡巴嗪、丝裂霉素C；铂类衍生物，如顺铂或卡铂；多卡霉素A、多卡霉素SA、雷切霉素(CC-1065)或其类似物或衍生物；抗生素，如放线菌素、博来霉素、柔红霉素、多柔比星、伊达比星、光霉素、丝裂霉素、米托蒽醌、普力霉素、安定霉素(AMC)；吡咯并[2,1-c][1,4]-苯并二氮杂卓(PDB)；白喉毒素及 相关分子如白喉A链及其活性片段和杂合分子、蓖麻毒素如蓖麻毒素A或去糖基化蓖麻毒素A链毒素、霍乱毒素、志贺样毒素如SLT I、SLT II、SLT IIV、LT毒素、C3毒素、志贺毒素、百日咳毒素、破伤风毒素、大豆Bowman-Birk蛋白酶抑制剂、假单胞菌外毒素、阿罗林、皂草素、蒴莲根毒素、胶凝蛋白、相思豆毒素A链、蒴莲根毒素A链、α-sarcin、油桐(Aleurites fordii)蛋白、石竹素蛋白、美洲商陆蛋白如PAPI、PAPII和PAP-S、苦瓜(momordica charantia)抑制剂、泻果素、巴豆毒素、肥阜草(sapaonaria officinalis)抑制剂、白树毒素、丝裂霉素、局限曲菌素、酚霉素和依诺霉素毒素；核糖核酸酶(RNase)；DNase I、葡萄球菌内毒素A；商陆抗病毒蛋白；白喉毒素和假单胞菌内毒素；
    优选地，所述细胞因子选自IL-2、IL-4、IL-6、IL-7、IL-10、IL-12、IL-13、IL-15、IL-18、IL-23、IL-24、IL-27、IL-28a、IL-28b、IL-29、KGF、IFNα、IFNβ、IFNγ、GM-CSF、CD40L、Flt3配体、干细胞因子、安西司亭和TNFα；
    优选地，所述放射性同位素选自 3H、 14C、 15N、 35S、 67Cu、 90Y、 99Tc、 125I、 131I、 186Re、 188Re、 211At、 212Bi、 212Pb、 213Bi、 225Ac和 227Th。
  15. 一种试剂盒，其含权利要求1-8任一项所述的特异性抗体或其抗原结合部分、权利要求9所述的结合BCMA的抗体或其抗原结合部分、权利要求10所述的核酸分子、权利要求11所述的载体、权利要求12所述的细胞、权利要求13所述的组合物和/或权利要求14的抗体-药物偶联物。
  16. 含权利要求1-8任一项所述的特异性抗体或其抗原结合部分、权利要求9所述的结合BCMA的抗体或其抗原结合部分、权利要求10所述的核酸分子、权利要求11所述的载体、权利要求12所述的细胞、权利要求13所述的组合物和/或权利要求14的抗体-药物偶联物在制备用于诊断、治疗或预防与BCMA相关的疾病的药物或试剂盒中的用途；
    优选地，与BCMA相关的疾病包括B细胞疾病；
    优选地，所述疾病是癌症；更优选地，所述癌症是B-细胞相关癌症，其选自多发性骨髓瘤、恶性浆细胞瘤、霍奇金淋巴瘤、结节性淋巴细胞为主的霍奇金淋巴瘤、Kahler’s病和骨髓性白血病、浆细胞白血病、浆细胞瘤、B-细胞幼淋巴细胞白血病、毛细胞白血病、B-细胞非霍奇金淋巴瘤(NHL)、急性髓性白血病(AML)、慢性淋巴细胞白血病(CLL)、急性淋巴细胞白血病(ALL)、慢性髓性白血病(CML)、滤泡性淋巴瘤、伯基特淋巴瘤、边缘区淋巴瘤、套细胞淋巴瘤、大细胞淋巴瘤、前体B-淋巴细胞淋巴瘤、髓性白血病、瓦尔登斯特伦巨球蛋白血症、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、边缘区淋巴瘤、粘膜相关淋巴组织淋巴瘤、小细胞淋巴细胞性淋巴瘤、套细胞淋巴瘤、伯基特淋巴瘤、原发性纵隔(胸腺)大B细胞淋巴瘤、淋巴浆细胞淋巴瘤、瓦尔登斯特伦巨球蛋白血症、***边缘区B细胞淋巴瘤、脾边缘区淋巴瘤、血管内大B-细胞淋巴瘤、原发性渗出性淋巴瘤、淋巴瘤样肉芽肿病、富含T细胞/组织细胞的大B-细胞淋巴瘤、原发性中枢神经***淋巴瘤、原发性皮肤弥漫性大B-细胞淋巴瘤(腿型)、老年人EBV阳性弥漫性大B-细胞淋巴瘤、炎症相关的弥漫性大B-细胞淋巴瘤、血管内大B-细胞淋巴瘤、ALK阳性大B-细胞淋巴瘤、浆母细胞淋巴瘤、HHV8相关的多中心Castleman病中产生的大B-细胞淋巴瘤、未分类的具有弥漫性大B-细胞淋巴瘤和伯基特淋巴瘤中间特征的B-细胞淋巴瘤、未分类的具有弥漫性大B-细胞淋巴瘤和经典霍奇金淋巴瘤中间特征的B-细胞淋巴瘤以及其他B-细胞相关淋巴瘤；
    更优选地，所述B细胞疾病是B细胞障碍；优选地，浆细胞障碍选自：多发性骨髓瘤、浆细胞瘤、浆细胞白血病、巨球蛋白血症、淀粉样变性、华氏巨球蛋白血症、孤立性骨浆细胞瘤、髓外浆细胞瘤、骨硬化性骨髓瘤、重链病、意义不明确的单克隆丙种球蛋白病以及郁积型多发性骨髓瘤；
    所述疾病是自身免疫性病症，如***性红斑性狼疮或类风湿性关节炎。
PCT/CN2021/135121 2020-12-02 2021-12-02 一种t细胞衔接器治疗剂的开发和应用 WO2022117045A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2021390122A AU2021390122A1 (en) 2020-12-02 2021-12-02 Development and application of t-cell engager therapeutic agent
KR1020237022053A KR20230117178A (ko) 2020-12-02 2021-12-02 T 세포 인게이저 치료제의 개발 및 적용
JP2023533951A JP2023552198A (ja) 2020-12-02 2021-12-02 Ｔ細胞アダプター治療剤の開発及び使用
EP21900071.8A EP4257607A1 (en) 2020-12-02 2021-12-02 Development and application of t-cell engager therapeutic agent
CA3200652A CA3200652A1 (en) 2020-12-02 2021-12-02 Development and application of t-cell engager therapeutic agent
CN202180081608.XA CN116669761A (zh) 2020-12-02 2021-12-02 一种t细胞衔接器治疗剂的开发和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011402180.8A CN114573703A (zh) 2020-12-02 2020-12-02 一种t细胞衔接器治疗剂的开发和应用
CN202011402180.8 2020-12-02

Publications (1)

Publication Number Publication Date
WO2022117045A1 true WO2022117045A1 (zh) 2022-06-09

Family

ID=81770769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/135121 WO2022117045A1 (zh) 2020-12-02 2021-12-02 一种t细胞衔接器治疗剂的开发和应用

Country Status (7)

Country Link
EP (1) EP4257607A1 (zh)
JP (1) JP2023552198A (zh)
KR (1) KR20230117178A (zh)
CN (2) CN114573703A (zh)
AU (1) AU2021390122A1 (zh)
CA (1) CA3200652A1 (zh)
WO (1) WO2022117045A1 (zh)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005081711A2 (en) 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
WO2007000860A1 (ja) 2005-06-28 2007-01-04 Pioneer Corporation 放送受信装置、妨害検出装置および妨害検出方法
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
CN104114578A (zh) * 2011-11-15 2014-10-22 安进研发（慕尼黑）股份有限公司 Bcma和cd3的结合分子
WO2020018820A1 (en) * 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005081711A2 (en) 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
WO2007000860A1 (ja) 2005-06-28 2007-01-04 Pioneer Corporation 放送受信装置、妨害検出装置および妨害検出方法
WO2007042261A2 (en) * 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN103703024A (zh) * 2011-05-21 2014-04-02 宏观基因有限公司 能够与人和非人cd3结合的cd3结合分子
CN104114578A (zh) * 2011-11-15 2014-10-22 安进研发（慕尼黑）股份有限公司 Bcma和cd3的结合分子
WO2020018820A1 (en) * 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
US20200024356A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends", 1994, HARWOOD ACADEMIC PUBLISHERS
"Genbank", Database accession no. AB052772.1
"GenBank", Database accession no. BAB71849.1
"NCBI", Database accession no. NP_000724.1
"Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING COMPANY
"Remington's Pharmaceutical Sciences: The Science And Practice Of Pharmacy", vol. 42, 1995, MACK PUB. CO.
"UniProt", Database accession no. P07766
ANTONOW D. ET AL., CANCER J, vol. 14, no. 3, 2008, pages 154 - 169
ARMOUR KL ET AL.: "Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities", EUR J IMMUNOL., vol. 29, no. 8, August 1999 (1999-08-01), pages 2613 - 24, XP002116082, DOI: 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J
BRUMMELL ET AL., BIOCHEM, vol. 32, 1993, pages 1180 - 1187
BURKS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 412 - 417
E. DIAMANDIST. CHRISTOPOULUS: "Immunoassay", 1996, ACADEMIC PRESS, INC.
EMBO J, vol. 4, no. 2, 1985, pages 337 - 344
HARTLEY J.A. ET AL., CANCER RES, vol. 70, no. 17, 2010, pages 6849 - 6858
HOWARD P.W. ET AL., BIOORG MED CHEM LETT, vol. 19, 2009, pages 6463 - 6466
IDUSOGIE EE ET AL.: "Mapping of the Clq Binding Site on Rituxan, a Chimeric Antibody with a Human IgGl Fc", J IMMUNOL, vol. 164, no. 8, 15 April 2000 (2000-04-15), pages 4178 - 4184
J. IMMUNOL., vol. 137, no. 4, 1986, pages 1097 - 100
J. IMMUNOL., vol. 147, no. 9, 1991, pages 3047 - 52
J.EXP.MED., vol. 174, 1991, pages 319 - 326
KOBAYASHI ET AL., PROTEIN ENG, vol. 12, no. 10, 1999, pages 879 - 884
MARASCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7889 - 7893
NELSON ET AL., J CLIN PATHOL, vol. 53, 2000, pages 111 - 117
NEWMAN R. ET AL.: "Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees", CLIN IMMUNOL, vol. 98, no. 2, February 2001 (2001-02-01), pages 164 - 74, XP001098835, DOI: 10.1006/clim.2000.4975
SAGNOU ET AL., BIOORG MED CHEM LETT, vol. 10, no. 18, 2000, pages 2083 - 2086
SCHAEFER W ET AL., PNAS, 2011
SMITH ET AL., J. CLIN. PATHOL., vol. 57, 2004, pages 912 - 917
XIE, ZHI-GANG ET AL.: "Construction Formats of Engineered Bispecific Antibodies", BULLETIN OF THE ACADEMY OF MILITARY MEDICAL SCIENCES, vol. 28, no. 4, 31 August 2004 (2004-08-31), pages 375 - 378, XP055937934, ISSN: 1674-9960 *

Also Published As

Publication number Publication date
CA3200652A1 (en) 2022-06-09
CN116669761A (zh) 2023-08-29
CN114573703A (zh) 2022-06-03
EP4257607A1 (en) 2023-10-11
AU2021390122A1 (en) 2023-07-13
JP2023552198A (ja) 2023-12-14
KR20230117178A (ko) 2023-08-07

Similar Documents

Publication Publication Date Title
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
CA2597717C (en) Antibodies against cxcr4 and methods of use thereof
WO2022007808A1 (zh) 一种结合紧密连接蛋白-18.2的抗体及其用途
US20220162331A1 (en) Anti-cd73 monoclonal antibody and application thereof
WO2021027674A1 (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
WO2021104053A1 (zh) 一种tslp相关病症治疗剂的开发和应用
KR20160007478A (ko) 인간 IgG1 Fc 영역 변이체 및 그의 용도
WO2021088838A1 (zh) 对cd39具有特异性的结合分子及其用途
WO2022042661A1 (zh) 含有衔接器的药物治疗剂的开发和应用
WO2022105924A1 (zh) 一种双特异性抗体及其用途
WO2022143951A1 (zh) 一种功能增强型抗体阻断剂的开发及其应用
WO2022117045A1 (zh) 一种t细胞衔接器治疗剂的开发和应用
WO2021104052A1 (zh) 药物组合物及其制备方法和应用
WO2022117050A1 (zh) 一种新型肿瘤衔接器治疗药物的开发和应用
WO2024002308A1 (zh) 一种新型多特异肿瘤抑制剂的开发和应用
WO2024046384A1 (zh) 结合促甲状腺激素受体的抗体及其用途
JPWO2022117045A5 (zh)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21900071

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3200652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202180081608.X

Country of ref document: CN

Ref document number: 2023533951

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20237022053

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021900071

Country of ref document: EP

Effective date: 20230703

ENP Entry into the national phase

Ref document number: 2021390122

Country of ref document: AU

Date of ref document: 20211202

Kind code of ref document: A